

Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine

New England Journal of Medicine

384, 2187-2201

DOI: [10.1056/nejmoa2101544](https://doi.org/10.1056/nejmoa2101544)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multi-epitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. <i>Emerging Microbes and Infections</i> , 2021, 10, 1931-1946.	3.0	11
2	Determining the Incidence of Asymptomatic SARS-CoV-2 Among Early Recipients of COVID-19 Vaccines (DISCOVER-COVID-19): A Prospective Cohort Study of Healthcare Workers Before, During and After Vaccination. <i>Clinical Infectious Diseases</i> , 2022, 74, 1275-1278.	2.9	23
3	The clinical correlates of vaccine-induced immune thrombotic thrombocytopenia after immunisation with adenovirus vector-based SARS-CoV-2 vaccines. <i>Immunotherapy Advances</i> , 2021, 1, Itab019.	1.2	4
4	Neutralizing Antibody-Independent SARS-CoV-2 Control Correlated with Intranasal Vaccine-Induced CD8 ⁺ T-Cell Responses. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
5	Efficacy and Safety of the CVnCoV SARS-CoV-2 mRNA Vaccine Candidate: Results from Herald, a Phase 2b/3, Randomised, Observer-Blinded, Placebo-Controlled Clinical Trial in Ten Countries in Europe and Latin America. <i>SSRN Electronic Journal</i> , 0, , .	0.4	7
6	An Update on the Pathogenesis of COVID-19 and the Reportedly Rare Thrombotic Events Following Vaccination. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110214.	0.7	29
7	Concern About the Adverse Effects of Thrombocytopenia and Thrombosis After Adenovirus-Vectored COVID-19 Vaccination. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2021, 27, 107602962110401.	0.7	6
8	Contact-Adjusted Immunity Levels against SARS-CoV-2 in Korea and Prospects for Achieving Herd Immunity. <i>Journal of Korean Medical Science</i> , 2021, 36, e272.	1.1	2
9	Acute Myocardial Injury Following COVID-19 Vaccination: A Case Report and Review of Current Evidence from Vaccine Adverse Events Reporting System Database. <i>Journal of Primary Care and Community Health</i> , 2021, 12, 215013272110292.	1.0	42
10	Severe Acute Respiratory Syndrome Coronavirus 2: Manifestations of Disease and Approaches to Treatment and Prevention in Humans. <i>Comparative Medicine</i> , 2021, 71, 342-358.	0.4	3
13	No country or continent is on its own in the ongoing COVID-19 pandemic. <i>Eurosurveillance</i> , 2021, 26, .	3.9	4
16	Will SARS-CoV-2 variants of concern affect the promise of vaccines?. <i>Nature Reviews Immunology</i> , 2021, 21, 340-341.	10.6	162
17	Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. <i>Nature Reviews Immunology</i> , 2021, 21, 395-404.	10.6	223
19	SARS-CoV-2 vaccines: a triumph of science and collaboration. <i>JCI Insight</i> , 2021, 6, .	2.3	72
23	Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine in the United States, March-April 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 680-684.	9.0	152
26	Attention all anti-vaccinators: The cutaneous adverse events from the mRNA COVID-19 vaccines are not an excuse to avoid them!. <i>Clinics in Dermatology</i> , 2021, 39, 674-687.	0.8	14
27	Bell's palsy following the Ad26.COV2.S COVID-19 vaccination. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2021, 114, 657-658.	0.2	22
30	Delivery Routes for COVID-19 Vaccines. <i>Vaccines</i> , 2021, 9, 524.	2.1	37

#	ARTICLE	IF	CITATIONS
31	Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism. <i>Vaccines</i> , 2021, 9, 559.	2.1	64
32	Rivalry between human ideation and virus mutation: two competing means of sustainability. <i>Women Health Care and Issues</i> , 2021, 4, 01-03.	0.0	0
33	Indirect Protection by Reducing Transmission: Ending the Pandemic With Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	38
34	COVID-19 Vaccine Breakthrough Infections Reported to CDC â€” United States, January 1â€”April 30, 2021. <i>Morbidity and Mortality Weekly Report</i> , 2021, 70, 792-793.	9.0	350
35	The path to find an HIV vaccine. <i>Journal of the International AIDS Society</i> , 2021, 24, e25749.	1.2	6
40	Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 35-45.	3.8	634
42	Interplay between Emerging SARS-CoV-2 Variants and Pandemic Control. <i>New England Journal of Medicine</i> , 2021, 384, 1952-1954.	13.9	19
44	Development of leading first-generation vaccines against SARS-CoV-2. <i>Microbes and Infection</i> , 2021, 23, 104841.	1.0	0
47	Canadian Rheumatology Association Recommendation for the Use of COVID-19 Vaccination for Patients With Autoimmune Rheumatic Diseases. <i>Journal of Rheumatology</i> , 2021, 48, 1330-1339.	1.0	26
49	Behind the Scenes Heroes: The COVID-19 Vaccine Data and Safety Monitoring Board. <i>Journal of Infectious Diseases</i> , 2021, 224, 1993-1994.	1.9	2
52	COVID-19 vaccination for patients with primary immunodeficiency. <i>LymphoSign Journal</i> , 2021, 8, 37-45.	0.1	8
53	Using observational epidemiology to evaluate COVID-19 vaccines: integrating traditional methods with new data sources and tools. <i>Canadian Journal of Public Health</i> , 2021, 112, 867-871.	1.1	1
56	Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans. <i>Vaccines</i> , 2021, 9, 588.	2.1	12
57	Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques. <i>Nature</i> , 2021, 596, 423-427.	13.7	40
58	Preparing for COVID-19 Vaccination: Guidances for Healthcare Personnel. <i>Korean Journal of Healthcare-Associated Infection Control and Prevention</i> , 2021, 26, 3-15.	0.1	1
59	Varicellaâ€”Zoster virus reactivation following SARSâ€”CoVâ€”2 immunization in two patients with leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29191.	0.8	6
60	Aspectos clave en la vacunaci3n contra la COVID-19 en pacientes con enfermedad inflamatoria intestinal. <i>Revista Colombiana De Gastroenterologia</i> , 2021, 36, 241-251.	0.1	0
61	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	1.6	4

#	ARTICLE	IF	CITATIONS
64	Immunological Approaches to the Treatment of Novel Coronavirus Infection (Review). <i>Sovremennyye Tehnologii V Medicine</i> , 2021, 13, 81.	0.4	4
66	Updates on the coronavirus disease 2019 vaccine and consideration in children. <i>Clinical and Experimental Pediatrics</i> , 2021, 64, 328-338.	0.9	8
67	Meta-Analysis and Structural Dynamics of the Emergence of Genetic Variants of SARS-CoV-2. <i>Frontiers in Microbiology</i> , 2021, 12, 676314.	1.5	17
69	Mathematical Modeling to Inform Vaccination Strategies and Testing Approaches for Coronavirus Disease 2019 (COVID-19) in Nursing Homes. <i>Clinical Infectious Diseases</i> , 2022, 74, 597-603.	2.9	29
70	Immunogenicity of Ad26.COVS vaccine against SARS-CoV-2 variants in humans. <i>Nature</i> , 2021, 596, 268-272.	13.7	290
72	Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis. <i>Lancet Rheumatology</i> , The, 2021, 3, e470-e472.	2.2	44
73	Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies. <i>Blood</i> , 2021, 138, 811-814.	0.6	81
77	Six months of COVID vaccines: what 1.7 billion doses have taught scientists. <i>Nature</i> , 2021, 594, 164-167.	13.7	61
78	From Editor-in-Chief: On current issue, important cardiovascular documents and trials, COVID-19 sequelae, and welcome to a new Editor. <i>Heart Vessels and Transplantation</i> , 0, 5, .	0.0	0
79	Interpreting vaccine efficacy trial results for infection and transmission. <i>Vaccine</i> , 2021, 39, 4082-4088.	1.7	55
80	Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 1529-1538.	4.6	146
81	Bell's Palsy After 24 Hours of mRNA-1273 SARS-CoV-2 Vaccine. <i>Cureus</i> , 2021, 13, e15935.	0.2	23
83	Willingness to Receive COVID-19 Vaccination Among People Living With HIV and AIDS in China: Nationwide Cross-sectional Online Survey. <i>JMIR Public Health and Surveillance</i> , 2021, 7, e31125.	1.2	33
84	Interim Estimates of COVID-19 Vaccine Effectiveness in a Mass Vaccination Setting: Data from an Italian Province. <i>Vaccines</i> , 2021, 9, 628.	2.1	42
85	Vaccinations and Autoimmune Diseases. <i>Vaccines</i> , 2021, 9, 815.	2.1	45
87	In Vitro and In Vivo Evaluation of Human Adenovirus Type 49 as a Vector for Therapeutic Applications. <i>Viruses</i> , 2021, 13, 1483.	1.5	4
88	Multisociety statement on coronavirus disease 2019 (COVID-19) vaccination as a condition of employment for healthcare personnel. <i>Infection Control and Hospital Epidemiology</i> , 2022, 43, 3-11.	1.0	21
89	Evaluation of the safety profile of COVID-19 vaccines: a rapid review. <i>BMC Medicine</i> , 2021, 19, 173.	2.3	156

#	ARTICLE	IF	CITATIONS
90	Efficacy of COVID-19 vaccines: Several modes of expression should be presented in scientific publications. <i>Fundamental and Clinical Pharmacology</i> , 2022, 36, 218-220.	1.0	7
91	Differences in the Protection Motivation Theory Constructs between People with Various Latent Classes of Motivation for Vaccination and Preventive Behaviors against COVID-19 in Taiwan. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7042.	1.2	22
92	A Quantitative ELISA Protocol for Detection of Specific Human IgG against the SARS-CoV-2 Spike Protein. <i>Vaccines</i> , 2021, 9, 770.	2.1	8
93	A Big Problem and Debate in COVID-19 Pandemics: Equitable and Effective Access of the COVID-19 Vaccines and Waiver of Intellectual Property. , 2021, 56, 283-284.		1
96	Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	10
98	Recent updates on immunological, pharmacological, and alternative approaches to combat COVID-19. <i>Inflammopharmacology</i> , 2021, 29, 1331-1346.	1.9	7
100	Educational Interventions to Promote COVID-19 Vaccination Among Parents. <i>Delaware Journal of Public Health</i> , 2021, 7, 100-108.	0.2	2
101	One Year of the COVID-19 Pandemic. What Do We Know and What Is Yet to Come? â€” The Summarising Review. <i>International Journal of Public Health</i> , 2021, 66, 1603975.	1.0	3
102	Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC:) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	2.1	94
105	Impact of an interactive web tool on patientsâ€™™ intention to receive COVID-19 vaccination: a before-and-after impact study among patients with chronic conditions in France. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 228.	1.5	7
106	Sex Disparities in Efficacy in COVID-19 Vaccines: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2021, 9, 825.	2.1	57
107	N-Acetylcysteine as Adjuvant Therapy for COVID-19 â€” A Perspective on the Current State of the Evidence. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 2993-3013.	1.6	31
111	Antibody and B cell responses to SARS-CoV-2 infection and vaccination. <i>Cell Host and Microbe</i> , 2021, 29, 1063-1075.	5.1	99
112	Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination. <i>Nature Medicine</i> , 2021, 27, 1525-1529.	15.2	363
113	Effectiveness of SARS-CoV-2 vaccination in fully vaccinated solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2021, 21, 2916-2918.	2.6	62
114	An Appraisal of the Current Scenario in Vaccine Research for COVID-19. <i>Viruses</i> , 2021, 13, 1397.	1.5	6
117	Explicit and Intrinsic Intention to Receive COVID-19 Vaccination among Heterosexuals and Sexual Minorities in Taiwan. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 7260.	1.2	7
119	Efficacy of COVID-19 vaccines: From clinical trials to real life. <i>Therapie</i> , 2021, 76, 277-283.	0.6	30

#	ARTICLE	IF	CITATIONS
122	The success of SARS-CoV-2 vaccines and challenges ahead. <i>Cell Host and Microbe</i> , 2021, 29, 1111-1123.	5.1	67
124	Take Your Best Shot: Which SARS-CoV-2 Vaccine Should I Get?. <i>MDM Policy and Practice</i> , 2021, 6, 238146832110312.	0.5	0
125	A COVID-Positive 52-Year-Old Man Presented With Venous Thromboembolism and Disseminated Intravascular Coagulation Following Johnson & Johnson Vaccination: A Case-Study. <i>Cureus</i> , 2021, 13, e16383.	0.2	8
126	Living Organ Donor Hesitancy about COVID-19 Vaccines: A New Kind of "Source Control Issue". <i>Kidney360</i> , 2021, 2, 1076-1077.	0.9	0
128	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. <i>Biomolecules</i> , 2021, 11, 993.	1.8	136
129	COVID-19 Pathogenesis: From Molecular Pathway to Vaccine Administration. <i>Biomedicines</i> , 2021, 9, 903.	1.4	5
130	COVID-19 vaccines that reduce symptoms but do not block infection need higher coverage and faster rollout to achieve population impact. <i>Scientific Reports</i> , 2021, 11, 15531.	1.6	70
131	Efficacy of Single-Dose Ad26.COVS Vaccine against Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, 288-288.	13.9	9
135	Interpreting estimates of coronavirus disease 2019 (COVID-19) vaccine efficacy and effectiveness to inform simulation studies of vaccine impact: a systematic review. <i>Wellcome Open Research</i> , 0, 6, 185.	0.9	17
136	Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research. <i>Cancer Cell</i> , 2021, 39, 897-899.	7.7	1
137	Coronavirus disease 2019 in children. <i>Current Opinion in Infectious Diseases</i> , 2021, 34, 500-509.	1.3	8
138	Vaccine Development against COVID-19: Study from Pre-Clinical Phases to Clinical Trials and Global Use. <i>Vaccines</i> , 2021, 9, 836.	2.1	15
139	Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. <i>Lancet, The</i> , 2021, 398, 213-222.	6.3	683
140	Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. <i>New England Journal of Medicine</i> , 2021, 385, 320-329.	13.9	394
141	Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. <i>Npj Vaccines</i> , 2021, 6, 104.	2.9	241
142	Correspondence on "SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response" by Bonelli <i>et al</i> . <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e164-e164.	0.5	17
143	Educating society about the unseen, but not unknown, risk factors for severe COVID-19: a step towards overcoming vaccine hesitancy through a more informed public. <i>Journal of Global Health Reports</i> , 0, 5, .	1.0	0
144	Public Health Leadership in a VUCA World Environment: Lessons Learned during the Regional Emergency Rollout of SARS-CoV-2 Vaccinations in Heidelberg, Germany, during the COVID-19 Pandemic. <i>Vaccines</i> , 2021, 9, 887.	2.1	16

#	ARTICLE	IF	CITATIONS
145	COVID-19 Vaccine among Actively-Treated People with Cancer: A Glimpse into the Known Unknowns?. Journal of the National Cancer Institute, 2021, , .	3.0	0
146	FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system. Med, 2021, 2, 979-992.e8.	2.2	127
147	Liver Transplant Society of India Guidelines for Liver Transplant During COVID-19 times. Journal of Clinical and Experimental Hepatology, 2022, 12, 180-185.	0.4	9
148	SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies. Infection, 2021, 49, 855-876.	2.3	61
149	Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases. Annals of the Rheumatic Diseases, 2021, 80, 1365-1366.	0.5	22
151	Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. Vaccines, 2021, 9, 910.	2.1	50
153	Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years – COVID-NET, 13 States, February–April 2021. Morbidity and Mortality Weekly Report, 2021, 70, 1088-1093.	9.0	130
158	Temporal Association Between the COVID-19 Ad26.COVS Vaccine and Acute Myocarditis: A Case Report and Literature Review. Cardiovascular Revascularization Medicine, 2022, 38, 117-123.	0.3	40
159	SARS-CoV-2 Vaccines: Where Are We Now?. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3535-3543.	2.0	36
160	Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial. EClinicalMedicine, 2021, 38, 101010.	3.2	28
161	Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Cell, 2021, 184, 4401-4413.e10.	13.5	65
163	Current development of Zika virus vaccines with special emphasis on virus-like particle technology. Expert Review of Vaccines, 2021, 20, 1483-1498.	2.0	8
165	COVID-19 Vaccine-Associated Cerebral Venous Thrombosis in Germany. Annals of Neurology, 2021, 90, 627-639.	2.8	122
166	Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell, 2021, 39, 1091-1098.e2.	7.7	199
167	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity, 2021, 54, 1636-1651.	6.6	165
168	Cross-reactive CD4 ⁺ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination. Science, 2021, 374, eabh1823.	6.0	221
169	Seroconversion rates following COVID-19 vaccination among patients with cancer. Cancer Cell, 2021, 39, 1081-1090.e2.	7.7	285
170	COVID-19 vaccination in solid-organ transplant recipients: generating new data as fast as possible, but taking clinical decisions as slow as necessary. Clinical Microbiology and Infection, 2021, 27, 1070-1071.	2.8	2

#	ARTICLE	IF	CITATIONS
171	The COVID-19 Citizen Science Study: Protocol for a Longitudinal Digital Health Cohort Study. JMIR Research Protocols, 2021, 10, e28169.	0.5	21
173	The hindrances to perform the COVID-19 vaccination in Brazil. Human Vaccines and Immunotherapeutics, 2021, 17, 3989-4004.	1.4	13
174	The COVID-19 Vaccination Strategy in Brazil—A Case Study. Epidemiologia, 2021, 2, 338-359.	1.1	6
175	Effect of azithromycin and hydroxychloroquine in patients hospitalized with COVID-19: Network meta-analysis of randomized controlled trials. Journal of Medical Virology, 2021, 93, 6737-6749.	2.5	13
176	COVID-19 Vaccines in Patients with Maintenance Hemodialysis. Journal of Personalized Medicine, 2021, 11, 789.	1.1	14
177	Interpretation of vaccine associated neurological adverse events: a methodological and historical review. Journal of Neurology, 2022, 269, 493-503.	1.8	7
179	A Modeling Study on Vaccination and Spread of SARS-CoV-2 Variants in Italy. Vaccines, 2021, 9, 915.	2.1	10
180	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. Signal Transduction and Targeted Therapy, 2021, 6, 317.	7.1	68
183	Playing vaccine roulette: Why the current strategy of staking everything on Covid-19 vaccines is a high-stakes wager. Vaccine, 2021, 39, 4921-4924.	1.7	10
184	Facing the wrath of enigmatic mutations: a review on the emergence of severe acute respiratory syndrome coronavirus 2 variants amid coronavirus disease-19 pandemic. Environmental Microbiology, 2022, 24, 2615-2629.	1.8	23
185	Major Insights in Dynamics of Host Response to SARS-CoV-2: Impacts and Challenges. Frontiers in Microbiology, 2021, 12, 637554.	1.5	8
186	Vaccine-induced immune thrombotic thrombocytopenia presenting with normal platelet count. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12596.	1.0	12
187	Evaluation of Immune Response and Disease Status in Systemic Lupus Erythematosus Patients Following SARS-CoV-2 Vaccination. Arthritis and Rheumatology, 2022, 74, 284-294.	2.9	103
188	Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nature Reviews Immunology, 2021, 21, 626-636.	10.6	777
190	Thrombosis and severe acute respiratory syndrome coronavirus 2 vaccines: vaccine-induced immune thrombotic thrombocytopenia. Clinical and Experimental Pediatrics, 2021, 64, 400-405.	0.9	4
191	Expert Perspectives on COVID-19 Vaccination for People Living with Multiple Sclerosis. Neurology and Therapy, 2021, 10, 415-425.	1.4	5
192	An Overview of Vaccines against SARS-CoV-2 in the COVID-19 Pandemic Era. Pathogens, 2021, 10, 1030.	1.2	33
193	The coronavirus disease 2019 (COVID-19) pandemic—Looking back and looking forward. Infection Control and Hospital Epidemiology, 2021, 42, 1-6.	1.0	0

#	ARTICLE	IF	CITATIONS
194	Perioperative Coronavirus Vaccinationâ€™Timing and Implications: A Guidance Document. <i>Annals of Thoracic Surgery</i> , 2021, 112, 1707-1715.	0.7	14
195	Immunization Update 2021. <i>Pharmacy Today</i> , 2021, 27, 52-62.	0.0	0
197	Interactions of adenoviruses with platelets and coagulation and the vaccine-induced immune thrombotic thrombocytopenia syndrome. <i>Haematologica</i> , 2021, 106, 3034-3045.	1.7	24
198	Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems. <i>Drugs and Therapy Perspectives</i> , 2021, 37, 376-382.	0.3	30
200	Brugada syndrome and COVID-19 vaccines. <i>Europace</i> , 2021, 23, 1871-1872.	0.7	10
201	Rhabdomyolysis Following Ad26.COVS COVID-19 Vaccination. <i>Vaccines</i> , 2021, 9, 956.	2.1	18
202	A Review of Treatment and Prevention of Coronavirus Disease 2019 among Solid Organ Transplant Recipients. <i>Viruses</i> , 2021, 13, 1706.	1.5	9
203	COVID -19: EFFICACY AND SAFETY PROFILE OF MAIN VACCINES APPROVED FOR EMERGENCY USE AUTHORIZATION IN 2021. <i>International Journal of Research -GRANTHAALAYAH</i> , 2021, 9, 271-283.	0.1	1
204	Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1144-1151.	0.9	37
206	Efficient Maternal to Neonate Transfer of Neutralizing Antibodies after SARS-CoV-2 Vaccination with BNT162b2: A Case-Report and Discussion of the Literature. <i>Vaccines</i> , 2021, 9, 907.	2.1	9
207	Efficacy and safety of hydroxychloroquine as pre-and post-exposure prophylaxis and treatment of COVID-19: A systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials.. <i>The Lancet Regional Health Americas</i> , 2021, 2, 100062.	1.5	33
208	Evolution, Mode of Transmission, and Mutational Landscape of Newly Emerging SARS-CoV-2 Variants. <i>MBio</i> , 2021, 12, e0114021.	1.8	58
210	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. <i>Nature Immunology</i> , 2021, 22, 1306-1315.	7.0	57
211	Single-Dose Intranasal Administration of AdCOVID Elicits Systemic and Mucosal Immunity against SARS-CoV-2 and Fully Protects Mice from Lethal Challenge. <i>Vaccines</i> , 2021, 9, 881.	2.1	86
212	Emergency use of COVID-19 vaccines recommended by the World Health Organization (WHO) as of June 2021. <i>Drug Discoveries and Therapeutics</i> , 2021, 15, 222-224.	0.6	16
214	The Efficacy of COVID-19 Vaccines in Chronic Kidney Disease and Kidney Transplantation Patients: A Narrative Review. <i>Vaccines</i> , 2021, 9, 885.	2.1	57
217	Adenoviral Vector COVID-19 Vaccines: Process and Cost Analysis. <i>Processes</i> , 2021, 9, 1430.	1.3	18
218	A Retrospective Survey among SARS-CoV-1 Infected Healthcare Workers after Three Years Post-Infection. <i>Pathogens</i> , 2021, 10, 1078.	1.2	0

#	ARTICLE	IF	CITATIONS
221	Potential Immunomodulatory Properties of Biologically Active Components of Spices Against SARS-CoV-2 and Pan Î²-Coronaviruses. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 729622.	1.8	11
222	Evaluation of Antibody Responses to COVID-19 Vaccines among Solid Tumor and Hematologic Patients. <i>Cancers</i> , 2021, 13, 4312.	1.7	11
223	Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. <i>Postgraduate Medical Journal</i> , 2022, 98, 389-394.	0.9	137
225	Overcoming Immune Resistance in Prostate Cancer: Challenges and Advances. <i>Cancers</i> , 2021, 13, 4757.	1.7	10
228	Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 289-291.	0.5	69
229	COVID-19 Outbreak Among Vaccinated Staff and Residents at a Skilled Nursing Facility in Los Angeles County. <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-5.	1.0	1
230	Immunity elicited by natural infection or Ad26.COVS vaccination protects hamsters against SARS-CoV-2 variants of concern. <i>Science Translational Medicine</i> , 2021, 13, eabj3789.	5.8	32
231	Anti-COVID-19 Vaccination in Patients with Autoimmune-Autoinflammatory Disorders and Primary/Secondary Immunodeficiencies: The Position of the Task Force on Behalf of the Italian Immunological Societies. <i>Biomedicines</i> , 2021, 9, 1163.	1.4	18
232	Impact of disease-modifying antirheumatic drugs on vaccine immunogenicity in patients with inflammatory rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1255-1265.	0.5	77
235	Work Absence Following COVID-19 Vaccination in a Cohort of Healthcare Personnel. <i>Journal of Occupational and Environmental Medicine</i> , 2022, 64, 6-9.	0.9	5
236	Vaccines Against SARS-CoV-2 in Psoriasis Patients on Immunosuppressive Therapy: Implications of Vaccination Nationwide Campaign on Clinical Practice in Italy. <i>Dermatology and Therapy</i> , 2021, 11, 1889-1903.	1.4	6
237	Adverse events and preventive measures related to COVID-19 vaccines. <i>Clinical and Experimental Emergency Medicine</i> , 2021, 8, 153-159.	0.5	1
238	Population Immunity Against COVID-19 in the United States. <i>Annals of Internal Medicine</i> , 2021, 174, 1586-1591.	2.0	20
239	COVID-19 Infection in Children, Infants and Pregnant Subjects: An Overview of Recent Insights and Therapies. <i>Microorganisms</i> , 2021, 9, 1964.	1.6	13
240	Immune response (IgG) following full inoculation with BNT162b2 COVID-19 mRNA among healthcare professionals. <i>International Journal of Molecular Medicine</i> , 2021, 48, .	1.8	16
241	Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 258-270.	2.7	27
242	How the Global COVID-19 Pandemic Brought Drug and Vaccine Development into the Public Mainstream. <i>Pharmaceutical Medicine</i> , 2021, 35, 287-295.	1.0	1
243	COVID-19 pandemic: lessons learned from more than a century of pandemics and current vaccine development for pandemic control. <i>International Journal of Infectious Diseases</i> , 2021, 112, 300-317.	1.5	21

#	ARTICLE	IF	CITATIONS
245	COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations. <i>Vaccines</i> , 2021, 9, 1097.	2.1	27
246	Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2. <i>Cell Reports</i> , 2021, 36, 109664.	2.9	99
248	Durable Humoral and Cellular Immune Responses 8 Months after Ad26.COVS.2.S Vaccination. <i>New England Journal of Medicine</i> , 2021, 385, 951-953.	13.9	192
249	COVID-19 Delta variants: Current status and implications as of August 2021. <i>Precision Clinical Medicine</i> , 2021, 4, 287-292.	1.3	18
252	Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission. <i>Viruses</i> , 2021, 13, 1921.	1.5	10
253	Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. <i>Science Advances</i> , 2021, 7, eabj5365.	4.7	83
254	Perspectives on administration of COVID-19 vaccine to pregnant and lactating women: a challenge for low- and middle-income countries. <i>AJOG Global Reports</i> , 2021, 1, 100020.	0.4	6
256	A comprehensive analysis of the efficacy and safety of COVID-19 vaccines. <i>Molecular Therapy</i> , 2021, 29, 2794-2805.	3.7	105
257	Cancer or COVID-19? A Review of Recommendations for COVID-19 Vaccination in Cancer Patients. <i>Current Treatment Options in Oncology</i> , 2021, 22, 95.	1.3	13
258	Severe COVID-19 vaccine associated myocarditis: Zebra or unicorn?. <i>International Journal of Cardiology</i> , 2021, 343, 197-198.	0.8	6
259	Rapid and Quantitative Detection of Human Antibodies against the 2019 Novel Coronavirus SARS CoV2 and Its Variants as a Result of Vaccination and Infection. <i>Microbiology Spectrum</i> , 2021, 9, e0089021.	1.2	2
261	The Rise of Vectored Vaccines: A Legacy of the COVID-19 Global Crisis. <i>Vaccines</i> , 2021, 9, 1101.	2.1	11
262	Vaccines for COVID-19: Where do we stand in 2021?. <i>Paediatric Respiratory Reviews</i> , 2021, 39, 22-31.	1.2	53
263	Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. <i>Eurosurveillance</i> , 2021, 26, .	3.9	48
264	Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1273 mRNA vaccine by commercial antibody tests. <i>Vaccine</i> , 2021, 39, 5563-5570.	1.7	14
265	Shooting at a Moving Target: Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. <i>Vaccines</i> , 2021, 9, 1052.	2.1	22
266	Enfermedades autoinmunes y vacunas contra la COVID-19. Toma de decisiones en escenarios de incertidumbre. <i>Medicina Clínica</i> , 2021, 157, 247-252.	0.3	4
267	Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain. <i>International Journal of Infectious Diseases</i> , 2021, 112, 81-88.	1.5	21

#	ARTICLE	IF	CITATIONS
269	Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia. <i>International Journal of Infectious Diseases</i> , 2021, 110, 359-362.	1.5	45
270	Ocular Adverse Events After COVID-19 Vaccination. <i>Ocular Immunology and Inflammation</i> , 2021, 29, 1216-1224.	1.0	130
271	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
273	Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings. <i>New England Journal of Medicine</i> , 2021, 385, 1355-1371.	13.9	353
274	The Immune Response to SARS-CoV-2 and Variants of Concern. <i>Viruses</i> , 2021, 13, 1911.	1.5	18
275	Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic. <i>International Journal of Hygiene and Environmental Health</i> , 2021, 238, 113851.	2.1	13
277	The Revolving Door of Adenovirus Cell Entry: Not All Pathways Are Equal. <i>Pharmaceutics</i> , 2021, 13, 1585.	2.0	12
279	Beginning to understand clinical events and immune responses of hematopoietic cell transplant recipients receiving SARS-CoV-2 vaccination. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 700-701.	0.6	2
280	An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates. <i>Cell Host and Microbe</i> , 2021, 29, 1437-1453.e8.	5.1	53
281	The First Chemically-Synthesised, Highly Immunogenic Anti-SARS-CoV-2 Peptides in DNA Genotyped Aotus Monkeys for Human Use. <i>Frontiers in Immunology</i> , 2021, 12, 724060.	2.2	5
282	Cutaneous small vessel vasculitis following single-dose Janssen Ad26.COVS.S vaccination. <i>JAAD Case Reports</i> , 2021, 15, 11-14.	0.4	17
284	Viral vector-based gene therapies in the clinic. <i>Bioengineering and Translational Medicine</i> , 2022, 7, e10258.	3.9	97
285	Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 1192-1197.	1.5	67
288	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. <i>International Immunology</i> , 2021, 33, 529-540.	1.8	28
290	Covid-19 vaccination: evidence of waning immunity is overstated. <i>BMJ</i> , The, 2021, 374, n2320.	3.0	30
292	Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. <i>Lancet Regional Health - Europe</i> , The, 2021, 8, 100171.	3.0	70
294	The real-life impact of vaccination on COVID-19 mortality in Europe and Israel. <i>Public Health</i> , 2021, 198, 230-237.	1.4	70
296	Vaccines and variants: Modelling insights into emerging issues in COVID-19 epidemiology. <i>Paediatric Respiratory Reviews</i> , 2021, 39, 32-39.	1.2	18

#	ARTICLE	IF	CITATIONS
297	Current Status of HIV-1 Vaccines. <i>Vaccines</i> , 2021, 9, 1026.	2.1	17
298	SARS-CoV-2 vaccination in solid organ transplant recipients: What the clinician needs to know. <i>Transplant International</i> , 2021, 34, 1776-1788.	0.8	32
299	Autoimmune diseases and vaccines against COVID-19. Decision making in uncertain scenarios. <i>Medicina Clínica (English Edition)</i> , 2021, 157, 247-252.	0.1	9
300	The right to bare arms. <i>Transplant Infectious Disease</i> , 2021, 23, e13723.	0.7	0
302	Discussion on "Estimating vaccine efficacy over time after a randomized study is unblinded" by Anastasios A. Tsiatis and Marie Davidian. <i>Biometrics</i> , 2022, 78, 841-843.	0.8	1
303	Safety and Efficacy of COVID-19 Vaccines: A Systematic Review and Meta-Analysis of Different Vaccines at Phase 3. <i>Vaccines</i> , 2021, 9, 989.	2.1	90
306	Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	44
307	Alcohol use disorder in the COVID-19 era: Position paper of the Italian Society on Alcohol (SIA). <i>Addiction Biology</i> , 2022, 27, e13090.	1.4	9
309	Recent advances and developments in COVID-19 in the context of allergic diseases. <i>Clinical and Translational Allergy</i> , 2021, 11, e12065.	1.4	7
310	Invited Editorial: Characteristics and outcomes of adverse events following COVID-19 vaccination. <i>Journal of the American College of Emergency Physicians Open</i> , 2021, 2, e12566.	0.4	1
311	An immunologist's perspective on anti-COVID-19 vaccines. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2021, Publish Ahead of Print, 545-552.	1.1	4
312	SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review. <i>International Journal of Biological Macromolecules</i> , 2021, 188, 740-750.	3.6	83
313	Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity. <i>Journal of Biological Chemistry</i> , 2021, 297, 101266.	1.6	64
314	The associations between air pollutant exposure and neutralizing antibody titers of an inactivated SARS-CoV-2 vaccine. <i>Environmental Science and Pollution Research</i> , 2022, 29, 13720-13728.	2.7	7
315	Trajectory of Growth of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in Houston, Texas, January through May 2021, Based on 12,476 Genome Sequences. <i>American Journal of Pathology</i> , 2021, 191, 1754-1773.	1.9	26
317	Sensory Guillain-Barre syndrome following the ChAdOx1 nCov-19 vaccine: Report of two cases and review of literature. <i>Journal of Neuroimmunology</i> , 2021, 359, 577691.	1.1	42
318	Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina. <i>EClinicalMedicine</i> , 2021, 40, 101126.	3.2	60
319	Is It Ethical to Mandate SARS-CoV-2 Vaccinations among Incarcerated Persons?. <i>American Journal of Bioethics</i> , 2022, 22, 8-10.	0.5	2

#	ARTICLE	IF	CITATIONS
320	Administration of COVID-19 vaccines in immunocompromised patients. <i>International Immunopharmacology</i> , 2021, 99, 108021.	1.7	51
321	Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: A phase 2 randomized placebo-controlled trial. <i>PLoS Medicine</i> , 2021, 18, e1003769.	3.9	83
322	Perspectives for Potential Therapies for SARS-CoV-2. <i>International Journal of Quantitative Structure-Property Relationships</i> , 2021, 6, 1-24.	1.1	0
323	Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity. <i>Virology</i> , 2021, 563, 134-145.	1.1	74
324	Real-World Effectiveness of the mRNA-1273 Vaccine Against COVID-19: Interim Results from a Prospective Observational Cohort Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	22
325	Updates on Coronavirus Disease-2019 Vaccine and Consideration in Children. <i>Pediatric Infection and Vaccine</i> , 2021, 28, 7.	0.1	7
327	Post SARS-CoV-2 vaccination Guillain-Barre syndrome in 19 patients. <i>Clinics</i> , 2021, 76, e3286.	0.6	41
328	Immunology of SARS-CoV-2 infections and vaccines. <i>Advances in Immunology</i> , 2021, 151, 49-97.	1.1	12
329	Protecting Our Most Vulnerable: Vaccine Responses in Patients With Blood Cancers. , 2021, 18, .		0
330	Coronavirus Disease 2019 Vaccines and Pregnancy: Present and Future. <i>Perinatology</i> , 2021, 32, 111.	0.0	0
331	Cancer Therapy and Immunogenicity of COVID Vaccine – CANINE Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
332	Antibody Response to COVID-19 Vaccination in Adults with Haematological Malignancies: A Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
333	Comparing Immune Responses to Inactivated Vaccines Against SARS-CoV-2 Between People Living With HIV and HIV-Negative Individuals: A Cross-Sectional Study in China. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
334	Effectiveness of COVID-19 Vaccines in Preventing Hospitalizations and Deaths in Colombia: A Pair-Matched, National-Wide Cohort Study in Older Adults. <i>SSRN Electronic Journal</i> , 0, , .	0.4	6
335	Adenoviral vector-based platforms for developing effective vaccines to combat respiratory viral infections. <i>Clinical and Translational Immunology</i> , 2021, 10, e1345.	1.7	14
336	Usability of an At-Home Anterior Nares SARS-CoV-2 RT-PCR Sample Collection Kit: Human Factors Feasibility Study. <i>JMIR Human Factors</i> , 2021, 8, e29234.	1.0	0
337	COVID-19 Vaccines: Adenoviral Vectors. <i>Annual Review of Medicine</i> , 2022, 73, 41-54.	5.0	46
338	Effectiveness of COVID-19 vaccines and their challenges (Review). <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1407.	0.8	23

#	ARTICLE	IF	CITATIONS
339	Sex-related susceptibility in coronavirus disease 2019 (COVID-19): Proposed mechanisms. <i>European Journal of Pharmacology</i> , 2021, 912, 174548.	1.7	14
340	Association Between Risk of COVID-19 Infection in Nonimmune Individuals and COVID-19 Immunity in Their Family Members. <i>JAMA Internal Medicine</i> , 2021, 181, 1589.	2.6	15
342	Novel Vaccine Adjuvants as Key Tools for Improving Pandemic Preparedness. <i>Bioengineering</i> , 2021, 8, 155.	1.6	13
343	T cell immunity to SARS-CoV-2. <i>Seminars in Immunology</i> , 2021, 55, 101505.	2.7	55
345	COVID-19 Risk Assessment for the Tokyo Olympic Games. <i>Frontiers in Public Health</i> , 2021, 9, 730611.	1.3	9
346	Actions and attitudes on the immunized patients against SARS-CoV-2. <i>Revista Espanola De Quimioterapia</i> , 2021, , .	0.5	3
347	Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies. <i>Scientific Reports</i> , 2021, 11, 20274.	1.6	33
348	Measuring the impact of a single dose of ChAdOx1 nCoV-19 (recombinant) coronavirus vaccine on hospital stay, ICU requirement, and mortality outcome in a tertiary care centre. <i>International Journal of Infectious Diseases</i> , 2021, 113, 282-287.	1.5	5
349	A Comprehensive Review about the Molecular Structure of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Insights into Natural Products against COVID-19. <i>Pharmaceutics</i> , 2021, 13, 1759.	2.0	42
350	Effectiveness of heterologous ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic Covid-19 infection in Sweden: A nationwide cohort study. <i>Lancet Regional Health - Europe</i> , The, 2021, 11, 100249.	3.0	115
351	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. <i>Expert Review of Vaccines</i> , 2022, 21, 47-67.	2.0	3
352	The quest for a better fight: How can nanomaterials address the current therapeutic and diagnostic obstacles in the fight against COVID-19?. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 67, 102899.	1.4	3
353	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil. <i>Nature Communications</i> , 2021, 12, 5861.	5.8	38
354	Multiple Sclerosis, COVID-19 and Vaccines: Making the Point. <i>Neurology and Therapy</i> , 2021, 10, 627-649.	1.4	9
355	Coagulopathies after Vaccination against SARS-CoV-2 May Be Derived from a Combined Effect of SARS-CoV-2 Spike Protein and Adenovirus Vector-Triggered Signaling Pathways. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10791.	1.8	20
356	SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers. <i>Nature Communications</i> , 2021, 12, 6032.	5.8	55
357	The safety profile of COVID-19 vaccinations in the United States. <i>American Journal of Infection Control</i> , 2022, 50, 15-19.	1.1	53
358	Trust issues in vaccine uptake. <i>Journal of Critical Care</i> , 2021, 67, 198-198.	1.0	1

#	ARTICLE	IF	CITATIONS
359	Does infection with or vaccination against SARS-CoV-2 lead to lasting immunity?. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1450-1466.	5.2	110
360	COVID-19 Vaccine Platforms: Challenges and Safety Contemplations. <i>Vaccines</i> , 2021, 9, 1196.	2.1	15
361	American perspectives on COVID-19 vaccination hesitancy and refusal: Time for a new approach?. <i>Journal of Critical Care</i> , 2021, 67, 189-189.	1.0	2
363	SARS-CoV-2 binding and neutralizing antibody levels after Ad26.COVS2.S vaccination predict durable protection in rhesus macaques. <i>Nature Communications</i> , 2021, 12, 5877.	5.8	21
364	Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 Variants. <i>MBio</i> , 2021, 12, e0181321.	1.8	28
365	Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy. <i>Vaccines</i> , 2021, 9, 1195.	2.1	90
366	Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates. <i>Science</i> , 2021, 374, 1343-1353.	6.0	83
367	Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 714170.	2.2	145
368	Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond. <i>Immunity and Ageing</i> , 2021, 18, 38.	1.8	20
369	Fatal vaccine-induced immune thrombotic thrombocytopenia (VITT) post Ad26.COVS2.S: first documented case outside US. <i>Infection</i> , 2022, 50, 531-536.	2.3	16
370	Comparative characteristics of COVID-19 vaccines used for mass immunisation. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2021, 21, 158-166.	0.2	6
371	The COVID-19 pandemic: viral variants and vaccine efficacy. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2022, 59, 66-75.	2.7	61
372	Peptides and peptidomimetics as therapeutic agents for Covid-19. <i>Peptide Science</i> , 2022, 114, e24245.	1.0	8
375	Characteristics and outcomes of adverse events after COVID-19 vaccination. <i>Journal of the American College of Emergency Physicians Open</i> , 2021, 2, e12565.	0.4	11
376	Measuring Vaccine Efficacy Against Infection and Disease in Clinical Trials: Sources and Magnitude of Bias in Coronavirus Disease 2019 (COVID-19) Vaccine Efficacy Estimates. <i>Clinical Infectious Diseases</i> , 2022, 75, e764-e773.	2.9	5
378	Evaluation of the Effectiveness and Safety of the BNT162b2 COVID-19 Vaccine in the Vaccination Campaign among the Health Workers of Fondazione Policlinico Universitario Agostino Gemelli IRCCS. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 11098.	1.2	9
379	Early clinical trial data and real-world assessment of COVID-19 vaccines: Insights from the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , 2021, 41, 837-850.	1.2	6
380	Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines. <i>Viruses</i> , 2021, 13, 2127.	1.5	6

#	ARTICLE	IF	CITATIONS
381	Exploration of non-pharmalogical interventions in the management of behavioural and psychological symptoms of dementia. Singapore Medical Journal, 2021, , .	0.3	2
383	COVID-19 Vaccinations in EMS Professionals: Prevalence and Predictors. Prehospital Emergency Care, 2022, 26, 632-640.	1.0	15
384	Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients. Journal of Experimental Medicine, 2021, 218, .	4.2	24
385	SARS-CoV-2 Antibody Binding and Neutralization in Dried Blood Spot Eluates and Paired Plasma. Microbiology Spectrum, 2021, 9, e0129821.	1.2	15
386	COVID-19 and the Gastrointestinal Tract. Gastroenterology Insights, 2021, 12, 394-404.	0.7	4
387	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. Science Translational Medicine, 2022, 14, eabj1996.	5.8	18
388	A case series of acute pericarditis following COVID-19 vaccination in the context of recent reports from Europe and the United States. Vaccine, 2021, 39, 6585-6590.	1.7	26
390	Prior infection with SARS-CoV-2 boosts and broadens Ad26.COVS immunogenicity in a variant-dependent manner. Cell Host and Microbe, 2021, 29, 1611-1619.e5.	5.1	106
395	COVID-19 and idiopathic nephrotic syndrome in children: systematic review of the literature and recommendations from a highly affected area. Pediatric Nephrology, 2022, 37, 757-764.	0.9	28
397	Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. EBioMedicine, 2021, 73, 103636.	2.7	85
398	Vaccine-induced immune thrombotic thrombocytopenia after the BNT162b2 mRNA Covid-19 vaccine: A case study. Thrombosis Research, 2021, 208, 1-3.	0.8	7
399	Challenges of evaluating and modelling vaccination in emerging infectious diseases. Epidemics, 2021, 37, 100506.	1.5	14
400	What Happens to the Immune System after Vaccination or Recovery from COVID-19?. Life, 2021, 11, 1152.	1.1	5
401	Vaccine development and technology for SARS-CoV-2: Current insight. Journal of Medical Virology, 2022, 94, 878-896.	2.5	8
403	Safe Surgery During the COVID-19 Pandemic. Current Obesity Reports, 2022, 11, 203-214.	3.5	2
404	Clinical outcomes and cost-effectiveness of COVID-19 vaccination in South Africa. Nature Communications, 2021, 12, 6238.	5.8	31
405	COVID-19 vaccine mandate for healthcare workers in the United States: a social justice policy. Expert Review of Vaccines, 2022, 21, 37-45.	2.0	22
406	Scientific rationale for developing potent RBD-based vaccines targeting COVID-19. Npj Vaccines, 2021, 6, 128.	2.9	102

#	ARTICLE	IF	CITATIONS
407	Lives saved and hospitalizations averted by COVID-19 vaccination in New York City: a modeling study. <i>The Lancet Regional Health Americas</i> , 2022, 5, 100085.	1.5	30
408	Adverse events of active and placebo groups in SARS-CoV-2 vaccine randomized trials: A systematic review. <i>Lancet Regional Health - Europe</i> , The, 2022, 12, 100253.	3.0	46
409	Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. <i>Cells</i> , 2021, 10, 2949.	1.8	26
410	Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2022, 108, 91-98.	1.1	17
411	COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network. <i>Lancet Haematology</i> , the, 2021, 8, e934-e946.	2.2	46
412	Equivalency of Protection From Natural Immunity in COVID-19 Recovered Versus Fully Vaccinated Persons: A Systematic Review and Pooled Analysis. <i>Cureus</i> , 2021, 13, e19102.	0.2	50
413	Age- and Sex-Specific Incidence of Cerebral Venous Sinus Thrombosis Associated With Ad26.COVS.2.S COVID-19 Vaccination. <i>JAMA Internal Medicine</i> , 2022, 182, 80.	2.6	11
415	SARS-CoV-2 immunity and an overview of the COVID-19 vaccines. <i>Medicinski Podmladak</i> , 2021, 72, 20-29.	0.2	3
418	SARS-CoV-2 and COVID-19. , 2021, , ,		0
419	Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn. <i>Gene Reports</i> , 2021, 25, 101417.	0.4	15
420	Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. <i>Vaccine</i> , 2021, 39, 7394-7400.	1.7	63
421	Acute disseminated encephalomyelitis (ADEM) following recent Oxford/AstraZeneca COVID-19 vaccination. <i>Forensic Science, Medicine, and Pathology</i> , 2022, 18, 74-79.	0.6	42
423	SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. <i>Epidemiology and Infection</i> , 2021, 149, 1-24.	1.0	43
424	Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HT α , ϕ adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice. <i>Vaccine: X</i> , 2021, 9, 100126.	0.9	13
425	The way of SARS-CoV-2 vaccine development: success and challenges. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 387.	7.1	42
426	A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice. <i>Science Translational Medicine</i> , 2022, 14, eabj7125.	5.8	93
429	Willingness to Receive the Booster COVID-19 Vaccine Dose in Poland. <i>Vaccines</i> , 2021, 9, 1286.	2.1	117
431	COVID-19 vaccine uptake among health care workers in Ghana: a case for targeted vaccine deployment campaigns in the global south. <i>Human Resources for Health</i> , 2021, 19, 136.	1.1	31

#	ARTICLE	IF	CITATIONS
432	Antibody Responses to COVID-19 Vaccination in Cancer: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 759108.	1.3	25
433	Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19. <i>JAMA Network Open</i> , 2021, 4, e2132540.	2.8	68
434	COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. <i>Drug Safety</i> , 2021, 44, 1247-1269.	1.4	85
435	Single-Dose Ad26.COV2.S Vaccine Room for Improvement. <i>JAMA Network Open</i> , 2021, 4, e2133012.	2.8	3
436	Unmet needs on the management of COVID-19 vaccination in patients with neuromuscular disorders. <i>Acta Myologica</i> , 2021, 40, 113-115.	1.5	1
437	Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines. <i>Journal of Infectious Diseases</i> , 2022, 225, 327-331.	1.9	12
438	Survival and Incidence of COVID-19 After SARS-CoV-2 Vaccination in a Series of 2391 Cancer Patients. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
439	Nocebo affects after COVID-19 vaccination. <i>Lancet Regional Health - Europe</i> , The, 2022, 12, 100273.	3.0	9
440	Thromboembolic and hemorrhagic risks after vaccination against SARS-CoV-2: a systematic review and meta-analysis of randomized controlled trials. <i>Thrombosis Journal</i> , 2021, 19, 86.	0.9	15
442	Vaccines and Vaccination Strategies for Older Adults. <i>Healthy Ageing and Longevity</i> , 2022, , 119-164.	0.2	1
443	A review of COVID-19 vaccination and the reported cardiac manifestations. <i>Singapore Medical Journal</i> , 2023, 64, 543-549.	0.3	17
444	Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 12-23.	0.8	75
445	Vaccination against SARS-CoV-2 in Patients with Inflammatory Bowel Diseases: Where Do We Stand?. <i>Life</i> , 2021, 11, 1220.	1.1	8
446	The Use of COVID-19 Vaccines in Patients with SLE. <i>Current Rheumatology Reports</i> , 2021, 23, 79.	2.1	32
448	Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. <i>Scientific Reports</i> , 2021, 11, 22777.	1.6	159
449	Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses. <i>Journal of Thoracic Oncology</i> , 2022, 17, 239-251.	0.5	51
453	Real-world effectiveness of COVID-19 vaccines: a literature review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 114, 252-260.	1.5	380
454	Adenovirus vector-based vaccine for infectious diseases. <i>Drug Metabolism and Pharmacokinetics</i> , 2022, 42, 100432.	1.1	55

#	ARTICLE	IF	CITATIONS
455	The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries. <i>Viruses</i> , 2021, 13, 2391.	1.5	11
456	COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, 22, e321-e326.	0.2	9
457	Vaccine efficacy and SARS-CoV-2 control in California and U.S. during the session 2020â€“2026: A modeling study. <i>Infectious Disease Modelling</i> , 2022, 7, 62-81.	1.2	14
458	Lower SARS-CoV-2 viral shedding following COVID-19 vaccination among healthcare workers in Los Angeles, California. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab526.	0.4	5
459	The Function of Immunoproteasomesâ€”An Immunologistsâ€™ Perspective. <i>Cells</i> , 2021, 10, 3360.	1.8	9
461	A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues. <i>Vaccines</i> , 2021, 9, 1387.	2.1	51
462	Impact of Chronic HIV Infection on SARS-CoV-2 Infection, COVID-19 Disease and Vaccines. <i>Current HIV/AIDS Reports</i> , 2022, 19, 5-16.	1.1	9
463	VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants. <i>Vaccines</i> , 2021, 9, 1409.	2.1	22
464	Developmental Aspects of SARS-CoV-2, Potential Role of Exosomes and Their Impact on the Human Transcriptome. <i>Journal of Developmental Biology</i> , 2021, 9, 54.	0.9	5
465	SARS-CoV-2 Targets and COVID-19 Vaccines. <i>Covid</i> , 2021, 1, 608-621.	0.7	4
466	Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies. <i>Vaccines</i> , 2021, 9, 1338.	2.1	17
467	The association of maternal SARSâ€“CoVâ€“2 vaccinationâ€”toâ€”delivery interval and the levels of maternal and cord blood antibodies. <i>International Journal of Gynecology and Obstetrics</i> , 2021, , .	1.0	8
468	Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study. <i>The Lancet Regional Health Americas</i> , 2022, 6, 100134.	1.5	54
469	Safety and Seroconversion of Immunotherapies against SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis of Clinical Trials. <i>Pathogens</i> , 2021, 10, 1537.	1.2	19
470	The Disease Severity and Clinical Outcomes of the SARS-CoV-2 Variants of Concern. <i>Frontiers in Public Health</i> , 2021, 9, 775224.	1.3	156
471	Mechanisms of COVID-19-induced kidney injury and current pharmacotherapies. <i>Inflammation Research</i> , 2022, 71, 39-56.	1.6	23
472	The role of mild and asymptomatic infections on COVID-19 vaccines performance: A modeling study. <i>Journal of Advanced Research</i> , 2022, 39, 157-166.	4.4	14
474	Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 771242.	2.2	15

#	ARTICLE	IF	CITATIONS
475	COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	28
476	Covid-19 vaccines and variants of concern: A review. <i>Reviews in Medical Virology</i> , 2022, 32, e2313.	3.9	201
477	Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 329-340.	4.6	103
478	De-Novo Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Following the mRNA-1273 (Moderna) Vaccine for COVID-19. <i>Cureus</i> , 2021, 13, e19616.	0.2	17
480	Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor- α inhibitors. <i>Med</i> , 2021, 2, 1327-1341.e4.	2.2	31
482	Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 163-177.	2.8	120
483	A Systematic Review of the Sex and Gender Reporting in COVID-19 Clinical Trials. <i>Vaccines</i> , 2021, 9, 1322.	2.1	30
484	Vaccine versus Variants (3Vs): Are the COVID-19 Vaccines Effective against the Variants? A Systematic Review. <i>Vaccines</i> , 2021, 9, 1305.	2.1	39
485	Spectrum of Neuroimaging Findings in Post-COVID-19 Vaccination: A Case Series and Review of Literature. <i>Neurology International</i> , 2021, 13, 622-639.	1.3	13
486	COVID-19 Vaccine Boosters: The Good, the Bad, and the Ugly. <i>Vaccines</i> , 2021, 9, 1299.	2.1	58
487	A Review Article on Vaccine Development and Therapeutics Approach Against SARS-CoV-2. <i>The Open Covid Journal</i> , 2021, 1, 117-138.	0.4	0
489	How to Maintain Safety and Maximize the Efficacy of Cardiopulmonary Resuscitation in COVID-19 Patients: Insights from the Recent Guidelines. <i>Journal of Clinical Medicine</i> , 2021, 10, 5667.	1.0	3
490	Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats. <i>Frontiers in Immunology</i> , 2021, 12, 791764.	2.2	14
491	Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data. <i>Inflammatory Bowel Diseases</i> , 2021, , .	0.9	3
493	Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. <i>Scientific Reports</i> , 2021, 11, 22848.	1.6	57
494	Optic neuritis after COVID-19 vaccine application. <i>Clinical and Experimental Neuroimmunology</i> , 2022, 13, 72-74.	0.5	35
495	Population impact of SARS-CoV-2 variants with enhanced transmissibility and/or partial immune escape. <i>Cell</i> , 2021, 184, 6229-6242.e18.	13.5	72
496	Gross hematuria after SARS-CoV-2 vaccination: questionnaire survey in Japan. <i>Clinical and Experimental Nephrology</i> , 2022, 26, 316-322.	0.7	18

#	ARTICLE	IF	CITATIONS
497	Immuno-Endocrinology of COVID-19: The Key Role of Sex Hormones. <i>Frontiers in Endocrinology</i> , 2021, 12, 726696.	1.5	16
498	Protection from SARS-CoV-2 Delta one year after mRNA-1273 vaccination in rhesus macaques coincides with anamnestic antibody response in the lung. <i>Cell</i> , 2022, 185, 113-130.e15.	13.5	64
499	Heterologous Vaccination for Preparing COVID-19 Pandemic. <i>Korean Journal of Medicine</i> , 2021, 96, 450-454.	0.1	0
501	Immune variants of SARS-CoV-2 could be a significant challenge for developing a pan genotype-specific vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 5145-5147.	1.4	0
502	Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?. <i>Human Vaccines and Immunotherapeutics</i> , 2024, 17, 4714-4740.	1.4	16
503	Effectiveness of COVID-19 vaccination in patients after allogeneic haematopoietic cell transplant: how much protection are we getting?. <i>British Journal of Haematology</i> , 2021, , .	1.2	0
504	Immunomodulation of COVID-19 severity by helminth co-infection: Implications for COVID-19 vaccine efficacy. <i>Immunity, Inflammation and Disease</i> , 2021, , .	1.3	10
505	The intestinal microbiota and improving the efficacy of COVID-19 vaccinations. <i>Journal of Functional Foods</i> , 2021, 87, 104850.	1.6	23
506	mRNA-Based COVID-19 Vaccine Boosters Induce Neutralizing Immunity Against SARS-CoV-2 Omicron Variant. <i>SSRN Electronic Journal</i> , 0, , .	0.4	34
507	Recent Advances on Drugs and Vaccines for COVID-19. <i>Inquiry (United States)</i> , 2021, 58, 004695802110556.	0.5	3
508	OUP accepted manuscript. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2022, 29, 489-499.	2.2	2
509	Effectiveness of COVID-19 Vaccines in Older Adults in Colombia: First Report of the Esperanza Cohort. A Matched-Pair, National Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	3
510	Comprehensive literature review on COVID-19 vaccines and role of SARS-CoV-2 variants in the pandemic. , 2021, 9, 251513552110597.	1.4	15
511	Assessment of novel technologies in healthcare - off-label use of drugs and the ethics of implementation and distribution of COVID-19 vaccines. <i>Einstein (Sao Paulo, Brazil)</i> , 2021, 19, eED6840.	0.3	0
512	Viral Vector Vaccines. , 2021, , .		0
513	Efficacy and effectiveness of COVID-19 vaccines: Progress and prospect. , 2021, 1, 17.		2
515	Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern. <i>Cell Reports</i> , 2022, 38, 110210.	2.9	96
516	A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant. <i>International Journal of Biological Sciences</i> , 2022, 18, 889-900.	2.6	40

#	ARTICLE	IF	CITATIONS
517	Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines. <i>Current Opinion in Virology</i> , 2022, 52, 89-101.	2.6	2
518	Genomic analysis of SARS-CoV-2 variants of concern identified from the ChAdOx1 nCoV-19 immunized patients from Southwest part of Bangladesh. <i>Journal of Infection and Public Health</i> , 2022, 15, 156-163.	1.9	10
519	Efficacy of mRNA, adenoviral vector, and perfusion protein COVID-19 vaccines. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112527.	2.5	34
520	Hypertension and COVID-19: Updates from the era of vaccines and variants. <i>Journal of Clinical and Translational Endocrinology</i> , 2022, 27, 100285.	1.0	9
521	Effectiveness of the Ad26.Cov2.S Vaccine in Health Care Workers in South Africa. <i>SSRN Electronic Journal</i> , 0, , .	0.4	4
522	Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110615.	0.5	10
524	A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs. <i>Cell Research</i> , 2022, 32, 269-287.	5.7	54
525	Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8+ T cell responses. <i>Cell Reports Medicine</i> , 2022, 3, 100520.	3.3	29
526	Homologous and Heterologous Covid-19 Booster Vaccinations. <i>New England Journal of Medicine</i> , 2022, 386, 1046-1057.	13.9	418
527	Adenovirus-based vaccinesâ€”a platform for pandemic preparedness against emerging viral pathogens. <i>Molecular Therapy</i> , 2022, 30, 1822-1849.	3.7	24
528	Great Expectations of COVID-19 Herd Immunity. <i>MBio</i> , 2022, 13, e0349521.	1.8	9
529	Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination. <i>Oncologist</i> , 2022, 27, e357-e361.	1.9	15
530	Impact of prior SARS-CoV-2 infection on incidence of hospitalization and adverse events following mRNA SARS-CoV-2 vaccination: A nationwide, retrospective cohort study. <i>Vaccine</i> , 2022, 40, 1082-1089.	1.7	9
531	CD4+ T cells from COVID-19 mRNA vaccine recipients recognize a conserved epitope present in diverse coronaviruses. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	16
532	Clinical characteristics of COVIDâ€”19 in solid organ transplant recipients following COVIDâ€”19 vaccination: A multicenter case series. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	16
533	Immune imprinting, breadth of variant recognition, and germinal center response in human SARS-CoV-2 infection and vaccination. <i>Cell</i> , 2022, 185, 1025-1040.e14.	13.5	243
535	Evaluating the Impact of SARS-CoV-2 Variants on the COVID-19 Epidemic and Social Restoration in the United States: A Mathematical Modelling Study. <i>Frontiers in Public Health</i> , 2021, 9, 801763.	1.3	9
537	Eosinophilic Granulomatosis With Polyangiitis Diagnosed in an Elderly Female After the Second Dose of mRNA Vaccine Against COVID-19. <i>Cureus</i> , 2022, 14, e21176.	0.2	14

#	ARTICLE	IF	CITATIONS
538	Natural Immunity Boosters as Therapeutic Interventions in the Era of the COVID-19 Pandemic. <i>Endocrine, Metabolic and Immune Disorders - Drug Targets</i> , 2022, 22, 842-851.	0.6	5
539	A Case of Acute Viral Pericarditis Complicated With Pericardial Effusion Induced by Third Dose of COVID Vaccination. <i>Cureus</i> , 2022, 14, e21207.	0.2	2
541	Antibody responses after two doses of CoronaVac of the participants with or without the diagnosis of COVID-19. <i>Irish Journal of Medical Science</i> , 2022, 191, 2833-2838.	0.8	1
542	Characteristics and outcomes among vaccinated lung transplant patients with breakthrough COVID-19. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	9
543	Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease. <i>Journal of Clinical Medicine</i> , 2022, 11, 641.	1.0	6
544	SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity. <i>Cell Reports Medicine</i> , 2022, 3, 100510.	3.3	51
545	Comparing Immune Responses to Inactivated Vaccines against SARS-CoV-2 between People Living with HIV and HIV-Negative Individuals: A Cross-Sectional Study in China. <i>Viruses</i> , 2022, 14, 277.	1.5	31
547	Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1242-1252.e12.	1.5	23
548	mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. <i>Immunity</i> , 2022, 55, 355-365.e4.	6.6	76
549	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
550	COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research. <i>Blood Reviews</i> , 2022, 54, 100931.	2.8	49
551	Association Between Menstrual Cycle Length and Coronavirus Disease 2019 (COVID-19) Vaccination. <i>Obstetrics and Gynecology</i> , 2022, 139, 481-489.	1.2	151
553	Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. <i>International Journal of Biological Sciences</i> , 2022, 18, 459-472.	2.6	65
554	Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. <i>Lancet, The</i> , 2022, 399, 461-472.	6.3	69
555	COVID-19 vaccines and risks of hematological abnormalities: Nested case-control and self-controlled case series study. <i>American Journal of Hematology</i> , 2022, 97, 470-480.	2.0	37
556	Role of vitamin D deficiency and comorbidities in COVID-19. <i>World Journal of Virology</i> , 2022, 11, 85-89.	1.3	2
557	Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients with primary brain tumors: a prospective cohort study. <i>Journal of Neuro-Oncology</i> , 2022, 156, 483-489.	1.4	5
558	Estimating COVID-19 Infections, Hospitalizations, and Deaths Following the US Vaccination Campaigns During the Pandemic. <i>JAMA Network Open</i> , 2022, 5, e2142725.	2.8	38

#	ARTICLE	IF	CITATIONS
559	A Pre-Vaccination Baseline of SARS-CoV-2 Genetic Surveillance and Diversity in the United States. <i>Viruses</i> , 2022, 14, 104.	1.5	1
560	Anti-SARS-CoV-2 IgG against the S Protein: A Comparison of BNT162b2, mRNA-1273, ChAdOx1 nCoV-2019 and Ad26.COV2.S Vaccines. <i>Vaccines</i> , 2022, 10, 99.	2.1	13
561	Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters. <i>Npj Vaccines</i> , 2022, 7, 2.	2.9	2
562	Efficacy and Safety of Third Dose of the COVID-19 Vaccine among Solid Organ Transplant Recipients: A Systemic Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 95.	2.1	28
563	Effectiveness and Efficacy of Vaccine on Mutated SARS-CoV-2 Virus and Post Vaccination Surveillance: A Narrative Review. <i>Vaccines</i> , 2022, 10, 82.	2.1	16
564	Longevity of vaccine protection: Immunological mechanism, assessment methods, and improving strategy. <i>View</i> , 2022, 3, .	2.7	7
565	Comorbidities and Vaccination Status of COVID-19 All-Cause Mortality at a Tertiary Care Center of Western India. <i>Cureus</i> , 2022, 14, e21721.	0.2	4
566	Hypertension Is Associated With Antibody Response and Breakthrough Infection in Health Care Workers Following Vaccination With Inactivated SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
567	Effectiveness of Vaccination against SARS-CoV-2 Infection in the Pre-Delta Era: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 157.	2.1	10
568	Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2. <i>Biomedicines</i> , 2022, 10, 171.	1.4	21
569	Response to vaccination against SARS-CoV-2 in 168 patients with Waldenström macroglobulinaemia: A French Innovative Leukaemia Organization study. <i>British Journal of Haematology</i> , 2022, , .	1.2	3
570	mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. <i>Cell</i> , 2022, 185, 457-466.e4.	13.5	881
571	Biometrics from a wearable device reveal temporary effects of COVID-19 vaccines on cardiovascular, respiratory, and sleep physiology. <i>Journal of Applied Physiology</i> , 2022, 132, 448-458.	1.2	12
572	Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. <i>Nature Communications</i> , 2022, 13, 153.	5.8	45
573	The risk of anaphylaxis behind authorized COVID-19 vaccines: a meta-analysis. <i>Clinical and Molecular Allergy</i> , 2022, 20, 1.	0.8	15
575	SARS-CoV2 Vaccination Adverse Events Trend in Italy: A Retrospective Interpretation of the Last Year (December 2020–September 2021). <i>Vaccines</i> , 2022, 10, 216.	2.1	14
576	Viral Load in COVID-19 Patients: Implications for Prognosis and Vaccine Efficacy in the Context of Emerging SARS-CoV-2 Variants. <i>Frontiers in Medicine</i> , 2021, 8, 836826.	1.2	15
577	Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. <i>Nature</i> , 2022, 603, 493-496.	13.7	326

#	ARTICLE	IF	CITATIONS
578	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22
579	Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COVS SARS-CoV-2 vector vaccines. <i>Haematologica</i> , 2022, 107, 947-957.	1.7	37
580	Eight Good Reasons for Careful Monitoring and Evaluation of the Vaccine Campaign against COVID-19: Lessons Learned through the Lombardy Experience for Dealing with Next Challenges. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 1073.	1.2	4
581	Obstetric Outpatient Management During the COVID-19 Pandemic: Prevention, Treatment of Mild Disease, and Vaccination. <i>Clinical Obstetrics and Gynecology</i> , 2022, 65, 161-178.	0.6	2
582	Incidence of SARS-CoV-2 infection among COVID-19 vaccinated and unvaccinated healthcare personnel, first responders, and other essential and frontline workers: Eight US locations, January–September 2021. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 585-593.	1.5	7
583	The Population-Wide Risk-Benefit Profile of Extending the Primary COVID-19 Vaccine Course Compared with an mRNA Booster Dose Program. <i>Vaccines</i> , 2022, 10, 140.	2.1	7
585	A Prospective Cohort Study of COVID-19 Vaccination, SARS-CoV-2 Infection, and Fertility. <i>American Journal of Epidemiology</i> , 2022, 191, 1383-1395.	1.6	66
586	Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study. <i>Blood Advances</i> , 2022, , .	2.5	14
588	Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. <i>Lancet</i> , The, 2022, 399, 237-248.	6.3	143
589	Genome-scale CRISPR screens identify host factors that promote human coronavirus infection. <i>Genome Medicine</i> , 2022, 14, 10.	3.6	26
590	Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina. <i>New England Journal of Medicine</i> , 2022, 386, 933-941.	13.9	238
591	Massive bullous local reaction following administration of Ad26.COVS COVID-19 vaccine. <i>International Journal of Dermatology</i> , 2022, , .	0.5	2
592	COVID-19 Vaccines. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 481-494.	1.9	13
593	COVID-19 scenario and recommendations on the continuity of immunobiological therapy in patients with atopic asthma in Brazil and Latin America. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 211-220.	1.0	0
595	Calcium Signals during SARS-CoV-2 Infection: Assessing the Potential of Emerging Therapies. <i>Cells</i> , 2022, 11, 253.	1.8	24
596	The Effectiveness of a Diverse COVID-19 Vaccine Portfolio and Its Impact on the Persistence of Positivity and Length of Hospital Stays: The Veneto Region's Experience. <i>Vaccines</i> , 2022, 10, 107.	2.1	13
599	The Effectiveness of COVID-19 Vaccines in Improving the Outcomes of Hospitalized COVID-19 Patients. <i>Cureus</i> , 2022, 14, e21485.	0.2	10
600	Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates. <i>Npj Vaccines</i> , 2022, 7, 7.	2.9	35

#	ARTICLE	IF	CITATIONS
601	Kinetics and persistence of cellular and humoral immune responses to SARS-CoV-2 vaccine in healthcare workers with or without prior COVID-19. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 1293-1305.	1.6	28
603	Lymphadenopathy post-COVID-19 vaccination with increased FDG uptake may be falsely attributed to oncological disorders: A systematic review. <i>Journal of Medical Virology</i> , 2022, 94, 1833-1845.	2.5	25
605	Clinical validation of engineered CRISPR/Cas12a for rapid SARS-CoV-2 detection. <i>Communications Medicine</i> , 2022, 2, .	1.9	24
606	Characteristics of Reported Deaths Among Fully Vaccinated Persons With Coronavirus Disease 2019—United States, January–April 2021. <i>Clinical Infectious Diseases</i> , 2022, 75, e645-e652.	2.9	9
607	Booster vaccination strategy: Necessity, immunization objectives, immunization strategy, and safety. <i>Journal of Medical Virology</i> , 2022, 94, 2369-2375.	2.5	24
608	Differentiation of Individuals Previously Infected with and Vaccinated for SARS-CoV-2 in an Inner-City Emergency Department. <i>Journal of Clinical Microbiology</i> , 2022, 60, jcm0239021.	1.8	5
609	Differential immunogenicity of homologous versus heterologous boost in Ad26.COVS vaccine recipients. <i>Med</i> , 2022, 3, 104-118.e4.	2.2	38
610	Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry. <i>Viruses</i> , 2022, 14, 178.	1.5	18
611	Vaccines to prevent COVID-19: A living systematic review with Trial Sequential Analysis and network meta-analysis of randomized clinical trials. <i>PLoS ONE</i> , 2022, 17, e0260733.	1.1	60
612	Identifying and Alleviating Bias Due to Differential Depletion of Susceptible People in Postmarketing Evaluations of COVID-19 Vaccines. <i>American Journal of Epidemiology</i> , 2022, 191, 800-811.	1.6	53
613	SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity. <i>Frontiers in Immunology</i> , 2022, 13, 825256.	2.2	54
614	Narrative Messages, Information Seeking and COVID-19 Vaccine Intention: The Moderating Role of Perceived Behavioral Control. <i>American Journal of Health Promotion</i> , 2022, 36, 923-933.	0.9	7
615	Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COVS Priming. <i>New England Journal of Medicine</i> , 2022, 386, 951-963.	13.9	102
616	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55
617	Imaging and Clinical Features of COVID-19 Breakthrough Infections: A Multicenter Study. <i>Radiology</i> , 2022, 303, 682-692.	3.6	44
618	Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac). <i>Scientific Reports</i> , 2022, 12, 1727.	1.6	11
619	Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac053.	0.4	38
620	Allergies and COVID-19 vaccines: An ENDA/EAAI Position paper. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2292-2312.	2.7	55

#	ARTICLE	IF	CITATIONS
621	Comparison of Neutralizing Antibody Responses at 6 Months Post Vaccination with BNT162b2 and AZD1222. <i>Biomedicines</i> , 2022, 10, 338.	1.4	21
622	Safety and antibody response to inactivated COVID-19 vaccine in patients with chronic hepatitis B virus infection. <i>Liver International</i> , 2022, 42, 1287-1296.	1.9	36
623	Moving Forward from the COVID-19 Pandemic: Needed Changes in Movement Disorders Care and Research. <i>Current Neurology and Neuroscience Reports</i> , 2022, 22, 113-122.	2.0	4
624	Comparison of immune responses induced by two or three doses of an alum-adjuvanted inactivated SARS-CoV-2 vaccine in mice. <i>Journal of Medical Virology</i> , 2022, , .	2.5	4
626	SARS-CoV-2 E484K Mutation Narrative Review: Epidemiology, Immune Escape, Clinical Implications, and Future Considerations. <i>Infection and Drug Resistance</i> , 2022, Volume 15, 373-385.	1.1	24
627	A comprehensive review on COVID-19 vaccines: development, effectiveness, adverse effects, distribution and challenges. <i>VirusDisease</i> , 2022, 33, 1-22.	1.0	47
628	Implication of the emergence of the delta (B.1.617.2) variants on vaccine effectiveness. <i>Infection</i> , 2022, , 1.	2.3	15
629	Covid-19 vaccine acceptance and associated factors among pregnant women in Pennsylvania 2020. <i>Preventive Medicine Reports</i> , 2022, 26, 101713.	0.8	20
630	HLA-A*03:01 is associated with increased risk of fever, chills, and stronger side effects from Pfizer-BioNTech COVID-19 vaccination. <i>Human Genetics and Genomics Advances</i> , 2022, 3, 100084.	1.0	21
631	County-level vaccination coverage and rates of COVID-19 cases and deaths in the United States: An ecological analysis. <i>The Lancet Regional Health Americas</i> , 2022, 9, 100191.	1.5	13
632	Acquired Thrombotic Thrombocytopenic Purpura After BNT162b2 COVID-19 Vaccine: Case Report and Literature Review. <i>Laboratory Medicine</i> , 2022, 53, e145-e148.	0.8	8
633	A Qualitative RT-PCR Assay for the Specific Identification of the SARS-CoV-2 B.1.1.529 (Omicron) Variant of Concern. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
634	Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. <i>European Heart Journal</i> , 2022, 43, 1157-1172.	1.0	297
635	Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. <i>Lancet Microbe</i> , The, 2022, 3, e274-e283.	3.4	51
636	Long-term efficacy and safety of SARS-CoV-2 vaccination in patients with chronic kidney disease, on dialysis or after kidney transplantation: a national prospective observational cohort study. <i>BMC Nephrology</i> , 2022, 23, 55.	0.8	20
637	Severity of COVID-19 Infection Using Chest Computed Tomography Severity Score Index Among Vaccinated and Unvaccinated COVID-19-Positive Healthcare Workers: An Analytical Cross-Sectional Study. <i>Cureus</i> , 2022, 14, e22087.	0.2	7
638	COVID-19 Vaccination Coverage in Patients with Rheumatic Diseases in a German Outpatient Clinic: An Observational Study. <i>Vaccines</i> , 2022, 10, 253.	2.1	6
639	Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines. <i>Canadian Journal of Infectious Diseases and Medical Microbiology</i> , 2022, 2022, 1-16.	0.7	2

#	ARTICLE	IF	CITATIONS
640	Comparative Effectiveness of mRNA-based BNT162b2 Vaccine versus Adenovirus Vectorâ€‘Based Ad26.COVS Vaccine for the Prevention of COVID-19 among Dialysis Patients. <i>Journal of the American Society of Nephrology</i> : JASN, 2022, 33, 688-697.	3.0	14
643	Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults. <i>Lancet Microbe</i> , The, 2022, 3, e173-e183.	3.4	31
644	Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients. <i>JAMA Internal Medicine</i> , 2022, 182, 165.	2.6	100
645	Survival and risk of COVID-19 after SARS-COV-2 vaccination in a series of 2391 cancer patients. <i>European Journal of Cancer</i> , 2022, 165, 174-183.	1.3	14
646	Humoral and cellular response to COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases under real-life conditions. <i>Rheumatology</i> , 2022, 61, SI180-SI188.	0.9	37
647	Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months. <i>Clinical Journal of the American Society of Nephrology</i> : CJASN, 2022, 17, 403-413.	2.2	43
649	Final Analysis of Efficacy and Safety of Single-Dose Ad26.COVS. <i>New England Journal of Medicine</i> , 2022, 386, 847-860.	13.9	132
650	Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. <i>Cell</i> , 2022, 185, 896-915.e19.	13.5	189
651	Comparing real-life effectiveness of various COVID-19 vaccine regimens during the delta variant-dominant pandemic: a test-negative case-control study. <i>Emerging Microbes and Infections</i> , 2022, 11, 585-592.	3.0	50
652	A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	94
653	COVIDâ€‘19 vaccination in patients receiving allergen immunotherapy (AIT) or biologicalsâ€‘EAAACI recommendations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2313-2336.	2.7	12
654	Ad26.COVS breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern. <i>Cell Reports Medicine</i> , 2022, 3, 100535.	3.3	31
655	A review of the safety and efficacy of current COVID-19 vaccines. <i>Frontiers of Medicine</i> , 2022, 16, 39-55.	1.5	19
656	Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	77
657	Roadmap for Sex-Responsive Influenza and COVID-19 Vaccine Research in Older Adults. <i>Frontiers in Aging</i> , 2022, 3, .	1.2	9
658	The efficacy and effectiveness of the COVID-19 vaccines in reducing infection, severity, hospitalization, and mortality: a systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-20.	1.4	163
659	Asthma, from mild to severe, is an independent prognostic factor for mild to severe Coronavirus disease 2019 (COVIDâ€‘19). <i>Clinical Respiratory Journal</i> , 2022, 16, 293-300.	0.6	11
660	Advanced Materials for SARSâ€‘CoVâ€‘2 Vaccines. <i>Advanced Materials</i> , 2022, 34, e2107781.	11.1	25

#	ARTICLE	IF	CITATIONS
661	COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies. <i>Expert Review of Vaccines</i> , 2022, 21, 435-451.	2.0	48
662	Cancer gene therapy goes viral: viral vector platforms come of age. <i>Radiology and Oncology</i> , 2022, 56, 1-13.	0.6	16
663	Analysis of COVID-19 Risk Following a Ring Vaccination Intervention to Address SARS-CoV-2 Alpha Variant Transmission in Montreal, Canada. <i>JAMA Network Open</i> , 2022, 5, e2147042.	2.8	2
664	Experience of danaparoid to treat vaccine-induced immune thrombocytopenia and thrombosis, VITT. <i>Thrombosis Journal</i> , 2022, 20, 4.	0.9	6
666	Divergent SARS-CoV-2 Omicron-reactive T and B cell responses in COVID-19 vaccine recipients. <i>Science Immunology</i> , 2022, 7, eabo2202.	5.6	337
667	No Effect of Inactivated SARS-CoV-2 Vaccination on in vitro Fertilization Outcomes: A Propensity Score-Matched Study. <i>Journal of Inflammation Research</i> , 2022, Volume 15, 839-849.	1.6	36
668	SARS-CoV-2-specific Vaccine Candidates; the Contribution of Structural Vaccinology. <i>Vaccines</i> , 2022, 10, 236.	2.1	14
669	Analyzing the U.S. Post-marketing safety surveillance of COVID-19 vaccines. <i>Saudi Pharmaceutical Journal</i> , 2022, 30, 180-184.	1.2	5
670	Deterministic and Stochastic Dynamics of COVID-19: The Case Study of Italy and Spain. <i>Computational and Mathematical Methods</i> , 2022, 2022, 1-16.	0.3	2
671	Effectiveness of 3 COVID-19 Vaccines in Preventing SARS-CoV-2 Infections, January-May 2021, Aragon, Spain. <i>Emerging Infectious Diseases</i> , 2022, 28, 591-598.	2.0	7
672	COVID-19 vaccination and breakthrough infections in patients with cancer. <i>Annals of Oncology</i> , 2022, 33, 340-346.	0.6	76
673	Analysis of COVID-19 Vaccine Type and Adverse Effects Following Vaccination. <i>JAMA Network Open</i> , 2021, 4, e2140364.	2.8	243
674	B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab. <i>Arthritis and Rheumatology</i> , 2022, 74, 934-947.	2.9	55
675	The variants of SARS-CoV-2 and the challenges of vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 1366-1372.	2.5	29
676	COVID-19: comprehensive review on mutations and current vaccines. <i>Archives of Microbiology</i> , 2022, 204, 8.	1.0	26
677	Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. <i>Nature</i> , 2022, 602, 676-681.	13.7	72
678	SARS-CoV-2 breakthrough infections in vaccinated individuals: measurement, causes and impact. <i>Nature Reviews Immunology</i> , 2022, 22, 57-65.	10.6	217
679	Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. <i>Nature</i> , 2022, 602, 676-681.	13.7	1,038

#	ARTICLE	IF	CITATIONS
680	Covid-19 Rates by Time since Vaccination during Delta Variant Predominance. , 2022, 1, .		7
681	Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID. <i>Inflammatory Bowel Diseases</i> , 2022, 28, 1497-1505.	0.9	60
682	Comparative Immunogenicity and Effectiveness of mRNA-1273, BNT162b2, and Ad26.COV2.S COVID-19 Vaccines. <i>Journal of Infectious Diseases</i> , 2022, 225, 1141-1150.	1.9	102
683	SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systemic review and meta-analysis. <i>Journal of the Chinese Medical Association</i> , 2022, 85, 421-430.	0.6	10
694	Can a combination of vaccination and face mask wearing contain the COVID-19 pandemic?. <i>Microbial Biotechnology</i> , 2022, 15, 721-737.	2.0	41
695	Cellular and humoral immune response to mRNA COVID-19 vaccination in subjects with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 1207-1211.	2.5	12
696	SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 777212.	1.8	29
698	Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains. <i>Science Translational Medicine</i> , 2021, , eabm3302.	5.8	13
699	Randomised Clinical Trials of COVID-19 Vaccines: Do Adenovirus-Vector Vaccines Have Beneficial Non-Specific Effects?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	10
700	Neutralizing antibody responses against SARS-CoV-2 in vaccinated people with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732210873.	0.5	4
701	The long-term effectiveness of coronavirus disease 2019 (COVID-19) vaccines: A systematic literature review and meta-analysis. <i>Antimicrobial Stewardship & Healthcare Epidemiology</i> , 2022, 2, .	0.2	1
702	An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. <i>Practical Considerations for COVID-19 Special Populations. Clinical and Applied Thrombosis/Hemostasis</i> , 2022, 28, 107602962110566.	0.7	13
703	Reactogenicity to COVID-19 vaccination in the United States of America. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 104.	1.1	6
704	Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines. <i>Npj Vaccines</i> , 2022, 7, 22.	2.9	14
705	Knowledge, Attitudes, and Perception towards COVID-19 Vaccination among the Adult Population: A Cross-Sectional Study in Turkey. <i>Vaccines</i> , 2022, 10, 278.	2.1	19
706	Vaccination provides protection from respiratory deterioration and death among hospitalized COVID-19 patients: Differences between vector and mRNA vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 2849-2854.	2.5	19
707	Delayed Mortality Among Solid Organ Transplant Recipients Hospitalized for COVID-19. <i>Clinical Infectious Diseases</i> , 2024, 78, 711-718.	2.9	6
709	Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany. <i>Frontiers in Immunology</i> , 2022, 13, 828053.	2.2	11

#	ARTICLE	IF	CITATIONS
710	Efficacy and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis. <i>Vaccines</i> , 2022, 10, 350.	2.1	44
711	COVID-19 Vaccine: Between Myth and Truth. <i>Vaccines</i> , 2022, 10, 349.	2.1	12
712	Non-clinical immunogenicity, biodistribution and toxicology evaluation of a chimpanzee adenovirus-based COVID-19 vaccine in rat and rhesus macaque. <i>Archives of Toxicology</i> , 2022, 96, 1437-1453.	1.9	5
713	The COVID-19 vaccine: Attitudes and vaccination in patients with autoimmune inflammatory rheumatic diseases. <i>Rheumatology & Autoimmunity</i> , 2022, 2, 82-91.	0.3	11
714	Fighting the SARS-CoV-2 pandemic requires a global approach to understanding the heterogeneity of vaccine responses. <i>Nature Immunology</i> , 2022, 23, 360-370.	7.0	34
715	Durability and expansion of neutralizing antibody breadth following Ad26.COV2.S vaccination of mice. <i>Npj Vaccines</i> , 2022, 7, 23.	2.9	6
717	SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic. <i>Frontiers of Medicine</i> , 2022, 16, 185-195.	1.5	11
718	Efficacy of COVID-19 vaccines in patients taking immunosuppressants. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 875-880.	0.5	38
719	Exploring Data and Literature Currently Available on the COVID-19 Vaccines. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2022, 12, 7-12.	0.4	1
720	Therapeutic peptides: current applications and future directions. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 48.	7.1	454
721	Clinical and Molecular Relationships between COVID-19 and Feline Infectious Peritonitis (FIP). <i>Viruses</i> , 2022, 14, 481.	1.5	9
723	COVID-19: vaccines, efficacy and effects on variants. <i>Current Opinion in Pulmonary Medicine</i> , 2022, 28, 180-191.	1.2	24
724	Intracellular Reverse Transcription of Pfizer BioNTech COVID-19 mRNA Vaccine BNT162b2 In Vitro in Human Liver Cell Line. <i>Current Issues in Molecular Biology</i> , 2022, 44, 1115-1126.	1.0	63
725	COVID-19 in the Critically Ill Patient. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 365-377.	1.9	5
726	Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: a cross-sectional study. <i>BMC Infectious Diseases</i> , 2022, 22, 179.	1.3	18
727	COVID-19 Vaccines: An Overview of Different Platforms. <i>Bioengineering</i> , 2022, 9, 72.	1.6	32
729	Comparative Evaluation of Rapid Isothermal Amplification and Antigen Assays for Screening Testing of SARS-CoV-2. <i>Viruses</i> , 2022, 14, 468.	1.5	4
730	Adverse Events Reporting Quality of Randomized Controlled Trials of COVID-19 Vaccine Using the CONSORT Criteria for Reporting Harms: A Systematic Review. <i>Vaccines</i> , 2022, 10, 313.	2.1	5

#	ARTICLE	IF	CITATIONS
755	Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It. <i>Frontiers in Drug Discovery</i> , 2022, 2, .	1.1	4
756	Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System. <i>Annals of Neurology</i> , 2022, 91, 756-771.	2.8	78
758	Characterization of Serum and Mucosal SARS-CoV-2-Antibodies in HIV-1-Infected Subjects after BNT162b2 mRNA Vaccination or SARS-CoV-2 Infection. <i>Viruses</i> , 2022, 14, 651.	1.5	17
759	SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021. <i>Emerging Infectious Diseases</i> , 2022, 28, 753-756.	2.0	5
760	Immunity to SARS-CoV-2: What Do We Know and Should We Be Testing for It?. <i>Journal of Clinical Microbiology</i> , 2022, 60, e0048221.	1.8	21
761	Efficacy of approved vaccines to prevent COVID-19: a systematic review and network meta-analysis of reconstructed individual patient data from randomized trials. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2022, , 1-10.	0.8	3
762	A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders. <i>Dermatologic Therapy</i> , 2022, 35, e15461.	0.8	31
763	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac124.	0.4	25
764	SARS-CoV-2 Vaccination and the Bridge between First and Fourth Dose: Where Are We?. <i>Vaccines</i> , 2022, 10, 444.	2.1	11
765	A Recombinant Subunit Vaccine Induces a Potent, Broadly Neutralizing, and Durable Antibody Response in Macaques against the SARS-CoV-2 P.1 (Gamma) Variant. <i>ACS Infectious Diseases</i> , 2022, 8, 825-840.	1.8	3
767	Longitudinal Humoral and Cellular Immune Responses Following SARS-CoV-2 Vaccination in Patients with Myeloid and Lymphoid Neoplasms Compared to a Reference Cohort: Results of a Prospective Trial of the East German Study Group for Hematology and Oncology (OSHO). <i>Cancers</i> , 2022, 14, 1544.	1.7	3
768	COVID-19 Vaccine Effectiveness: A Review of the First 6 Months of COVID-19 Vaccine Availability (1) Tj ETQq1 1 0.784314 rgBT /Overbo	2.1	9
769	Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1032.	3.8	57
770	Best practice approaches to outpatient management of people living with Parkinson's disease during the COVID-19 pandemic. <i>Journal of Neural Transmission</i> , 2022, 129, 1377-1385.	1.4	2
771	A bacterial extracellular vesicle-based intranasal vaccine against SARS-CoV-2 protects against disease and elicits neutralizing antibodies to wild-type and Delta variants. <i>Journal of Extracellular Vesicles</i> , 2022, 11, e12192.	5.5	60
772	Not All That Is Droopy Post Ad26.COVS (JNJ) Vaccine Is Bell's Palsy: A Rare Case of Isolated Dorsal Pontine Stroke Causing Ipsilateral Complete Hemi-Facial Palsy. <i>Cureus</i> , 2022, 14, e23195.	0.2	2
773	Durability of the Single-Dose Ad26.COVS Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge. <i>JAMA Network Open</i> , 2022, 5, e222959.	2.8	42
774	Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention. <i>Stem Cell Research and Therapy</i> , 2022, 13, 112.	2.4	14

#	ARTICLE	IF	CITATIONS
776	Vaccine protection against the SARS-CoV-2 Omicron variant in macaques. <i>Cell</i> , 2022, 185, 1549-1555.e11.	13.5	59
777	Selection and Validation of siRNAs Preventing Uptake and Replication of SARS-CoV-2. <i>Frontiers in Bioengineering and Biotechnology</i> , 2022, 10, 801870.	2.0	13
778	Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. <i>PeerJ</i> , 2022, 10, e13083.	0.9	14
779	Pulmonary Procedures in the COVID-19 Era. <i>Current Pulmonology Reports</i> , 2022, 11, 39-47.	0.5	2
780	COVID-19 Vaccination of Individuals with Down Syndrome—Data from the Trisomy 21 Research Society Survey on Safety, Efficacy, and Factors Associated with the Decision to Be Vaccinated. <i>Vaccines</i> , 2022, 10, 530.	2.1	8
781	Antigen—Antibody Complex-Guided Exploration of the Hotspots Conferring the Immune-Escaping Ability of the SARS-CoV-2 RBD. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 797132.	1.6	3
782	Effectiveness of Ad26.COV2.S Vaccine vs BNT162b2 Vaccine for COVID-19 Hospitalizations. <i>JAMA Network Open</i> , 2022, 5, e220868.	2.8	20
783	Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. <i>Lancet, The</i> , 2022, 399, 1141-1153.	6.3	51
784	Nurturing Innovation at the Roots: The Success of COVID-19 Vaccination in American Indian and Alaska Native Communities. <i>American Journal of Public Health</i> , 2022, 112, 383-387.	1.5	24
785	Onset of Oral Lichenoid Lesions and Oral Lichen Planus Following COVID-19 Vaccination: A Retrospective Analysis of about 300,000 Vaccinated Patients. <i>Vaccines</i> , 2022, 10, 480.	2.1	15
786	The Immune Response, Safety, and Efficacy of Emergency Use Authorization-Granted COVID-19 Vaccines: A Review. <i>Open Microbiology Journal</i> , 2022, 16, .	0.2	1
788	Comparative effectiveness of the BNT162b2 and ChAdOx1 vaccines against Covid-19 in people over 50. <i>Nature Communications</i> , 2022, 13, 1519.	5.8	13
789	Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients. <i>Frontiers in Microbiology</i> , 2022, 13, 816778.	1.5	12
791	Extension and Severity of Self-Reported Side Effects of Seven COVID-19 Vaccines in Mexican Population. <i>Frontiers in Public Health</i> , 2022, 10, 834744.	1.3	16
792	Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies. <i>Frontiers in Immunology</i> , 2022, 13, 797589.	2.2	30
793	Neuroimmunology and Neurological Manifestations of COVID-19. , 0, , .		0
795	Divergent trajectories of antiviral memory after SARS-CoV-2 infection. <i>Nature Communications</i> , 2022, 13, 1251.	5.8	20
796	COVID-19 Vaccination and Rates of Infections, Hospitalizations, ICU Admissions, and Deaths in the European Economic Area during Autumn 2021 Wave of SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 437.	2.1	21

#	ARTICLE	IF	CITATIONS
797	A Comparative Analysis of COVID-19 Vaccines Based on over 580,000 Cases from the Vaccination Adverse Event Reporting System. <i>Vaccines</i> , 2022, 10, 408.	2.1	9
798	Postvaccination SARS-CoV-2 Infections among Healthcare Professionals: A Real World Evidence Study. <i>Vaccines</i> , 2022, 10, 511.	2.1	1
799	SARS-CoV-2 Infection and Vaccination Outcomes in Multiple Sclerosis. <i>Neurology: Clinical Practice</i> , 2022, 12, .	0.8	9
801	COVID-19 Outbreaks in Nursing Homes Despite Full Vaccination with BNT162b2 of a Majority of Residents. <i>Gerontology</i> , 2022, 68, 1384-1392.	1.4	9
802	COVID-19 vaccination in patients with immune thrombocytopenia. <i>Blood Advances</i> , 2022, 6, 1637-1644.	2.5	30
803	A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection. <i>Science Immunology</i> , 2022, 7, eabo0226.	5.6	22
804	Insights for Oncology Trials Garnered From the Rapid Development of an mRNA COVID-19 Vaccine. <i>Cancer Journal (Sudbury, Mass)</i> , 2022, 28, 146-150.	1.0	0
805	COVID-19 mRNA vaccine in patients with lymphoid malignancy or anti-CD20 antibody therapy: a systematic review and meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	7
806	Does the COVID-19 personal protective equipment impair the surgeon's performance?. <i>Archives of Orthopaedic and Trauma Surgery</i> , 2023, 143, 1989-1997.	1.3	2
807	The vaccinia-based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses. <i>Immunology and Cell Biology</i> , 2022, 100, 250-266.	1.0	1
808	No increased incidence of venous thrombosis or pulmonary embolism after SARS-CoV-2 vaccination in Germany. <i>Public Health</i> , 2022, 207, 14-18.	1.4	5
809	RapidQ: A reader-free microfluidic platform for the quantitation of antibodies against the SARS-CoV-2 spike protein. <i>Biomicrofluidics</i> , 2022, 16, 024105.	1.2	2
810	Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination. <i>Npj Vaccines</i> , 2022, 7, 31.	2.9	21
812	SARS-CoV-2 and its variants of concern including Omicron: A never ending pandemic. <i>Chemical Biology and Drug Design</i> , 2022, 99, 769-788.	1.5	37
813	Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial. <i>Vaccine</i> , 2022, 40, 1483-1492.	1.7	32
814	The Fragility of Statistically Significant Results in Randomized Clinical Trials for COVID-19. <i>JAMA Network Open</i> , 2022, 5, e222973.	2.8	16
816	High Asymptomatic Carriage With the Omicron Variant in South Africa. <i>Clinical Infectious Diseases</i> , 2022, 75, e289-e292.	2.9	74
817	ChAdOx1 adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination. <i>European Journal of Immunology</i> , 2022, 52, 936-945.	1.6	12

#	ARTICLE	IF	CITATIONS
818	A SARS-CoV-2 Wuhan spike virosome vaccine induces superior neutralization breadth compared to one using the Beta spike. <i>Scientific Reports</i> , 2022, 12, 3884.	1.6	11
819	A COVID-19 Primer for Primary Care Clinicians. <i>Current Problems in Pediatric and Adolescent Health Care</i> , 2022, , 101180.	0.8	2
820	Study of humoral and cellular immunity in vaccinated with mRNA. <i>Apms</i> , 2022, 130, 261-269.	0.9	3
821	Adverse events following vaccination against coronavirus disease 2019. <i>Kosin Medical Journal</i> , 2022, 37, 18-26.	0.1	0
822	Safety and immunogenicity of 3 formulations of a Sabin inactivated poliovirus vaccine produced on the PER.C6 [®] cell line: A phase 2, double-blind, randomized, controlled study in infants vaccinated at 6, 10 and 14 weeks of age. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-11.	1.4	1
823	Human adenovirus type 26 basic biology and its usage as vaccine vector. <i>Reviews in Medical Virology</i> , 2022, 32, e2338.	3.9	4
824	Utilization of Viral Vector Vaccines in Preparing for Future Pandemics. <i>Vaccines</i> , 2022, 10, 436.	2.1	4
826	A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques. <i>Science Translational Medicine</i> , 2022, 14, eabm4996.	5.8	13
827	Current challenges in different approaches to control COVID-19: a comprehensive review. <i>Bulletin of the National Research Centre</i> , 2022, 46, 47.	0.7	4
828	Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong. <i>EBioMedicine</i> , 2022, 77, 103904.	2.7	93
829	Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis. <i>Journal of Headache and Pain</i> , 2022, 23, 41.	2.5	43
830	SARS-CoV-2 infection in public hospital medical doctors in an Eastern Cape metro. <i>Southern African Journal of Infectious Diseases</i> , 2022, 37, 335.	0.3	1
831	Association of severity and mortality of Covid-19 cases among acute kidney injury and sexual dimorphism. <i>Molecular Biology Reports</i> , 2022, 49, 6753-6762.	1.0	1
832	mRNA Vaccines as an Efficient Approach for the Rapid and Robust Induction of Host Immunity Against SARS-CoV-2. <i>SN Comprehensive Clinical Medicine</i> , 2022, 4, 88.	0.3	5
833	Comparison of Clinical Characteristics and Outcome Between Vaccinated and Non-Vaccinated Patients of Covid-19 During the Delta Variant-Dominated Fourth Wave in a Tertiary Care Hospital in Karachi, Pakistan. <i>Cureus</i> , 2022, 14, e23726.	0.2	3
834	Proporci3n de la poblaci3n con vacunaci3n completa contra Covid-19 a nivel mundial. <i>Repertorio De Medicina Y Cirugia</i> , 0, , 14-18.	0.0	0
835	Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort. <i>The Lancet Healthy Longevity</i> , 2022, 3, e242-e252.	2.0	54
836	Development of COVID 19 vaccine: A summarized review on global trials, efficacy, and effectiveness on variants. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022, 16, 102482.	1.8	9

#	ARTICLE	IF	CITATIONS
837	Real World Estimate of Vaccination Protection in Individuals Hospitalized for COVID-19. Vaccines, 2022, 10, 550.	2.1	4
838	Patients With Inflammatory Bowel Diseases Have Impaired Antibody Production After Anti-SARS-CoV-2 Vaccination: Results From a Panhellenic Registry. Inflammatory Bowel Diseases, 2023, 29, 228-237.	0.9	4
840	Antibody responses induced by the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in a single community hospital in Japan. Journal of Infection and Chemotherapy, 2022, 28, 539-542.	0.8	1
841	COVID-19 vaccine in patients with Dravet syndrome: Observations and real-world experiences. Epilepsia, 2022, 63, 1778-1786.	2.6	13
842	Advances in Pathogenesis, Progression, Potential Targets and Targeted Therapeutic Strategies in SARS-CoV-2-Induced COVID-19. Frontiers in Immunology, 2022, 13, 834942.	2.2	10
843	What have we learned about the allergenicity and adverse reactions associated with the severe acute respiratory syndrome coronavirus 2 vaccines: One year later. Annals of Allergy, Asthma and Immunology, 2022, 129, 40-51.	0.5	14
844	Vaccination and natural immunity: Advantages and risks as a matter of public health policy. The Lancet Regional Health Americas, 2022, 8, 100242.	1.5	1
845	Case Report: Precision COVID-19 Immunization Strategy to Overcome Individual Fragility: A Case of Generalized Lipodystrophy Type 4. Frontiers in Immunology, 2022, 13, 869042.	2.2	1
846	Reporting and data sharing level for COVID-19 vaccine trials: A cross-sectional study. EBioMedicine, 2022, 78, 103962.	2.7	8
847	The NJ Alliance for Clinical and Translational Science (NJ ACTS) experience: Responding at "warp speed" to COVID-19. Journal of Clinical and Translational Science, 2022, 6, .	0.3	2
848	High viral loads: what drives fatal cases of COVID-19 in vaccinees? " an autopsy study. Modern Pathology, 2022, 35, 1013-1021.	2.9	5
849	Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena. Viruses, 2022, 14, 759.	1.5	41
850	Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments. European Journal of Cancer, 2022, 166, 229-239.	1.3	17
851	Effectiveness estimates of three COVID-19 vaccines based on observational data from Puerto Rico. The Lancet Regional Health Americas, 2022, 9, 100212.	1.5	17
852	The humoral response to SARS-COV-2 vaccines in MS patients: A case series exploring the impact of DMT, lymphocyte count, immunoglobulins, and vaccine type. Multiple Sclerosis and Related Disorders, 2022, 61, 103785.	0.9	6
853	SARS-CoV-2 infections in mRNA vaccinated individuals are biased for viruses encoding spike E484K and associated with reduced infectious virus loads that correlate with respiratory antiviral IgG levels. Journal of Clinical Virology, 2022, 150-151, 105151.	1.6	11
854	Efficacy and safety of heterologous booster vaccination with Ad26.COV2.S after BNT162b2 mRNA COVID-19 vaccine in haematological patients with no antibody response. British Journal of Haematology, 2022, 196, 577-584.	1.2	33
856	Molecular and Clinical Aspects of COVID-19 Vaccines and Other Therapeutic Interventions Apropos Emerging Variants of Concern. Frontiers in Pharmacology, 2021, 12, 778219.	1.6	0

#	ARTICLE	IF	CITATIONS
857	ESGE and ESGENA Position Statement on gastrointestinal endoscopy and COVID-19: Updated guidance for the era of vaccines and viral variants. <i>Endoscopy</i> , 2022, 54, 211-216.	1.0	12
858	Antibody Response to SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Disease: Results of a Single-Center Cohort Study in a Tertiary Hospital in Germany. <i>Digestive Diseases</i> , 2022, 40, 719-727.	0.8	14
860	Immunogenicity and safety of adenovirus-based vector vaccines for COVID-19: a systematic review and meta-analysis. <i>Medical Journal of Indonesia</i> , 2022, 30, 264-78.	0.2	1
861	Vaccination Against COVID-19: Emerging Issues and Future Prospects. <i>Vestnik Rossiiskoi Akademii Meditsinskikh Nauk</i> , 2021, 76, 652-660.	0.2	1
863	Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population. <i>Vaccines</i> , 2021, 9, 1435.	2.1	8
865	HLA-A*02:01 restricted T cell receptors against the highly conserved SARS-CoV-2 polymerase cross-react with human coronaviruses. <i>Cell Reports</i> , 2021, 37, 110167.	2.9	18
866	A Cost-Benefit Analysis of COVID-19 Vaccination in Catalonia. <i>Vaccines</i> , 2022, 10, 59.	2.1	19
868	Headache Worsening after COVID-19 Vaccination: An Online Questionnaire-Based Study on 841 Patients with Migraine. <i>Journal of Clinical Medicine</i> , 2021, 10, 5914.	1.0	20
870	Criteria for judging the immune markers of COVID-19 disease vaccines. <i>MedComm</i> , 2022, 3, 1-12.	3.1	3
874	COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review. <i>3 Biotech</i> , 2022, 12, 15.	1.1	20
875	Factors Influencing COVID-19 Vaccination Intentions Among College Students: A Cross-Sectional Study in India. <i>Frontiers in Public Health</i> , 2021, 9, 735902.	1.3	28
876	Effectiveness of the WHO-Authorized COVID-19 Vaccines: A Rapid Review of Global Reports till 30 June 2021. <i>Vaccines</i> , 2021, 9, 1489.	2.1	18
877	An Overview of COVID-19 and Its Vaccines. <i>Biology Bulletin Reviews</i> , 2021, 11, 47-64.	0.3	0
879	Learning through a Pandemic: The Current State of Knowledge on COVID-19 and Cancer. <i>Cancer Discovery</i> , 2022, 12, 303-330.	7.7	24
883	Vaccination Opportunities in Multiple Sclerosis Patients Treated with Cladribine Tablets. <i>Current Neuropharmacology</i> , 2022, 20, 1811-1815.	1.4	1
884	Calibration of two validated SARS-CoV-2 pseudovirus neutralization assays for COVID-19 vaccine evaluation. <i>Scientific Reports</i> , 2021, 11, 23921.	1.6	44
886	Advances in the design and development of SARS-CoV-2 vaccines. <i>Military Medical Research</i> , 2021, 8, 67.	1.9	26
887	Uveitis and Other Ocular Complications Following COVID-19 Vaccination. <i>Journal of Clinical Medicine</i> , 2021, 10, 5960.	1.0	92

#	ARTICLE	IF	CITATIONS
888	COVID-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran. <i>Vaccines</i> , 2022, 10, 37.	2.1	15
890	Immune Response to COVID-19. , 0, , .		1
892	Disentangling post-vaccination symptoms from early COVID-19. <i>EClinicalMedicine</i> , 2021, 42, 101212.	3.2	8
896	Neuro-Ophthalmological Complications of the COVID-19 Vaccines: A Systematic Review. <i>Journal of Neuro-Ophthalmology</i> , 2022, 42, 154-162.	0.4	12
897	Cerebral Venous Sinus Thrombosis Associated with Vaccine-Induced Thrombotic Thrombocytopeniaâ€”A Narrative Review. <i>Clinical and Translational Neuroscience</i> , 2022, 6, 11.	0.4	0
898	A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques. <i>Frontiers in Immunology</i> , 2022, 13, 857440.	2.2	15
899	ChAdOx1 nCoV-19 vaccine elicits monoclonal antibodies with cross-neutralizing activity against SARS-CoV-2 viral variants. <i>Cell Reports</i> , 2022, 39, 110757.	2.9	10
900	Prevalence and Safety of COVID-19 Vaccination in Community-Dwelling People with Dementia: Findings from a Tertiary Memory Clinic in Italy. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1467-1474.	1.2	2
901	Drop the Needle; A Temperature Stable Oral Tablet Vaccine Is Protective against Respiratory Viral Pathogens. <i>Vaccines</i> , 2022, 10, 593.	2.1	7
904	Observations and perspectives on adaptive immunity to SARS-CoV-2. <i>Clinical Infectious Diseases</i> , 2022, , .	2.9	10
906	Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant. <i>JAMA Network Open</i> , 2022, 5, e226822.	2.8	71
907	Impact of Preexisting Antiâ€”Adenovirus 26 Humoral Immunity on Immunogenicity of the Ad26.COV2.S Coronavirus Disease 2019 Vaccine. <i>Journal of Infectious Diseases</i> , 2022, 226, 979-982.	1.9	7
908	Efficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction. <i>Expert Review of Vaccines</i> , 2022, 21, 873-875.	2.0	7
909	Vestibular Neuritis Following COVID-19 Vaccination: A Retrospective Study. <i>Cureus</i> , 2022, , .	0.2	2
910	Ad26.COV2.S prevents upregulation of SARS-CoV-2 induced pathways of inflammation and thrombosis in hamsters and rhesus macaques. <i>PLoS Pathogens</i> , 2022, 18, e1009990.	2.1	4
911	Research progress on vaccine efficacy against SARS-CoV-2 variants of concern. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	10
912	COVID-19 Neutralizing Antibodies in Breast Milk of Mothers Vaccinated with Three Different Vaccines in Mexico. <i>Vaccines</i> , 2022, 10, 629.	2.1	8
913	SARS-CoV-2 variants C.1.2 and B.1.621 (Mu) partially evade neutralization by antibodies elicited upon infection or vaccination. <i>Cell Reports</i> , 2022, 39, 110754.	2.9	5

#	ARTICLE	IF	CITATIONS
914	Reactogenicity of the Messenger RNA SARS-CoV-2 Vaccines Associated With Immunogenicity in Patients With Autoimmune and Inflammatory Disease. <i>Arthritis Care and Research</i> , 2022, 74, 1953-1960.	1.5	5
916	The Delta SARS-CoV-2 Variant of Concern Induces Distinct Pathogenic Patterns of Respiratory Disease in K18-hACE2 Transgenic Mice Compared to the Ancestral Strain from Wuhan. <i>MBio</i> , 2022, 13, e0068322.	1.8	17
917	Impact of SARS-CoV-2 Gamma lineage introduction and COVID-19 vaccination on the epidemiological landscape of a Brazilian city. <i>Communications Medicine</i> , 2022, 2, .	1.9	32
918	Cerebrovascular Complications of COVID-19 and COVID-19 Vaccination. <i>Circulation Research</i> , 2022, 130, 1187-1203.	2.0	20
919	Accelerating clinical trial development in vaccinology: COVID-19 and beyond. <i>Current Opinion in Immunology</i> , 2022, 76, 102206.	2.4	4
920	Impact of Remdesivir Incorporation along the Primer Strand on SARS-CoV-2 RNA-Dependent RNA Polymerase. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 2456-2465.	2.5	7
921	COVID-19 breakthrough infections and hospitalizations among vaccinated patients with dementia in the United States between December 2020 and August 2021. <i>Alzheimer's and Dementia</i> , 2023, 19, 421-432.	0.4	26
922	Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines. <i>Reviews in Medical Virology</i> , 2022, 32, e2346.	3.9	16
923	Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1949-1957.	1.5	39
924	Incidence and Risk Factors of COVID-19 Vaccine Breakthrough Infections: A Prospective Cohort Study in Belgium. <i>Viruses</i> , 2022, 14, 802.	1.5	30
925	The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines. <i>Vaccines</i> , 2022, 10, 591.	2.1	27
926	A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	62
929	Safety of Global SARS-CoV-2 Vaccines, a Meta-Analysis. <i>Vaccines</i> , 2022, 10, 596.	2.1	14
930	Quantitative serology for SARS-CoV-2 using self-collected saliva and finger-stick blood. <i>Scientific Reports</i> , 2022, 12, 6560.	1.6	10
931	SARS-CoV-2 Spike Protein Expression In Vitro and Hematologic Effects in Mice Vaccinated With AZD1222 (ChAdOx1 nCoV-19). <i>Frontiers in Immunology</i> , 2022, 13, 836492.	2.2	8
934	Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity. <i>Viruses</i> , 2022, 14, 803.	1.5	10
935	Cross-reactive antibodies elicited to conserved epitopes on SARS-CoV-2 spike protein after infection and vaccination. <i>Scientific Reports</i> , 2022, 12, 6496.	1.6	20
936	Effectiveness of mRNA-1273, BNT162b2, and JNJ-78436735 COVID-19 Vaccines Among US Military Personnel Before and During the Predominance of the Delta Variant. <i>JAMA Network Open</i> , 2022, 5, e228071.	2.8	11

#	ARTICLE	IF	CITATIONS
937	Attitudes of COVID-19 vaccination among college students: A systematic review and meta-analysis of willingness, associated determinants, and reasons for hesitancy. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-13.	1.4	16
938	Balancing Benefits and Harms of COVID-19 Vaccines: Lessons from the Ongoing Mass Vaccination Campaign in Lombardy, Italy. <i>Vaccines</i> , 2022, 10, 623.	2.1	2
939	Neurofibromatosis: New Clinical Challenges in the Era of COVID-19. <i>Biomedicines</i> , 2022, 10, 940.	1.4	4
940	New Frontier in Antiviral Drugs for Disorders of the Respiratory System. <i>Recent Advances in Anti-Infective Drug Discovery</i> , 2022, 17, 2-12.	0.4	1
941	COVID-19 Vaccination and Estimated Public Health Impact in California. <i>JAMA Network Open</i> , 2022, 5, e228526.	2.8	15
942	SARS-CoV-2 Infection: Host Response, Immunity, and Therapeutic Targets. <i>Inflammation</i> , 2022, 45, 1430-1449.	1.7	16
943	Impact of prior vaccination on clinical outcomes of patients with COVID-19. <i>Emerging Microbes and Infections</i> , 2022, 11, 1316-1324.	3.0	7
944	Seroconversion Rates After the Second COVID-19 Vaccination in Patients With Systemic Light Chain (AL) amyloidosis. <i>HemaSphere</i> , 2022, 6, e688.	1.2	1
945	Real-world evidence from over one million COVID-19 vaccinations is consistent with reactivation of the varicella-zoster virus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1342-1348.	1.3	28
946	SARS-COV-2 "the pandemic of the XXI century, clinical manifestations" neurological implications. <i>Journal of Medicine and Life</i> , 2022, 15, 319-327.	0.4	2
947	Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity.. <i>Science Translational Medicine</i> , 2021, , eabj6824.	5.8	11
949	Current strategies and future perspectives in COVID-19 therapy. , 2022, , 169-227.		0
950	COVID-19 vaccines and coronavirus 19 variants including alpha, delta, and omicron: present status and future directions. , 0, 2, .		7
951	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
952	Complete (Humoral and Cellular) Response to Vaccination against COVID-19 in a Group of Healthcare Workers-Assessment of Factors Affecting Immunogenicity. <i>Vaccines</i> , 2022, 10, 710.	2.1	9
953	Analysis of the Protective Efficacy of Approved COVID-19 Vaccines Against Various Mutants. <i>Frontiers in Immunology</i> , 2022, 13, 804945.	2.2	12
954	Effectiveness of COVID-19 Vaccines in the General Population of an Italian Region before and during the Omicron Wave. <i>Vaccines</i> , 2022, 10, 662.	2.1	17
955	A Bivalent COVID-19 Vaccine Based on Alpha and Beta Variants Elicits Potent and Broad Immune Responses in Mice against SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 702.	2.1	18

#	ARTICLE	IF	CITATIONS
956	Clinical and Immunologic Efficacy of the Recombinant Adenovirus Type-5-Vectored (CanSino Bio) Vaccine in University Professors during the COVID-19 Delta Wave. <i>Vaccines</i> , 2022, 10, 656.	2.1	4
957	Borrowing historical information for non-inferiority trials on Covid-19 vaccines. <i>International Journal of Biostatistics</i> , 2022, .	0.4	2
958	Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19. <i>MBio</i> , 2022, 13, e0018122.	1.8	20
959	Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines. <i>Frontiers in Immunology</i> , 2022, 13, 814365.	2.2	10
960	Determinants of the Hesitancy toward COVID-19 Vaccination in Eastern European Countries and the Relationship with Health and Vaccine Literacy: A Literature Review. <i>Vaccines</i> , 2022, 10, 672.	2.1	35
961	The Effect of Waning on Antibody Levels and Memory B Cell Recall following SARS-CoV-2 Infection or Vaccination. <i>Vaccines</i> , 2022, 10, 696.	2.1	11
962	COVID-19 vaccination status and testing rates in Finland—A potential cause for bias in observational vaccine effectiveness analysis. <i>Influenza and Other Respiratory Viruses</i> , 2022, 16, 842-845.	1.5	3
963	Adverse Audio-Vestibular Effects of Drugs and Vaccines Used in the Treatment and Prevention of COVID-19: A Review. <i>Audiology Research</i> , 2022, 12, 224-248.	0.8	6
964	Impaired Humoral Immunity with Concomitant Preserved T Cell Reactivity in IBD Patients on Treatment with Infliximab 6 Month after Vaccination with the SARS-CoV-2 mRNA Vaccine BNT162b2: A Pilot Study. <i>Journal of Personalized Medicine</i> , 2022, 12, 694.	1.1	6
965	Cytokine Responses to Adenovirus and Adenovirus Vectors. <i>Viruses</i> , 2022, 14, 888.	1.5	18
966	Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects. <i>Frontiers in Immunology</i> , 2022, 13, 843928.	2.2	25
967	Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants. <i>Med</i> , 2022, 3, 406-421.e4.	2.2	17
968	Recent developments in SARS-CoV-2 vaccines: A systematic review of the current studies. <i>Reviews in Medical Virology</i> , 2023, 33, e2359.	3.9	17
969	Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines. <i>Mucosal Immunology</i> , 2022, 15, 584-594.	2.7	41
970	COVID-19 Vaccination Is Safe among Mast Cell Disorder Patients, under Adequate Premedication. <i>Vaccines</i> , 2022, 10, 718.	2.1	9
971	An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19). <i>Cellular and Molecular Biology Letters</i> , 2022, 27, 38.	2.7	11
973	Gearing Up for a Vaccine Requirement: A Mixed Methods Study of COVID-19 Vaccine Confidence Among Workers at an Academic Medical Center. <i>Journal of Healthcare Management</i> , 2022, 67, 206-220.	0.4	2
974	Convergent Evolution of Multiple Mutations Improves the Viral Fitness of SARS-CoV-2 Variants by Balancing Positive and Negative Selection. <i>Biochemistry</i> , 2022, 61, 963-980.	1.2	12

#	ARTICLE	IF	CITATIONS
975	Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates. <i>PLoS Biology</i> , 2022, 20, e3001609.	2.6	14
976	Fear of COVID-19 predicts vaccination willingness 14 months later. <i>Journal of Anxiety Disorders</i> , 2022, 88, 102574.	1.5	32
977	COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants. <i>Scientific Reports</i> , 2022, 12, 7168.	1.6	15
978	Multi-site observational maternal and infant COVID-19 vaccine study (MOMI-vax): a study protocol. <i>BMC Pregnancy and Childbirth</i> , 2022, 22, 402.	0.9	4
979	COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants. <i>Cureus</i> , 2022, , .	0.2	3
980	New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine. <i>Vaccines</i> , 2022, 10, 716.	2.1	17
981	Seroprevalence of SARS-CoV-2 IgG Antibodies and Factors Associated with SARS-CoV-2 IgG Neutralizing Activity among Primary Health Care Workers 6 Months after Vaccination Rollout in France. <i>Viruses</i> , 2022, 14, 957.	1.5	5
982	Adverse Events and Safety of SARS-CoV-2 Vaccines: Whatâ€™s New and Whatâ€™s Next. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2254-2266.	2.0	4
983	Population-Level Effectiveness of COVID-19 Vaccination Program in the United States: Causal Analysis Based on Structural Nested Mean Model. <i>Vaccines</i> , 2022, 10, 726.	2.1	3
984	Timing of headache after COVID-19 vaccines and its association with cerebrovascular events: An analysis of 41,700 VAERS reports. <i>Cephalalgia</i> , 2022, 42, 1207-1217.	1.8	13
985	The Emergence of SARS-CoV-2 Variants With a Lower Antibody Response: A Genomic and Clinical Perspective. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	4
986	Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques. <i>Molecular Therapy</i> , 2022, 30, 2952-2967.	3.7	2
987	COVID-19 vaccines in pregnancy. <i>Trends in Molecular Medicine</i> , 2022, 28, 662-680.	3.5	16
988	Trends and Correlates of Breakthrough Infections With SARS-CoV-2. <i>Frontiers in Public Health</i> , 2022, 10, .	1.3	5
989	nSARS-CoV-2 and COVID-19 Pandemic: From Emergence to Vaccination. <i>Dr Sulaiman Al Habib Medical Journal</i> , 0, , 1.	0.3	0
990	COVID-19â€™from emerging global threat to ongoing pandemic crisis. <i>Baylor University Medical Center Proceedings</i> , 2022, 35, 468-475.	0.2	4
991	Instructing durable humoral immunity for COVID-19 and other vaccinable diseases. <i>Immunity</i> , 2022, 55, 945-964.	6.6	32
992	SARS-CoV-2 vaccine effectiveness against infection, symptomatic and severe COVID-19: a systematic review and meta-analysis. <i>BMC Infectious Diseases</i> , 2022, 22, 439.	1.3	155

#	ARTICLE	IF	CITATIONS
994	Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. <i>New England Journal of Medicine</i> , 2022, 386, 2097-2111.	13.9	147
995	A potential immunological silver bullet for COVID-19: The trivalent chimpanzee adenoviral serotype-68 vector (Tri:ChAd). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2565-2567.	2.7	0
996	COVID-19 in patients with hematologic malignancy. <i>Blood</i> , 2022, 140, 236-252.	0.6	69
997	Adults hospitalized with breakthrough COVID-19 have lower mortality than matched unvaccinated adults. <i>Journal of Internal Medicine</i> , 2022, 292, 377-384.	2.7	8
998	Systematic review and meta-analysis of the effectiveness and perinatal outcomes of COVID-19 vaccination in pregnancy. <i>Nature Communications</i> , 2022, 13, 2414.	5.8	157
1000	Risk Factors Associated With SARS-CoV-2 Breakthrough Infections in Fully mRNA-Vaccinated Individuals: Retrospective Analysis. <i>JMIR Public Health and Surveillance</i> , 2022, 8, e35311.	1.2	13
1001	Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants. <i>Nature Communications</i> , 2022, 13, 2674.	5.8	26
1002	Protocol of safe vaccination against COVID-19 in patients with high risk of allergic reactions. <i>Clinical and Translational Allergy</i> , 2022, 12, .	1.4	9
1003	Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. <i>PLoS Medicine</i> , 2022, 19, e1003991.	3.9	75
1004	High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination. <i>Leukemia and Lymphoma</i> , 2022, 63, 2484-2488.	0.6	7
1005	Cardiovascular and Hematologic Complications of COVID-19 Vaccines. <i>Cardiology in Review</i> , 2022, Publish Ahead of Print, .	0.6	2
1006	Public health impact of covid-19 vaccines in the US: observational study. <i>BMJ, The</i> , 2022, 377, e069317.	3.0	102
1007	Networks of necessity: Simulating COVID-19 mitigation strategies for disabled people and their caregivers. <i>PLoS Computational Biology</i> , 2022, 18, e1010042.	1.5	3
1008	Pre-clinical non-viral vectors exploited for <i>in vivo</i> CRISPR/Cas9 gene editing: an overview. <i>Biomaterials Science</i> , 2022, 10, 3410-3432.	2.6	9
1009	Understanding "Hybrid Immunity" Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines. <i>Clinical Infectious Diseases</i> , 2023, 76, e439-e449.	2.9	23
1010	The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?. <i>Expert Review of Vaccines</i> , 2022, 21, 1071-1086.	2.0	3
1012	Retinal vascular occlusion and SARS-CoV-2 vaccination. <i>Graefe's Archive for Clinical and Experimental Ophthalmology</i> , 2022, 260, 3455-3464.	1.0	13
1013	Correlation Analysis of Anti-SARS-CoV-2 RBD IgG and Neutralizing Antibody against SARS-CoV-2 Omicron Variants after Vaccination. <i>Diagnostics</i> , 2022, 12, 1315.	1.3	18

#	ARTICLE	IF	CITATIONS
1014	Allergic Reactions After the Administration of COVID-19 Vaccines. <i>Frontiers in Public Health</i> , 2022, 10, .	1.3	7
1016	Testing Different COVID-19 Vaccination Strategies Using an Agent-Based Modeling Approach. <i>SN Computer Science</i> , 2022, 3, .	2.3	2
1017	Phage-like particle vaccines are highly immunogenic and protect against pathogenic coronavirus infection and disease. <i>Npj Vaccines</i> , 2022, 7, .	2.9	8
1019	Effectiveness and Durability of mRNA Vaccine-Induced SARS-CoV-2-Specific Humoral and Cellular Immunity in Severe Asthma Patients on Biological Therapy. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	7
1020	A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. <i>Science Bulletin</i> , 2022, 67, 1372-1387.	4.3	54
1021	Role of COVID-19 Vaccines in SARS-CoV-2 Variants. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	37
1022	COVID-19 Outcomes and Vaccination in Patients with Spondyloarthritis. <i>Rheumatology and Therapy</i> , 0, .	1.1	1
1023	Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial. <i>EBioMedicine</i> , 2022, 80, 104073.	2.7	28
1024	A qualitative RT-PCR assay for the specific identification of the SARS-CoV-2 B.1.1.529 (Omicron) Variant of Concern. <i>Journal of Clinical Virology</i> , 2022, 152, 105191.	1.6	15
1025	Viral vector vaccines. <i>Current Opinion in Immunology</i> , 2022, 77, 102210.	2.4	28
1026	COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, , 176-188.	1.8	7
1027	Droplet Microfluidics for High-Resolution Virology. <i>Analytical Chemistry</i> , 2022, 94, 8085-8100.	3.2	6
1028	Benefitâ€“risk evaluation of COVID-19 vaccination in special population groups of interest. <i>Vaccine</i> , 2022, 40, 4348-4360.	1.7	5
1029	Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	16
1030	Humoral and cellular immune memory to four COVID-19 vaccines. <i>Cell</i> , 2022, 185, 2434-2451.e17.	13.5	289
1031	Use of adenovirus type-5 vector vaccines in COVID-19: potential implications for metabolic health?. <i>Minerva Endocrinology</i> , 2022, 47, .	0.6	5
1032	A Single Dose of the Deactivated Rabies-Virus Vected COVID-19 Vaccine, CORAVAX, Is Highly Efficacious and Alleviates Lung Inflammation in the Hamster Model. <i>Viruses</i> , 2022, 14, 1126.	1.5	2
1033	Vaccination against the new coronavirus infection SARS-CoV-2. The current state of the problem. <i>Russian Pediatric Journal</i> , 2022, 25, 139-146.	0.0	0

#	ARTICLE	IF	CITATIONS
1034	COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants. <i>IScience</i> , 2022, 25, 104457.	1.9	8
1035	COVID-19 vaccination hesitancy and its association with altered presentation of primary rhegmatogenous retinal detachment. <i>American Journal of Ophthalmology</i> , 2022, , .	1.7	0
1036	Adenoviral vectors for cardiovascular gene therapy applications: a clinical and industry perspective. <i>Journal of Molecular Medicine</i> , 2022, 100, 875-901.	1.7	8
1037	Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. <i>European Journal of Cancer</i> , 2022, 171, 64-74.	1.3	19
1038	Erythema multiforme in a young adult following COVID-19 infection and vaccination in Tanzania. <i>BMJ Case Reports</i> , 2022, 15, e247168.	0.2	2
1040	Comprehensive narrative review of real-world COVID-19 vaccines: viewpoints and opportunities. <i>Medical Review</i> , 2022, 2, 169-196.	0.3	5
1041	Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. <i>BMJ, The</i> , 0, , e069989.	3.0	78
1042	Changing Dynamics of SARS-CoV-2: A Global Challenge. <i>Applied Sciences (Switzerland)</i> , 2022, 12, 5546.	1.3	3
1043	SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies. <i>International Reviews of Immunology</i> , 2023, 42, 393-414.	1.5	26
1044	Newly Emerged Antiviral Strategies for SARS-CoV-2: From Deciphering Viral Protein Structural Function to the Development of Vaccines, Antibodies, and Small Molecules. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6083.	1.8	10
1045	Functional properties of the spike glycoprotein of the emerging SARS-CoV-2 variant B.1.1.529. <i>Cell Reports</i> , 2022, 39, 110924.	2.9	20
1046	Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2. <i>Vaccine</i> , 2022, 40, 4046-4056.	1.7	24
1047	Randomised trials of COVID-19 vaccines in Africa “ charting the path forward. <i>South African Journal of Science</i> , 2022, 118, .	0.3	1
1048	Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines. <i>Vaccine</i> , 2022, 40, 4017-4025.	1.7	7
1049	Safety of inactivated SARS-CoV-2 vaccines in patients with allergic diseases. <i>Respiratory Research</i> , 2022, 23, .	1.4	2
1050	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. <i>Expert Review of Vaccines</i> , 2022, 21, 1055-1070.	2.0	1
1051	SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition. <i>Cancers</i> , 2022, 14, 2796.	1.7	9
1052	Immunologic response, Efficacy, and Safety of Vaccines against COVID-19 Infection in Healthy and immunosuppressed Children and Adolescents Aged 2 “ 21 years old: A Systematic Review and Meta-analysis. <i>Journal of Clinical Virology</i> , 2022, 153, 105196.	1.6	18

#	ARTICLE	IF	CITATIONS
1053	Durable antibody responses elicited by 1 dose of Ad26.COVS2.S and substantial increase after boosting: 2 randomized clinical trials. <i>Vaccine</i> , 2022, 40, 4403-4411.	1.7	16
1054	Cutaneous leukocytoclastic vasculitis following COVID-19 vaccination with Ad26.COVS2.S vaccine: a case report and literature review. <i>Acta Dermatovenerologica Alpina, Panonica Et Adriatica</i> , 2022, 31, .	0.1	3
1055	Skin involvement in Francisella tularensis infection: a case report of two clinical cases. <i>Acta Dermatovenerologica Alpina, Panonica Et Adriatica</i> , 2022, 31, .	0.1	4
1056	SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 173.	1.1	0
1057	COVID-19 Vaccine Booster Significantly Decreases the Risk of Intensive Care Unit Hospitalization in Heart Failure Patients During the Omicron Variant Wave: A Population-Based Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1058	The efficacy of SARS-CoV-2 antibody response after two dose mRNA vaccination in kidney and heart transplant recipients using a multiplex bead-based assay: Evaluating the factors affecting vaccine response. <i>Archives of Organ Transplantation</i> , 2022, 7, 001-008.	0.2	2
1059	Comparison of BNT162b2-, mRNA-1273- and Ad26.COVS2.S-Elicited IgG and Neutralizing Titers against SARS-CoV-2 and Its Variants. <i>Vaccines</i> , 2022, 10, 858.	2.1	2
1060	Retrospective Cohort Study of the Effectiveness of the Sputnik V and EpiVacCorona Vaccines against the SARS-CoV-2 Delta Variant in Moscow (June-July 2021). <i>Vaccines</i> , 2022, 10, 984.	2.1	10
1061	Solid cancer patients achieve adequate immunogenicity and low rate of severe adverse events after SARS-CoV-2 vaccination. <i>Future Oncology</i> , 2022, 18, 2537-2550.	1.1	4
1062	Evaluating clinical effectiveness of SARS-CoV-2 vaccine in solid organ transplant recipients: A propensity score matched analysis. <i>Transplant Infectious Disease</i> , 2022, 24, .	0.7	5
1063	Adenovirus vector-based vaccines as forefront approaches in fighting the battle against flaviviruses. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	5
1064	Prognostic Value of SARS-CoV-2 Anti-RBD IgG Antibody Quantitation on Clinical Outcomes in Hospitalized COVID-19 Patients. <i>International Journal of General Medicine</i> , 0, Volume 15, 5693-5700.	0.8	1
1066	2022 update on the clinical outcome of coronavirus disease 2019 in haemato-oncology patients. <i>Leukemia Research</i> , 2022, , 106908.	0.4	2
1067	Comparison of the post-marketing safety profile between influenza and COVID-19 vaccines: An analysis of the vaccine adverse event reporting system. <i>Saudi Pharmaceutical Journal</i> , 2022, 30, 1137-1142.	1.2	2
1068	Strategies to improve the vaccine distribution and community awareness of taking COVID-19 vaccine in rural areas in Indonesia. <i>Pharmacia</i> , 2022, 69, 543-553.	0.4	1
1069	SARS-CoV-2: A Master of Immune Evasion. <i>Biomedicines</i> , 2022, 10, 1339.	1.4	24
1070	Plausibility of Claimed Covid-19 Vaccine Efficacies by Age: A Simulation Study. <i>American Journal of Therapeutics</i> , 2022, 29, e495-e499.	0.5	3
1071	Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	33

#	ARTICLE	IF	CITATIONS
1072	Antibody and T cell responses to COVID-19 vaccination in patients receiving anticancer therapies. , 2022, 10, e004766.		11
1073	Exploring the Role of Serology Testing to Strengthen Vaccination Initiatives and Policies for COVID-19 in Asia Pacific Countries and Territories: A Discussion Paper. International Journal of Translational Medicine, 2022, 2, 275-308.	0.1	1
1074	Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection. Nature Communications, 2022, 13, .	5.8	28
1075	Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. Nature Medicine, 2022, 28, 1715-1722.	15.2	29
1076	Addressing COVID-19 vaccine hesitancy. Drugs in Context, 0, 11, 1-19.	1.0	11
1077	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Africa: Current Considerations and Future Projections. Clinical Infectious Diseases, 2022, 75, S136-S140.	2.9	3
1078	Immune Response to SARS-CoV-2 Vaccines. Biomedicines, 2022, 10, 1464.	1.4	24
1079	Antiviral nanopharmaceuticals: Engineered surface interactions and virus-selective activity. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022, 14, .	3.3	4
1080	Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States. JAMA Network Open, 2022, 5, e2215934.	2.8	41
1082	Fever following Covid-19 vaccination in subjects with Brugada syndrome: Incidence and management. Journal of Cardiovascular Electrophysiology, 0, , .	0.8	6
1083	Acute kidney injury after COVID-19 vaccines: a real-world study. Renal Failure, 2022, 44, 958-965.	0.8	7
1084	Global prevalence and clinical manifestations of cutaneous adverse reactions following COVID-19 vaccination: A systematic review and meta-analysis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1947-1968.	1.3	26
1085	Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update. Frontiers in Medicine, 0, 9, .	1.2	8
1086	Advocacy for Migraine Relief: Strategic Planning to Eliminate the Burden. Current Pain and Headache Reports, 0, , .	1.3	1
1087	COVID-19 Vaccination Hesitancy among Healthcare Workers—A Review. Vaccines, 2022, 10, 948.	2.1	88
1088	Ocular Complications after COVID-19 Vaccination, Vaccine Adverse Event Reporting System. Vaccines, 2022, 10, 941.	2.1	12
1089	Nanologomers Targeting Human miRNA for the Treatment of Severe COVID-19 Are Safe and Nontoxic in Mice. ACS Biomaterials Science and Engineering, 2022, 8, 3087-3106.	2.6	20
1090	A Testing and Quarantine Algorithm for Individual International Travelers Using Published Data on WHO-Approved Vaccines and Bayes™ Theorem. Vaccines, 2022, 10, 902.	2.1	3

#	ARTICLE	IF	CITATIONS
1091	Population Immunity to Pre-Omicron and Omicron Severe Acute Respiratory Syndrome Coronavirus 2 Variants in US States and Counties Through 1 December 2021. <i>Clinical Infectious Diseases</i> , 2023, 76, e350-e359.	2.9	9
1092	Safety evaluation of the single-dose Ad26.COVS vaccine among healthcare workers in the Sisonke study in South Africa: A phase 3b implementation trial. <i>PLoS Medicine</i> , 2022, 19, e1004024.	3.9	10
1093	Vaccination of cats with Sad23L-nCoV-S vaccine candidate against major variants of SARS-CoV-2. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 26, 181-190.	1.8	2
1094	Comparative effectiveness and durability of COVID-19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign. <i>Journal of Medical Virology</i> , 2022, 94, 5044-5050.	2.5	27
1095	Clinical and Genetic Characteristics of Coronaviruses with Particular Emphasis on SARS-CoV-2 Virus. <i>Polish Journal of Microbiology</i> , 2022, 71, 141-159.	0.6	0
1096	Single-cell profiling of the antigen-specific response to BNT162b2 SARS-CoV-2 RNA vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	28
1098	COVID-19 vaccine safety monitoring in low and middle income countries â€œ Time for a bold new approach. <i>Vaccine</i> , 2022, 40, 4301-4302.	1.7	4
1099	Characteristics and outcomes of vaccinated and nonvaccinated patients hospitalized in a single Italian hub for COVID-19 during the Delta and Omicron waves in Northern Italy. <i>International Journal of Infectious Diseases</i> , 2022, 122, 420-426.	1.5	10
1101	COVID-19 Vaccines and Autoimmune Hematologic Disorders. <i>Vaccines</i> , 2022, 10, 961.	2.1	23
1102	COVID-19 Vaccines: Update of the vaccines in use and under development. <i>Vacunas</i> , 2022, , .	1.1	6
1103	Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials. <i>Vaccine</i> , 2022, 40, 4220-4230.	1.7	27
1104	Acute ischemic stroke and vaccine-induced immune thrombotic thrombocytopenia post COVID-19 vaccination; a systematic review. <i>Journal of the Neurological Sciences</i> , 2022, 439, 120327.	0.3	16
1105	Biopharmaceuticals for prevention of COVID-19: A scoping review. <i>Asian Pacific Journal of Tropical Medicine</i> , 2022, 15, 245.	0.4	2
1106	Pre-menstrual and menstrual changes reported after COVID-19 vaccination: The EVA project. <i>Women's Health</i> , 2022, 18, 174550572211122.	0.7	26
1108	Seroprevalence of neutralizing antibodies against adenovirus type 26 and 35 in healthy populations from Guangdong and Shandong provinces, China. <i>Virologica Sinica</i> , 2022, 37, 716-723.	1.2	5
1109	Durability analysis of the highly effective BNT162b2 vaccine against COVID-19. , 2022, 1, .		8
1110	Trends in the Utilization of Human Papillomavirus Vaccines and the Incidence of Malignant Cervical Cancer in Women and Teenagers: A Secondary Analysis. <i>Healthcare (Switzerland)</i> , 2022, 10, 1211.	1.0	1
1111	Anti-membrane Antibodies Persist at Least One Year and Discriminate Between Past Coronavirus Disease 2019 Infection and Vaccination. <i>Journal of Infectious Diseases</i> , 2022, 226, 1897-1902.	1.9	9

#	ARTICLE	IF	CITATIONS
1112	Otovestibular Symptoms of COVID-19 and Its Vaccines/Treatments. Encyclopedia, 2022, 2, 1200-1209.	2.4	0
1113	Effect of Sinovac or Biontech Vaccination on Mortality in COVID-19 Patients in The Intensive Care Unit. European Journal of Education and Pedagogy, 2022, 3, 18-20.	0.2	0
1114	Comparability of clinical trials and spontaneous reporting data regarding COVID-19 vaccine safety. Scientific Reports, 2022, 12, .	1.6	4
1115	Immunogenicity and efficacy of Ad26.<scp>COV2</scp>.S: An adenoviral vectorâ€‘based <scp>COVID</scp>â€‘19 vaccine. Immunological Reviews, 2022, 310, 47-60.	2.8	10
1116	Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination. Frontiers in Oncology, 0, 12, .	1.3	2
1117	Protection provided by vaccination, booster doses and previous infection against covid-19 infection, hospitalisation or death over time in Czechia. PLoS ONE, 2022, 17, e0270801.	1.1	18
1118	Symptoms and Duration of the Menstrual Cycle and Vaccination against Coronavirus Disease (COVID-19). UkraïnsË¼j Å¼urnal Medicini BÅ–ologÅ– Ta Sportu, 2022, 7, 92-98.	0.0	1
1119	KÅ©toldali Parsonageâ€‘Turner-szindrÅ³ma COVIDâ€‘19-vakcinÅ¡ciÅ³t kÅ¡vetÅ‘en.. Orvosi Hetilap, 2022, 163, 1055-1060.	0.1	3
1121	A prospective study of the association between SARS-CoV-2 infection and COVID-19 vaccination with changes in usual menstrual cycle characteristics. American Journal of Obstetrics and Gynecology, 2022, 227, 739.e1-739.e11.	0.7	33
1122	The crossâ€‘over of statistical thinking and practices: A pandemic catalyst. Pharmaceutical Statistics, 2022, 21, 778-789.	0.7	1
1123	Viral Vector Vaccine Development and Application during the COVID-19 Pandemic. Microorganisms, 2022, 10, 1450.	1.6	28
1124	Effects of Vaccination Against Influenza, Pertussis, and COVID-19 on Human Milk Antibodies: Current Evidence and Implications for Health Equity. Frontiers in Immunology, 0, 13, .	2.2	9
1126	Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines. IScience, 2022, 25, 104739.	1.9	4
1127	Clinical characteristics and immune profile alterations in vaccinated individuals with breakthrough Delta SARS-CoV-2 infections. Nature Communications, 2022, 13, .	5.8	10
1128	COVID-19 vaccination efficacy in numbers including SARS-CoV-2 variants and age comparison: a meta-analysis of randomized clinical trials. Annals of Clinical Microbiology and Antimicrobials, 2022, 21, .	1.7	6
1129	SARS-CoV-2 infection risk among vaccinated and unvaccinated household members during the Alpha variant surge â€‘ Denver, Colorado, and San Diego, California, Januaryâ€‘April 2021. Vaccine, 2022, 40, 4845-4855.	1.7	2
1130	Investigating trends in those who experience menstrual bleeding changes after SARS-CoV-2 vaccination. Science Advances, 2022, 8, .	4.7	68
1131	Rare Adverse Events Associated with BNT162b2 mRNA Vaccine (Pfizer-BioNTech): A Review of Large-Scale, Controlled Surveillance Studies. Vaccines, 2022, 10, 1067.	2.1	8

#	ARTICLE	IF	CITATIONS
1132	Quantifying the immunological distinctiveness of emerging SARS-CoV-2 variants in the context of prior regional herd exposure. , 0, , .		0
1134	Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. <i>Annals of Internal Medicine</i> , 2022, 175, 1258-1265.	2.0	63
1135	The Impact of Vaccination Against SARS-CoV-2 Virus on the Outcome of COVID-19 Disease. <i>Infection and Drug Resistance</i> , 0, Volume 15, 3477-3489.	1.1	2
1136	COVID-19 Vaccine Uptake Among Patients With Systemic Lupus Erythematosus in the American Midwest: The Lupus Midwest Network (LUMEN). <i>Journal of Rheumatology</i> , 0, , jrheum.220220.	1.0	4
1137	The effect of COVID-19 mRNA vaccines against postvaccination laboratory-confirmed SARS-CoV-2 infection, symptomatic COVID-19 infection, hospitalization, and mortality rate: a systematic review and meta-analysis. <i>Expert Review of Vaccines</i> , 2022, 21, 1455-1464.	2.0	7
1138	COVID-19: Challenges of Viral Variants. <i>Annual Review of Medicine</i> , 2023, 74, 31-53.	5.0	43
1139	The design and analysis of vaccine trials for <sc>COVID</sc> â€19 for the purpose of estimating efficacy. <i>Pharmaceutical Statistics</i> , 2022, 21, 790-807.	0.7	4
1140	Reinfection, recontamination and revaccination for SARS-CoV-2. <i>World Journal of Methodology</i> , 2022, 12, 258-263.	1.1	0
1141	Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (MAPSTM) SARS-CoV-2 Vaccine. <i>Vaccines</i> , 2022, 10, 1069.	2.1	2
1142	Is the Harm-to-Benefit Ratio a Key Criterion in Vaccine Approval?. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
1144	Protection of hamsters challenged with SARS-CoV-2 after two doses of MVC-COV1901 vaccine followed by a single intranasal booster with nanoemulsion adjuvanted S-2P vaccine. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
1145	Landscape of coronavirus disease 2019 clinical trials: New frontiers and challenges. <i>Clinical Trials</i> , 2022, 19, 561-572.	0.7	2
1146	<sc>COVID</sc> â€19 and plasma cells: Is there longâ€lived protection?*. <i>Immunological Reviews</i> , 2022, 309, 40-63.	2.8	26
1147	Effectiveness and protection duration of Covid-19 vaccines and previous infection against any SARS-CoV-2 infection in young adults. <i>Nature Communications</i> , 2022, 13, .	5.8	18
1148	The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	47
1149	COVIDâ€19 vaccine breakthrough infection among fully vaccinated healthcare workers in Duhok governorate, Iraqi Kurdistan; a retrospective cohort study.. <i>Journal of Medical Virology</i> , 0, , .	2.5	4
1150	Incidence and Characteristics of Adverse Events after COVID-19 Vaccination in a Population-Based Programme. <i>Vaccines</i> , 2022, 10, 1111.	2.1	3
1151	Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicity. <i>Immunity and Ageing</i> , 2022, 19, .	1.8	6

#	ARTICLE	IF	CITATIONS
1152	Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021. <i>International Immunology</i> , 2022, 34, 595-607.	1.8	19
1153	Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies. <i>Cancer</i> , 2022, 128, 3319-3329.	2.0	27
1154	The use of viral vectors in vaccine development. <i>Npj Vaccines</i> , 2022, 7, .	2.9	73
1155	Respuesta inmune humoral a cuatro vacunas contra el SARS-CoV-2 en profesionales de la salud. <i>Horizonte Médico</i> , 2022, 22, e1937.	0.1	0
1156	Incorporating Fuzzy Cognitive Inference for Vaccine Hesitancy Measuring. <i>Sustainability</i> , 2022, 14, 8434.	1.6	0
1157	Heterologous saRNA Prime, DNA Dual-Antigen Boost SARS-CoV-2 Vaccination Elicits Robust Cellular Immunogenicity and Cross-Variant Neutralizing Antibodies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1158	A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1159	The COVID-19 pandemic and its consequences for chronic pain: a narrative review. <i>Anaesthesia</i> , 2022, 77, 1039-1050.	1.8	28
1160	Clinical Performance Characteristics of the Swift Normalase Amplicon Panel for Sensitive Recovery of Severe Acute Respiratory Syndrome Coronavirus 2 Genomes. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 963-976.	1.2	7
1161	The Role of Cellular Immunity in the Protective Efficacy of the SARS-CoV-2 Vaccines. <i>Vaccines</i> , 2022, 10, 1103.	2.1	11
1162	The effect of COVID certificates on vaccine uptake, health outcomes, and the economy. <i>Nature Communications</i> , 2022, 13, .	5.8	41
1163	Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis. <i>Expert Review of Vaccines</i> , 2022, 21, 1301-1318.	2.0	12
1164	To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 65, 104014.	0.9	17
1165	Insights into COVID-19 vaccines development: Translation from benchside to bedside. <i>Health Sciences Review</i> , 2022, 4, 100040.	0.6	1
1166	A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies. <i>International Immunopharmacology</i> , 2022, 110, 109046.	1.7	8
1167	Identification of a novel immune-inflammatory signature of COVID-19 infections, and evaluation of pharmacokinetics and therapeutic potential of RXn-02, a novel small-molecule derivative of quinolone. <i>Computers in Biology and Medicine</i> , 2022, 148, 105814.	3.9	8
1168	Vacunas contra la COVID-19. <i>Ambiociencias</i> , 0, , 75-108.	0.0	1
1169	Short term safety of coronavirus disease 2019 vaccines in patients with solid tumors receiving systemic therapy. <i>World Journal of Clinical Oncology</i> , 2022, 13, 599-608.	0.9	0

#	ARTICLE	IF	CITATIONS
1170	Omicron BA.1 Mutations in SARS-CoV-2 Spike Lead to Reduced T-Cell Response in Vaccinated and Convalescent Individuals. <i>Viruses</i> , 2022, 14, 1570.	1.5	10
1171	The public's attitude to and acceptance of periodic doses of the COVID-19 vaccine: A survey from Jordan. <i>PLoS ONE</i> , 2022, 17, e0271625.	1.1	8
1172	Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York. <i>EBioMedicine</i> , 2022, 82, 104141.	2.7	11
1173	Estimating COVID-19 Vaccination and Booster Effectiveness Using Electronic Health Records From an Academic Medical Center in Michigan. , 2022, 1, 100015.		1
1174	SARS-CoV-2's Variants of Concern: A Brief Characterization. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	31
1176	Systemic sclerosis in the time of COVID-19. <i>Lancet Rheumatology</i> , The, 2022, 4, e566-e575.	2.2	14
1177	A Case Report for Acute Myopericarditis After NVX-CoV2373 (Novavax's COVID-19 Vaccination. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	5
1178	Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: a systemic review. <i>International Journal of Biological Sciences</i> , 2022, 18, 4629-4641.	2.6	24
1179	Predictors of COVID-19 booster vaccine hesitancy among fully vaccinated adults in Korea: a nationwide cross-sectional survey. <i>Epidemiology and Health</i> , 0, 44, e2022061.	0.8	10
1180	Comparative characterization of antibody responses induced by Ad5-vectored spike proteins of emerging SARS-CoV-2 VOCs. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	5
1181	Analysis of immunization time, amplitude, and adverse events of seven different vaccines against SARS-CoV-2 across four different countries. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
1182	COVID-19 Vaccine Booster Strategies for Omicron SARS-CoV-2 Variant: Effectiveness and Future Prospects. <i>Vaccines</i> , 2022, 10, 1223.	2.1	12
1184	Efficacy and safety of COVID-19 vaccination in patients with cirrhosis. <i>World Journal of Hepatology</i> , 2022, 14, 1470-1479.	0.8	2
1185	SARS-CoV-2 Breakthrough Infections: Incidence and Risk Factors in a Large European Multicentric Cohort of Health Workers. <i>Vaccines</i> , 2022, 10, 1193.	2.1	19
1186	Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S. <i>Npj Vaccines</i> , 2022, 7, .	2.9	13
1187	Report of Adverse Effects Following Population-Wide COVID-19 Vaccination: A Comparative Study between Six Different Vaccines in Baja-California, Mexico. <i>Vaccines</i> , 2022, 10, 1196.	2.1	3
1188	Appraisal of SARS-CoV-2 mutations and their impact on vaccination efficacy: an overview. <i>Journal of Diabetes and Metabolic Disorders</i> , 2022, 21, 1763-1783.	0.8	4
1189	Clinical Post-SARS-CoV-2 Infection Scenarios in Vaccinated and Non-Vaccinated Cancer Patients in Three German Cancer Centers: A Retrospective Analysis. <i>Cancers</i> , 2022, 14, 3746.	1.7	3

#	ARTICLE	IF	CITATIONS
1190	A bibliometric analysis of the 100 most cited articles describing SARS-CoV-2 variants. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
1191	The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	70
1192	The Epidemiology of Diabetic Kidney Disease. <i>Kidney and Dialysis</i> , 2022, 2, 433-442.	0.5	29
1193	Coronavirus Disease 2019 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection in the United States Before the Delta- and Omicron-Associated Surges: A Retrospective Cohort Study of Repeat Blood Donors. <i>Journal of Infectious Diseases</i> , 2022, 226, 1556-1561.	1.9	3
1194	Serum peptidome profiles immune response of COVID-19 Vaccine administration. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1195	Socioeconomic Inequities in Vaccine Hesitancy Among Native Hawaiians and Pacific Islanders. <i>Health Equity</i> , 2022, 6, 616-624.	0.8	6
1196	A universal <scp>SARSâ€CoV DNA</scp> vaccine inducing highly crossâ€reactive neutralizing antibodies and T cells. <i>EMBO Molecular Medicine</i> , 2022, 14, .	3.3	11
1197	Heterologous immunity induced by 1st generation COVID-19 vaccines and its role in developing a pan-coronavirus vaccine. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
1198	Intensity of Humoral Immune Responses, Adverse Reactions, and Post-Vaccination Morbidity after Adenovirus Vector-Based and mRNA Anti-COVID-19 Vaccines. <i>Vaccines</i> , 2022, 10, 1268.	2.1	4
1199	Surveillance of adverse events associated with 145 000 doses of COVID-19 vaccines in a Brazilian municipality. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2022, 46, 1.	0.6	0
1201	Intranasal vaccination induced cross-protective secretory IgA antibodies against SARS-CoV-2 variants with reducing the potential risk of lung eosinophilic immunopathology. <i>Vaccine</i> , 2022, 40, 5892-5903.	1.7	6
1202	A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
1203	Trends in reporting embolic and thrombotic events after COVID-19 vaccination: A retrospective, pharmacovigilance study. <i>PLoS ONE</i> , 2022, 17, e0269268.	1.1	3
1204	A public antibody class recognizes an S2 epitope exposed on open conformations of SARS-CoV-2 spike. <i>Nature Communications</i> , 2022, 13, .	5.8	34
1205	Current Vaccine Platforms in Enhancing T-Cell Response. <i>Vaccines</i> , 2022, 10, 1367.	2.1	8
1206	Rapid Implementation of a Communityâ€Academic Partnership Model to Promote COVID-19 Vaccine Equity within Racially and Ethnically Minoritized Communities. <i>Vaccines</i> , 2022, 10, 1364.	2.1	7
1207	Durability of Heterologous and Homologous COVID-19 Vaccine Boosts. <i>JAMA Network Open</i> , 2022, 5, e2226335.	2.8	42
1208	Confidence interval estimation for vaccine efficacy against COVID-19. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	2

#	ARTICLE	IF	CITATIONS
1209	COVID-19 vaccination effectiveness rates by week and sources of bias: a retrospective cohort study. <i>BMJ Open</i> , 2022, 12, e061126.	0.8	7
1210	Immunogenicity of SARS-CoV-2 vaccines in patients with cancer. <i>Trends in Molecular Medicine</i> , 2022, 28, 1082-1099.	3.5	11
1211	Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9297.	1.8	4
1212	Syringe Service Program Perspectives on Barriers, Readiness, and Programmatic Needs to Support Rollout of the COVID-19 Vaccine. <i>Journal of Addiction Medicine</i> , 0, Publish Ahead of Print, .	1.4	2
1213	An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves. <i>Cancers</i> , 2022, 14, 3931.	1.7	2
1214	Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	14
1215	Clinical presentation and cardiac imaging findings in patient cases of perimyocarditis and pericarditis with a temporal association to SARS-CoV-2 vaccination. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
1216	Health inequities in SARS-CoV-2 infection, seroprevalence, and COVID-19 vaccination: Results from the East Bay COVID-19 study. <i>PLOS Global Public Health</i> , 2022, 2, e0000647.	0.5	4
1217	Vaccination against SARS-CoV-2 in Haemodialysis Patients: Spike™s Ab Response and the Influence of BMI and Age. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 10091.	1.2	2
1218	Evaluation of serological response to anti-SARS-CoV-2 mRNA vaccination in hematological patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1219	Epidemiological aspects of headache after different types of COVID-19 vaccines: An online survey. <i>Headache</i> , 2022, 62, 1046-1052.	1.8	5
1220	Travel in the Time of COVID: A Review of International Travel Health in a Global Pandemic. <i>Current Infectious Disease Reports</i> , 2022, 24, 129-145.	1.3	17
1221	SARS-CoV-2 and Immunity: Natural Infection Compared with Vaccination. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8982.	1.8	4
1222	Evaluation and comparison of post-vaccination adverse effects among Janssen and Oxford-AstraZeneca vaccinated adult individuals in Debre Tabor Town: A cross-sectional survey in Northwest Ethiopia. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	3
1223	Impact of inactivated SARS-CoV-2 vaccination on embryo ploidy: a retrospective cohort study of 133 PGT-A cycles in China. <i>Biological Research</i> , 2022, 55, .	1.5	7
1224	Covid-19 vaccination in pregnancy. <i>BMJ, The</i> , 0, , e069741.	3.0	54
1225	Design and Immunoinformatic Assessment of Candidate Multivalent mRNA Vaccine Construct against Immune Escape Variants of SARS-CoV-2. <i>Polymers</i> , 2022, 14, 3263.	2.0	3
1227	Characteristics and Vaccines: Five Variants of Concern of SARS-CoV-2. , 0, 8, 630-634.		0

#	ARTICLE	IF	CITATIONS
1228	Efficacy and safety of COVID-19 vaccines: A network meta-analysis. <i>Journal of Evidence-Based Medicine</i> , 2022, 15, 245-262.	0.7	14
1229	Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1742-1749.	0.5	26
1230	CD8 T cells contribute to vaccine protection against SARS-CoV-2 in macaques. <i>Science Immunology</i> , 2022, 7, .	5.6	74
1231	Ad26.COVS Vaccine-Induced Thrombocytopenia Leading to Dural Sinus Thrombosis and Intracranial Hemorrhage Requiring Hemicraniectomy: A Case Report and Systematic Review. <i>Cureus</i> , 2022, , .	0.2	0
1232	The current status of COVID-19 vaccines. A scoping review. <i>Drug Discovery Today</i> , 2022, 27, 103336.	3.2	7
1233	Short-term mortality following COVID-19 vaccination in Bologna, Italy: a one-year study. <i>Vaccine</i> , 2022, 40, 5709-5715.	1.7	4
1234	SARS-CoV-2 Viroporins: A Multi-Omics Insight from Nucleotides to Amino Acids. <i>Applied Microbiology</i> , 2022, 2, 572-593.	0.7	1
1235	Neutralization activity of sera/IgG preparations from fully BNT162b2 vaccinated individuals against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Kappa variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
1236	ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants. <i>Nature Communications</i> , 2022, 13, .	5.8	23
1237	Neutralizing antibodies to SARS-CoV-2 variants of concern including Delta and Omicron in subjects receiving mRNA-1273, BNT162b2, and Ad26.COVS vaccines. <i>Journal of Medical Virology</i> , 2022, 94, 5678-5690.	2.5	16
1238	Influence of cancer on COVID-19 incidence, outcomes, and vaccine effectiveness: A prospective cohort study of U.S. veterans. <i>Seminars in Oncology</i> , 2022, , .	0.8	3
1239	Modular capsid decoration boosts adenovirus vaccine-induced humoral immunity against SARS-CoV-2. <i>Molecular Therapy</i> , 2022, 30, 3639-3657.	3.7	6
1240	STING-pathway modulation to enhance the immunogenicity of adenoviral-vectored vaccines. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
1241	SARS-CoV-2 immunity and vaccine strategies in people with HIV. <i>Oxford Open Immunology</i> , 2022, 3, .	1.2	12
1242	A comprehensive insight into current control of COVID-19: Immunogenicity, vaccination, and treatment.. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113499.	2.5	12
1243	Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination. <i>IScience</i> , 2022, 25, 104886.	1.9	5
1244	Host genetic diversity and genetic variations of SARS-CoV-2 in COVID-19 pathogenesis and the effectiveness of vaccination. <i>International Immunopharmacology</i> , 2022, 111, 109128.	1.7	9
1245	Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15

#	ARTICLE	IF	CITATIONS
1247	Differential vaccine-induced kinetics of humoral and cellular immune responses in SARS-CoV-2 naive and convalescent health care workers. <i>Pathogens and Disease</i> , 2022, 80, .	0.8	3
1248	Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers. <i>International Journal of Infectious Diseases</i> , 2022, 123, 183-191.	1.5	8
1249	Towards novel nano-based vaccine platforms for SARS-CoV-2 and its variants of concern: Advances, challenges and limitations. <i>Journal of Drug Delivery Science and Technology</i> , 2022, 76, 103762.	1.4	0
1250	COVID-19: Vaccines and therapeutics. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2022, 75, 128987.	1.0	4
1251	Development of a thermostable SARS-CoV-2 variant-based bivalent protein vaccine with cross-neutralizing potency against Omicron subvariants. <i>Virology</i> , 2022, 576, 61-68.	1.1	8
1252	Development of donor specific antibodies after SARS-CoV-2 vaccination in kidney and heart transplant recipients. <i>Transplant Immunology</i> , 2022, 75, 101722.	0.6	3
1253	Immunogenicity of SARS-CoV-2 vaccines in patients with breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211193.	1.4	2
1254	Global Biologic Characteristics of Variants of Concern and Variants of Interest of SARS-CoV-2. , 2022, , 161-181.		0
1255	Recent update on treatment and preventive modalities for COVID-19 Omicron variant (B.1.1.529) in India: A comprehensive review. <i>Saudi Journal for Health Sciences</i> , 2022, 11, 83.	0.1	1
1256	Assessing the Robustness of SARS-CoV-2 Vaccine Efficacy Trials: Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1257	Diaphragmatic Dysfunction due to Neuralgic Amyotrophy After SARS-CoV-2 Vaccination: A Case Report. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	4
1258	SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies. , 2022, , 143-160.		0
1259	COVID-19 Vaccines Authorized by Stringent Regulatory Authorities and Vaccine Candidates Expecting Approval in 2021. , 2022, , 575-594.		0
1260	Issues in Generalizing Results from Clinical Trials. , 2022, , 2227-2240.		0
1261	Covid-19: Treatment conclusion with kinds of vaccine and drugs. <i>AIP Conference Proceedings</i> , 2022, , .	0.3	0
1262	SARS-CoV-2 Vaccine Against Virus: Mission Accomplished!?. , 2022, , 561-574.		0
1263	Different Platforms, Immune Response Modulators and Challenges in SARS-CoV-2 Vaccination. , 2022, , 539-559.		0
1264	Mortality and prognostic factors in hospitalized COVID-19 patients with cancer: an analysis from a large healthcare system in the United States. <i>Annals of Translational Medicine</i> , 2022, 10, 1090-1090.	0.7	4

#	ARTICLE	IF	CITATIONS
1265	Guillain-Barre syndrome related to SARS-CoV-2 vaccinations. <i>Clinics</i> , 2022, 77, 100113.	0.6	4
1266	Effect of Fluvoxamine on Clinical Deterioration in Adult Patients with Symptomatic COVID-19 Infection: A Trial Sequential Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1267	Estimation and interpretation of vaccine efficacy in COVID-19 randomized clinical trials. <i>Statistical Communications in Infectious Diseases</i> , 2022, 14, .	0.2	0
1268	Safety and Efficacy of the Two Doses Conjugated Protein-Based SOBERANA-02 COVID-19 Vaccine and of a Heterologous Three-Dose Combination with SOBERANA-PLUS: Double-Blind, Randomised, Placebo-Controlled Phase 3 Clinical Trial. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
1269	Vaccine History: From Smallpox to Covid-19. <i>Engineering Materials</i> , 2022, , 519-543.	0.3	0
1270	Antibody-mediated immunity to SARS-CoV-2 spike. <i>Advances in Immunology</i> , 2022, , 1-69.	1.1	12
1271	SARS-COV-2 and Other mRNA Vaccines. <i>RNA Technologies</i> , 2022, , 113-138.	0.2	0
1272	Understanding COVID-19 Epidemics: A Multi-Scale Modeling Approach. <i>Modeling and Simulation in Science, Engineering and Technology</i> , 2022, , 11-42.	0.4	3
1273	SARS-CoV-2 Infection upon Leaving the Tokyo 2020 Olympic and Paralympic Games. <i>Internal Medicine</i> , 2022, 61, 3659-3666.	0.3	2
1274	Viral vector and nucleic acid vaccines against COVID-19: A narrative review. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	14
1275	Impact of COVID-19 Vaccination on Menstrual Cycle: A Cross-Sectional Study From Karachi, Pakistan. <i>Cureus</i> , 2022, , .	0.2	3
1276	Vaccine-Associated Uveitis after COVID-19 Vaccination. <i>Ophthalmology</i> , 2023, 130, 179-186.	2.5	25
1277	Effectiveness of the Inactivated SARS-CoV-2 (Vero Cell) Vaccine in Peruvian Health Workers. <i>Life</i> , 2022, 12, 1318.	1.1	3
1278	A Review of Humoral and Cellular Immune Responses to SARS-CoV-2 Vaccination Following Solid Organ Transplantation. <i>Annals of Transplantation</i> , 0, 27, .	0.5	0
1280	SARS-CoV-2 Delta variant induces enhanced pathology and inflammatory responses in K18-hACE2 mice. <i>PLoS ONE</i> , 2022, 17, e0273430.	1.1	17
1281	Evaluating real-world COVID-19 vaccine effectiveness using a test-negative case-control design. <i>Journal of Comparative Effectiveness Research</i> , 2022, 11, 1161-1172.	0.6	6
1282	Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COVS vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 1703-1715.	4.6	37
1283	A Quantitative ELISA to Detect Anti-SARS-CoV-2 Spike IgG Antibodies in Infected Patients and Vaccinated Individuals. <i>Microorganisms</i> , 2022, 10, 1812.	1.6	2

#	ARTICLE	IF	CITATIONS
1284	COVID-19 Vaccination Policies: Ethical Issues and Responsibility. <i>Vaccines</i> , 2022, 10, 1602.	2.1	1
1285	Gene Signatures of T-Cell Activation Can Serve as Predictors of Functionality for SARS-CoV-2-Specific T-Cell Receptors. <i>Vaccines</i> , 2022, 10, 1617.	2.1	0
1286	Covid-19 Vaccines – Immunity, Variants, Boosters. <i>New England Journal of Medicine</i> , 2022, 387, 1011-1020.	13.9	266
1287	Heterologous vector versus homologous mRNA COVID-19 booster vaccination in non-seroconverted immunosuppressed patients: a randomized controlled trial. <i>Nature Communications</i> , 2022, 13, .	5.8	18
1288	New insights into human immune memory from SARS-CoV-2 infection and vaccination. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 0, , .	2.7	5
1289	Race, Ethnicity, and Health Disparities in US Children With COVID-19: A Review of the Evidence and Recommendations for the Future. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, S132-S140.	0.6	13
1290	Impact of SARS-CoV-2 Delta and Omicron variants on viral burden and cycle threshold in BNT162b2-vaccinated 12–18-year group. <i>Brazilian Journal of Microbiology</i> , 2022, 53, 1937-1940.	0.8	2
1291	Durability of Protection Post-Primary COVID-19 Vaccination in the United States. <i>Vaccines</i> , 2022, 10, 1458.	2.1	8
1292	Intranasal Immunization with Liposome-Displayed Receptor-Binding Domain Induces Mucosal Immunity and Protection against SARS-CoV-2. <i>Pathogens</i> , 2022, 11, 1035.	1.2	10
1293	Humoral Immune Response and Safety of SARS-CoV-2 Vaccination in Pediatric Inflammatory Bowel Disease. <i>American Journal of Gastroenterology</i> , 2023, 118, 129-137.	0.2	8
1294	COVID-19 Vaccination Breakthrough Infections in a Real-World Setting: Using Community Reporters to Evaluate Vaccine Effectiveness. <i>Infection and Drug Resistance</i> , 0, Volume 15, 5167-5182.	1.1	9
1295	Virtual autopsy in SARS-CoV-2 breakthrough infection: a case report. <i>Forensic Imaging</i> , 2022, 30, 200520.	0.4	4
1296	Written Briefing and Oral Counseling Increase the Willingness to Receive the SARS-CoV-2 Vaccination among Women in Puerperium: A Qualitative Prospective Cohort Study. <i>Vaccines</i> , 2022, 10, 1505.	2.1	2
1297	Retrospective Cohort Study of COVID-19 in Patients of the Brazilian Public Health System with SARS-CoV-2 Omicron Variant Infection. <i>Vaccines</i> , 2022, 10, 1504.	2.1	2
1298	Need for focused pharmacovigilance in the face of rapid COVID-19 vaccine development. <i>Current Drug Safety</i> , 2022, 17, .	0.3	0
1300	Graves™ Disease Following SARS-CoV-2 Vaccination: A Systematic Review. <i>Vaccines</i> , 2022, 10, 1445.	2.1	12
1302	SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy. <i>Neurology</i> , 2023, 100, .	1.5	12
1303	Breakthrough SARS-CoV-2 infection outcomes in vaccinated patients with chronic liver disease and cirrhosis: A National COVID Cohort Collaborative study. <i>Hepatology</i> , 2023, 77, 834-850.	3.6	7

#	ARTICLE	IF	CITATIONS
1305	The effect of a proof-of-vaccination requirement, incentive payments, and employer-based mandates on COVID-19 vaccination rates in New York City: a synthetic-control analysis. <i>Lancet Public Health</i> , The, 2022, 7, e754-e762.	4.7	12
1306	Evidence of the Efficacy and the Effectiveness of First Generation COVID-19 Vaccines in Clinical Trials and Real-world Studies. <i>Zoonoses</i> , 2022, 2, .	0.5	0
1307	Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells. <i>Scientific Reports</i> , 2022, 12, .	1.6	19
1308	Transverse Myelitis Following <scp>SARSâ€CoV</scp>â€2 Vaccination: A Pharmacoepidemiological Study in the World Health Organization's Database. <i>Annals of Neurology</i> , 2022, 92, 1080-1089.	2.8	7
1309	Recursive state and parameter estimation of COVID-19 circulating variants dynamics. <i>Scientific Reports</i> , 2022, 12, .	1.6	3
1311	Real-world comparative effectiveness of mRNA-1273 and BNT162b2 vaccines among immunocompromised adults identified in administrative claims data in the United States. <i>Vaccine</i> , 2022, 40, 6730-6739.	1.7	7
1312	Optimizing global COVID-19 vaccine allocation: An agent-based computational model of 148 countries. <i>PLoS Computational Biology</i> , 2022, 18, e1010463.	1.5	8
1313	Immune responses to SARS-CoV-2 infection and COVID-19 vaccines. <i>Exploration of Immunology</i> , 2022, 2, 648-664.	1.7	1
1314	Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. <i>Vaccine</i> , 2022, 40, 5798-5805.	1.7	83
1315	Evaluating risk factors associated with COVID-19 infections among vaccinated people early in the U.S. vaccination campaign: an observational study of five states, Januaryâ€March 2021. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	0
1316	A global epidemiological analysis of COVID-19 vaccine types and clinical outcomes. <i>International Journal of Infectious Diseases</i> , 2022, 124, 206-211.	1.5	4
1317	Characteristics of replication and pathogenicity of SARS-CoV-2 Alpha and Delta isolates. <i>Virologica Sinica</i> , 2022, 37, 804-812.	1.2	4
1318	Managing two waves of the COVID-19 pandemic in northern emergency departments in Paris: COVIDORG II. <i>Journal European Des Urgences Et De Reanimation</i> , 2022, 34, 70-81.	0.1	0
1320	A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancers. <i>Heliyon</i> , 2022, 8, e10583.	1.4	2
1321	Detecting time-evolving phenotypic components of adverse reactions against BNT162b2 mRNA SARS-CoV-2 vaccine via non-negative tensor factorization.. <i>IScience</i> , 2022, , 105237.	1.9	3
1322	Safety and immune response kinetics of GRAd-COV2 vaccine: phase 1 clinical trial results. <i>Npj Vaccines</i> , 2022, 7, .	2.9	3
1323	<scp>COVID</scp>â€19 vaccination status and disease burden in patients with sickle cell disease. <i>British Journal of Haematology</i> , 2022, 199, .	1.2	4
1324	The Covid-19 Vaccines: The Current Standpoint. , 0, , .		0

#	ARTICLE	IF	CITATIONS
1326	Preliminary Analysis of the Effects of Ad26.COV2.S Vaccination on CT Findings and High Intensive Care Admission Rates of COVID-19 Patients. <i>Tomography</i> , 2022, 8, 2403-2410.	0.8	0
1327	Does potential antibody-dependent enhancement occur during SARS-CoV-2 infection after natural infection or vaccination? A meta-analysis. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	6
1328	High Frequency of COVID-19 Vaccine Hesitancy among Canadians Immunized for Influenza: A Cross-Sectional Survey. <i>Vaccines</i> , 2022, 10, 1514.	2.1	1
1329	COVID-19 vaccine hesitancy cannot fully explain disparities in vaccination coverage across the contiguous United States. <i>Vaccine</i> , 2022, 40, 5471-5482.	1.7	20
1331	Virological, Epidemiological Features and Prevention of SARS-CoV-2 Omicron (B.1.1.529) Variant: A Review. <i>Kocaeli Üniversitesi Saġlık Bilimleri Dergisi</i> , 0, , 162-171.	0.3	0
1332	A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	64
1333	Development of variant-proof severe acute respiratory syndrome coronavirus 2, SARS-CoV-2, and SARS-CoV-2 coronavirus vaccines. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	12
1334	COVID-19: Clinical status of vaccine development to date. <i>British Journal of Clinical Pharmacology</i> , 2023, 89, 114-149.	1.1	8
1335	Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	17
1336	A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	9
1337	Trends in willingness to receive COVID-19 vaccines among healthcare workers in India: Findings from repeated cross-sectional national surveys. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	1
1339	Spike-specific T-cell responses in patients with COVID-19 successfully treated with neutralizing monoclonal antibodies against SARS-CoV-2. <i>International Journal of Infectious Diseases</i> , 2022, 124, 55-64.	1.5	4
1340	Cutaneous leukocytoclastic vasculitis after ChAdOx1 nCoV-19 vaccine. <i>Indian Journal of Medical Specialities</i> , 2022, 13, 263.	0.1	1
1341	COVID-19 vaccination and immune thrombocytopenia. <i>Japanese Journal of Thrombosis and Hemostasis</i> , 2022, 33, 576-579.	0.1	0
1342	Mucosal delivery of RNA vaccines by Newcastle disease virus vectors. <i>Current Research in Immunology</i> , 2022, 3, 234-238.	1.2	3
1343	The use of adenoviral vectors in gene therapy and vaccine approaches. <i>Genetics and Molecular Biology</i> , 2022, 45, .	0.6	3
1344	Temperature Influences the Interaction between SARS-CoV-2 Spike from Omicron Subvariants and Human ACE2. <i>Viruses</i> , 2022, 14, 2178.	1.5	5
1345	Neurological manifestations associated with COVID-19 vaccine. <i>Neurologia (English Edition)</i> , 2022, , .	0.2	5

#	ARTICLE	IF	CITATIONS
1346	Effectiveness of vaccination against SARS-CoV-2 Omicron variant infection, symptomatic disease, and hospitalization: a systematic review and meta-analysis. <i>Expert Review of Vaccines</i> , 2022, 21, 1831-1841.	2.0	10
1347	Does Prophylactic Oral Zinc Reduce the Risk of Contracting COVID-19?. <i>Cureus</i> , 2022, , .	0.2	0
1348	Mapping Potential Vaccine Candidates Predicted by Vaxijen for Different Viral Pathogens between 2017–2021–A Scoping Review. <i>Vaccines</i> , 2022, 10, 1785.	2.1	5
1349	A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 1655.	2.1	12
1350	Knocking on heaven's door: The gap between health institutions and academies in generating knowledge utilizing real-world data. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	1
1351	Comparative Study of Vaccinated and Unvaccinated Hospitalised Patients: A Retrospective Population Study of 500 Hospitalised Patients with SARS-CoV-2 Infection in a Spanish Population of 220,000 Inhabitants. <i>Viruses</i> , 2022, 14, 2284.	1.5	5
1352	Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. <i>Vaccines</i> , 2022, 10, 1751.	2.1	10
1353	Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. <i>Journal of Pharmaceutical Analysis</i> , 2023, 13, 1-10.	2.4	1
1354	Association of COVID-19 Vaccinations With Intensive Care Unit Admissions and Outcome of Critically Ill Patients With COVID-19 Pneumonia in Lombardy, Italy. <i>JAMA Network Open</i> , 2022, 5, e2238871.	2.8	19
1355	COVID-19 vaccine booster significantly decreases the risk of intensive care unit hospitalization in heart failure patients during the Omicron variant wave: A population-based study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
1356	Identifying COVID-19 optimal vaccine dose using mathematical immunostimulation/immunodynamic modelling. <i>Vaccine</i> , 2022, 40, 7032-7041.	1.7	4
1357	Allergy Workup in the Diagnosis of COVID-19 Vaccines-Induced Hypersensitivity Reactions and Its Impact on Vaccination. <i>International Archives of Allergy and Immunology</i> , 2023, 184, 54-62.	0.9	1
1358	Comparative Analysis of Antibody Titers against the Spike Protein of SARS-CoV-2 Variants in Infected Patient Cohorts and Diverse Vaccination Regimes. <i>International Journal of Molecular Sciences</i> , 2022, 23, 12231.	1.8	4
1359	COVID-19 and HSCT (Hematopoietic stem cell transplant). <i>Best Practice and Research in Clinical Haematology</i> , 2022, 35, 101399.	0.7	8
1361	Association between regular physical activity and the protective effect of vaccination against SARS-CoV-2 in a South African case–control study. <i>British Journal of Sports Medicine</i> , 2023, 57, 205-211.	3.1	12
1362	SARS-CoV-2 variants of concern: a review. <i>Monaldi Archives for Chest Disease</i> , 0, , .	0.3	4
1363	Association of mRNA Vaccination With Clinical and Virologic Features of COVID-19 Among US Essential and Frontline Workers. <i>JAMA - Journal of the American Medical Association</i> , 2022, 328, 1523.	3.8	21
1364	SARS-COV-2 antibody responses to AZD1222 vaccination in West Africa. <i>Nature Communications</i> , 2022, 13, .	5.8	14

#	ARTICLE	IF	CITATIONS
1365	Improved control of SARS-CoV-2 by treatment with a nucleocapsid-specific monoclonal antibody. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	33
1366	Vaccine versus infection â€œ COVID-19-related loss of training time in elite athletes. <i>Journal of Science and Medicine in Sport</i> , 2022, 25, 950-959.	0.6	13
1367	Peptide ILE-GLU-TRP (Stemokin) Potential Adjuvant Stimulating a Balanced Immune Response. <i>International Journal of Peptide Research and Therapeutics</i> , 2022, 28, .	0.9	1
1368	Specific Pandemic-Related Worries Predict Higher Attention-Related Errors and Negative Affect Independent of Trait Anxiety in UK-Based Students. <i>Cognitive Therapy and Research</i> , 0, , .	1.2	1
1369	Analysis of Severe Illness After Postvaccination COVID-19 Breakthrough Among Adults With and Without HIV in the US. <i>JAMA Network Open</i> , 2022, 5, e2236397.	2.8	19
1370	Amphiphile-CpG vaccination induces potent lymph node activation and COVID-19 immunity in mice and non-human primates. <i>Npj Vaccines</i> , 2022, 7, .	2.9	4
1371	Fear of COVID-19 and Vaccine Hesitancy among Pregnant Women in Poland: A Cross-Sectional Study. <i>Vaccines</i> , 2022, 10, 1700.	2.1	7
1373	Management of patients with lymphoma and COVIDâ€™19: Narrative review and evidenceâ€™based practical recommendations. <i>Hematological Oncology</i> , 2023, 41, 3-15.	0.8	7
1375	Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2023, 76, 398-407.	2.9	24
1376	Micro and nanotechnologies: The little formulations that could. <i>Bioengineering and Translational Medicine</i> , 2023, 8, .	3.9	9
1377	Monoclonal antibodies for the treatment of COVID-19 infection in children. <i>Expert Review of Anti-Infective Therapy</i> , 2022, 20, 1529-1535.	2.0	1
1378	Case Report: Retinal vasculitis in two adolescents after COVID-19 vaccination. <i>Ocular Immunology and Inflammation</i> , 0, , 1-5.	1.0	4
1379	Evaluation of Seropositivity After Standard Doses of Vaccination Against SARS-CoV-2 in Patients With Early Breast Cancer Receiving Adjuvant Treatment. <i>Oncologist</i> , 2022, 27, e931-e937.	1.9	2
1380	Safety and adverse events following <sc>COVID</sc>â€™19 vaccination among people with epilepsy: A <sc>crossâ€™sectional</sc> study. <i>Epilepsia Open</i> , 2023, 8, 60-76.	1.3	3
1381	Naturally occurring spike mutations influence the infectivity and immunogenicity of SARS-CoV-2. , 2022, 19, 1302-1310.		17
1382	Fully understanding the efficacy profile of the COVID-19 vaccination and its associated factors in multiple real-world settings. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
1384	Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology. <i>Transplantation and Cellular Therapy</i> , 2023, 29, 10-18.	0.6	5
1387	Evaluation of humoral and cellular response to four vaccines against COVID-19 in different age groups: A longitudinal study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15

#	ARTICLE	IF	CITATIONS
1389	Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice. <i>PLoS ONE</i> , 2022, 17, e0272594.	1.1	1
1390	Zebrafish models of COVID-19. <i>FEMS Microbiology Reviews</i> , 2023, 47, .	3.9	6
1391	Intranasal delivery of a chimpanzee adenovirus vector expressing a pre-fusion spike (BV-AdCoV-1) protects golden Syrian hamsters against SARS-CoV-2 infection. <i>Frontiers in Cellular and Infection Microbiology</i> , 0, 12, .	1.8	3
1392	Neurological autoimmune diseases following vaccinations against severe acute respiratory syndrome coronavirus 2 (<sc>SARSâ€CoV</sc>â€2): A followâ€up study. <i>European Journal of Neurology</i> , 2023, 30, 463-473.	1.7	12
1393	A systematic review of current status and challenges of vaccinating children against SARS-CoV-2. <i>Journal of Infection and Public Health</i> , 2022, 15, 1212-1224.	1.9	2
1394	Durable spike-specific T cell responses after different COVID-19 vaccination regimens are not further enhanced by booster vaccination. <i>Science Immunology</i> , 2022, 7, .	5.6	39
1395	SARS-CoV-2 Mitigation Strategies, Testing, and Cases at 254 Jails in the US Southeast, October 2020 to May 2021. <i>American Journal of Public Health</i> , 2022, 112, 1589-1598.	1.5	0
1396	Covid-19 vaccination programme effectiveness against SARS-CoV-2 related infections, hospital admissions and deaths in the Apulia region of Italy: a one-year retrospective cohort study. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
1397	Novel coronavirus mutations: Vaccine development and challenges. <i>Microbial Pathogenesis</i> , 2022, 173, 105828.	1.3	7
1398	Factors associated with development of adverse events after taking COVID-19 vaccine in a tribal state of India: Regression analysis. <i>Journal of Family Medicine and Primary Care</i> , 2022, 11, 6260.	0.3	1
1399	Risk factors for critical forms of SARS-CoV-2 infection in fully vaccinated patients: a prospective observational study. <i>Pan African Medical Journal</i> , 0, 43, .	0.3	1
1400	A layman approach to adopt COVID-19 appropriate behaviour and vaccination: A narrative review. <i>Asian Journal of Pharmaceutical Research and Health Care</i> , 2022, 14, 1.	0.0	0
1402	Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial. <i>Nature Microbiology</i> , 2022, 7, 1996-2010.	5.9	39
1403	Effectiveness of COVID-19 vaccines in a large European hemodialysis cohort. , 0, 2, .		1
1404	SARS-CoV-2-specific humoral and cellular immune responses to BNT162b2 vaccine in Fibrodysplasia ossificans progressiva patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1405	COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	6
1406	Updated vaccine protects against SARS-CoV-2 variants including Omicron (B.1.1.529) and prevents transmission in hamsters. <i>Nature Communications</i> , 2022, 13, .	5.8	11
1407	Patient-Reported Outcomes for Fully Vaccinated COVID-19 Patients Over 6â€Weeks: The Experiences of Clinical Breakthrough Cases. <i>Patient</i> , 0, , .	1.1	1

#	ARTICLE	IF	CITATIONS
1408	Impact of vaccination on kinetics of neutralizing antibodies against SARS-CoV-2 by serum live neutralization test based on a prospective cohort. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	4
1409	Breakthrough SARS-CoV-2 Infections after Vaccination in North Carolina. <i>Vaccines</i> , 2022, 10, 1922.	2.1	5
1410	Analysis of the Prevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Student Cohorts Reveals Low-Prevalence Types and a Decline in Binding Antibody Levels during the SARS-CoV-2 Pandemic. <i>Journal of Virology</i> , 0, , .	1.5	3
1411	Enhanced virulence and waning vaccine-elicited antibodies account for breakthrough infections caused by SARS-CoV-2 delta and beyond. <i>IScience</i> , 2022, 25, 105507.	1.9	10
1412	Increased risk of myocarditis and pericarditis and reduced likelihood of severe clinical outcomes associated with COVID-19 vaccination: a cohort study in Lombardy, Italy. <i>BMC Infectious Diseases</i> , 2022, 22, .	1.3	6
1413	Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults. <i>Infectious Disease Clinics of North America</i> , 2023, 37, 27-45.	1.9	6
1414	The impact of vaccination on patients with COVID-19 during the wave of Omicron in Shanghai. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
1415	Clinical Outcomes, Immunogenicity, and Safety of BNT162b2 Vaccine in Primary Antibody Deficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, 11, 306-314.e2.	2.0	7
1416	Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir. <i>Nature</i> , 2023, 613, 558-564.	13.7	159
1417	Prospective longitudinal analysis of antibody response after standard and booster doses of SARS-COV2 vaccination in patients with early breast cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
1418	Efficacy of COVID-19 Booster Vaccines in Patients with Hematologic Malignancies: Experiences in a Real-World Scenario. <i>Cancers</i> , 2022, 14, 5512.	1.7	6
1419	A review of COVID vaccines: success against a moving target. <i>British Medical Bulletin</i> , 2022, 144, 12-44.	2.7	5
1420	Safety and immunogenicity of an AS03-adjuvanted plant-based SARS-CoV-2 vaccine in Adults with and without Comorbidities. <i>Npj Vaccines</i> , 2022, 7, .	2.9	10
1421	Case mistaken for leukemia after mRNA COVID-19 vaccine administration: A case report. <i>World Journal of Clinical Cases</i> , 0, 10, 12268-12277.	0.3	2
1422	Effect of vaccination against Covid-19 one year after its introduction in Brazil. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2022, 8, .	0.9	3
1423	An attenuated vaccinia vaccine encoding the severe acute respiratory syndrome coronavirus-2 spike protein elicits broad and durable immune responses, and protects cynomolgus macaques and human angiotensin-converting enzyme 2 transgenic mice from severe acute respiratory syndrome coronavirus-2 and its variants. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	4
1424	Risk factors for intensive care unit admission and death from COVID-19 in fully vaccinated patients hospitalized for severe COVID-19, Brazil, 2021â€“2022. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 2022, 46, 1.	0.6	0
1425	Vertigo/dizziness following COVID-19 vaccination. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 2023, 44, 103723.	0.6	4

#	ARTICLE	IF	CITATIONS
1426	Characterization of otologic symptoms appearing after COVID-19 vaccination. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2023, 44, 103725.	0.6	3
1427	COVID-19 Vaccination in Korea: Past, Present, and the Way Forward. Journal of Korean Medical Science, 2022, 37, .	1.1	20
1428	Heterologous vaccination of BNT162b2 in Ad26. COV2.S-vaccinated healthcare workers elicits long-term humoral immune response. South African Medical Journal, 2022, 112, 827-838.	0.2	0
1429	COVID-19 vaccines: Update of the vaccines in use and under development. Vacunas (English Edition), 2022, 23, S88-S102.	0.3	0
1430	Severe acute respiratory syndrome coronavirus 2 vaccine breakthrough infections: A single metro-based testing network experience. Frontiers in Medicine, 0, 9, .	1.2	0
1431	Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Hypertensive and/or Diabetic People Aged over 60 Years: A Prospective Open-Label Study. Diabetes Therapy, 2023, 14, 139-151.	1.2	4
1432	A multicenter study of ocular inflammation after COVID-19 vaccination. Japanese Journal of Ophthalmology, 2023, 67, 14-21.	0.9	12
1433	COVID-19 in Patients with Hematologic Diseases. Biomedicines, 2022, 10, 3069.	1.4	3
1435	COVID-19 Vaccines: An Updated Overview of Different Platforms. Bioengineering, 2022, 9, 714.	1.6	11
1436	Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN. Science Advances, 2022, 8, .	4.7	3
1437	Risk factors affecting COVID-19 vaccine effectiveness identified from 290 cross-country observational studies until February 2022: a meta-analysis and meta-regression. BMC Medicine, 2022, 20, .	2.3	8
1438	Quantitative Benefit-Risk Assessment of COVID-19 Vaccines Using the Multi-Criteria Decision Analysis. Vaccines, 2022, 10, 2029.	2.1	3
1439	Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution. Vaccines, 2022, 10, 2035.	2.1	3
1440	SARS-COV-2 infections in inborn errors of immunity: A single center study. Frontiers in Immunology, 0, 13, .	2.2	7
1441	Thrombosis and thrombocytopenia after vaccination against and infection with SARS-CoV-2 in Catalonia, Spain. Nature Communications, 2022, 13, .	5.8	9
1442	Mucosal delivery of nanovaccine strategy against COVID-19 and its variants. Acta Pharmaceutica Sinica B, 2023, 13, 2897-2925.	5.7	1
1443	Efficacy and Safety of COVID-19 Vaccines-An Update. Diseases (Basel, Switzerland), 2022, 10, 112.	1.0	11
1444	Headache After Vaccination: An Update on Recent Clinical Trials and Real-World Reporting. Current Pain and Headache Reports, 2022, 26, 895-918.	1.3	3

#	ARTICLE	IF	CITATIONS
1445	A Case of Purpura Annularis Telangiectodes of Majocchi after Anti-SARS-CoV-2 Pfizer-BioNTech Vaccine: Is There an Association?. <i>Vaccines</i> , 2022, 10, 1972.	2.1	2
1446	Neurological Complications Following COVID-19 Vaccination. <i>Current Neurology and Neuroscience Reports</i> , 2023, 23, 1-14.	2.0	12
1447	COVID-19 Vaccination Is Associated with a Better Outcome in Acute Ischemic Stroke Patients: A Retrospective Observational Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 6878.	1.0	3
1448	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. <i>Frontiers in Bioengineering and Biotechnology</i> , 0, 10, .	2.0	3
1449	Humoral immunity and B-cell memory in response to SARS-CoV-2 infection and vaccination. <i>Biochemical Society Transactions</i> , 2022, 50, 1643-1658.	1.6	6
1450	Areas of Uncertainty in SARS-CoV-2 Vaccination for Cancer Patients. <i>Vaccines</i> , 2022, 10, 2117.	2.1	0
1451	Immune Response and Effects of COVID-19 Vaccination in Patients with Lung Cancer”COVID Lung Vaccine Study. <i>Cancers</i> , 2023, 15, 137.	1.7	2
1452	Post COVID-19 vaccination side effects and associated factors among vaccinated health care providers in Oromia region, Ethiopia in 2021. <i>PLoS ONE</i> , 2022, 17, e0278334.	1.1	2
1453	COVID-19 Response in Uzbekistan: From RT-PCR Test System to the Clinical Trial of Subunit Vaccine. , 0, , .		0
1454	Effect of inactivated COVID-19 vaccines on seizure frequency in patients with epilepsy: A multicenter, prospective study. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1455	Effectiveness of Covid-19 vaccines against symptomatic and asymptomatic SARS-CoV-2 infections in an urgent care setting. <i>Vaccine</i> , 2023, 41, 989-998.	1.7	1
1456	Apparent risks of postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination and SARS-Cov-2 Infection. , 2022, 1, 1187-1194.		28
1457	Understanding the challenges to COVID-19 vaccines and treatment options, herd immunity and probability of reinfection. <i>Journal of Taibah University Medical Sciences</i> , 2023, 18, 600-638.	0.5	1
1458	AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants. <i>European Journal of Cancer</i> , 2023, 181, 102-118.	1.3	2
1459	COVID-19 vaccination boosts the potency and breadth of the immune response against SARS-CoV-2 among recovered patients in Wuhan. <i>Cell Discovery</i> , 2022, 8, .	3.1	3
1460	Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review. <i>Expert Review of Vaccines</i> , 2023, 22, 35-53.	2.0	8
1461	Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis. <i>Blood Cancer Journal</i> , 2022, 12, .	2.8	11
1462	Reduction in COVID-19 Vaccine Effectiveness against SARS-CoV-2 Variants in Seoul according to Age, Sex, and Symptoms: A Test-Negative Case-Control Study. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 16958.	1.2	1

#	ARTICLE	IF	CITATIONS
1463	Heterologous chimpanzee adenovirus vector immunizations for SARS-CoV-2 spike and nucleocapsid protect hamsters against COVID-19. <i>Microbes and Infection</i> , 2023, 25, 105082.	1.0	5
1464	Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression. <i>Vaccines</i> , 2022, 10, 2180.	2.1	16
1465	Repeated dosing improves oncolytic rhabdovirus therapy in mice via interactions with intravascular monocytes. <i>Communications Biology</i> , 2022, 5, .	2.0	0
1466	Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis. <i>Blood Advances</i> , 2022, 6, 6198-6207.	2.5	9
1467	CNS inflammatory demyelinating events after COVID-19 vaccines: A case series and systematic review. <i>Frontiers in Neurology</i> , 0, 13, .	1.1	11
1469	COVID-19 Vaccines, Effectiveness, and Immune Responses. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15415.	1.8	9
1471	Effectiveness of COVID-19 Vaccines in Adults with Diabetes Mellitus: A Systematic Review. <i>Vaccines</i> , 2023, 11, 24.	2.1	12
1473	Current evidence of COVID-19 vaccination-related cardiovascular events. <i>Postgraduate Medicine</i> , 2023, 135, 102-120.	0.9	5
1474	Comparative Benefits and Risks Associated with Currently Authorized COVID-19 Vaccines. <i>Vaccines</i> , 2022, 10, 2065.	2.1	1
1475	An observational study of adverse drug reactions to COVID-19 vaccines reported to the New Mexico poison center hotline. <i>Clinical Toxicology</i> , 0, , 1-7.	0.8	1
1476	Efficacy and safety of COVID-19 vaccines. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	60
1477	Vaccine-associated corneal graft rejection following SARS-CoV-2 vaccination: a CDC-VAERS database analysis. <i>British Journal of Ophthalmology</i> , 2024, 108, 17-22.	2.1	4
1478	Neutralizing Antibodies against the SARS-CoV-2 Delta and Omicron BA.1 following Homologous CoronaVac Booster Vaccination. <i>Vaccines</i> , 2022, 10, 2111.	2.1	1
1479	Vaccines and nephrotic syndrome: efficacy and safety. <i>Pediatric Nephrology</i> , 2023, 38, 2915-2928.	0.9	2
1480	SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patients. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
1481	Population-Based Analysis of the Immunoglobulin G Response to Different COVID-19 Vaccines in Brazil. <i>Vaccines</i> , 2023, 11, 21.	2.1	0
1482	Recent developments in the immunopathology of COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2023, 78, 369-388.	2.7	33
1483	Mixed formulation of mRNA and protein-based COVID-19 vaccines triggered superior neutralizing antibody responses. <i>MedComm</i> , 2022, 3, .	3.1	1

#	ARTICLE	IF	CITATIONS
1484	Vaccine Vigilance System: Considerations on the Effectiveness of Vigilance Data Use in COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 2115.	2.1	3
1485	Social participation and mental health of immunocompromised individuals before and after COVID-19 vaccination—Results of a longitudinal observational study over three time points. <i>Frontiers in Psychiatry</i> , 0, 13, .	1.3	6
1486	A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV. <i>Vaccines</i> , 2023, 11, 18.	2.1	3
1487	A genetically engineered, stem-cell-derived cellular vaccine. <i>Cell Reports Medicine</i> , 2022, 3, 100843.	3.3	0
1488	HIV and COVID-19 Disease. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 035-049.	0.8	2
1489	Effects of COVID-19 vaccination on clinical outcomes in patients hospitalized in Internal Medicine during Omicron variant spreading.. <i>Internal and Emergency Medicine</i> , 0, , .	1.0	0
1490	COVID-19 and hepatic injury: Diversity and risk assessment. <i>World Journal of Gastroenterology</i> , 0, 29, 425-449.	1.4	5
1491	COVID-19 in Latin America: A Snapshot in Time and the Road Ahead. <i>Infectious Diseases and Therapy</i> , 2023, 12, 389-410.	1.8	6
1492	Safety, reactogenicity, and immunogenicity of Ad26.COV2.S: Results of a phase 1, randomized, double-blind, placebo-controlled COVID-19 vaccine trial in Japan. <i>Vaccine</i> , 2023, 41, 1602-1610.	1.7	2
1493	Effectiveness of the BBV-152 and AZD1222 vaccines among adult patients hospitalized in tertiary hospitals in Odisha with symptomatic respiratory diseases: A test-negative case—control study. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	0
1494	Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic: A comprehensive review. <i>Cephalalgia</i> , 2023, 43, 033310242211313.	1.8	20
1496	Emerging heterologous mRNA-based booster strategies within the COVID-19 vaccine landscape. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	8
1497	Efficacy of Vaccine Protection Against COVID-19 Virus Infection in Patients with Chronic Liver Diseases. <i>Journal of Clinical and Translational Hepatology</i> , 2023, 000, 000-000.	0.7	0
1498	Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review. <i>Infectious Diseases and Therapy</i> , 2023, 12, 367-387.	1.8	22
1499	SARS-CoV-2 Breakthrough Infections in Health Care Workers: An Italian Retrospective Cohort Study on Characteristics, Clinical Course and Outcomes. <i>Journal of Clinical Medicine</i> , 2023, 12, 628.	1.0	8
1500	Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	13
1501	Full protection from SARS-CoV-2 brain infection and damage in susceptible transgenic mice conferred by MVA-CoV2-S vaccine candidate. <i>Nature Neuroscience</i> , 2023, 26, 226-238.	7.1	14
1502	Development and validation of a deep learning model to diagnose COVID-19 using time-series heart rate values before the onset of symptoms. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	4

#	ARTICLE	IF	CITATIONS
1503	Automatic Identification of Self-Reported COVID-19 Vaccine Information from Vaccine Adverse Events Reporting System. <i>Methods of Information in Medicine</i> , 0, , .	0.7	1
1504	COVID-19 Vaccinesâ€”All You Want to Know. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 143-172.	0.8	4
1505	Systematic review and meta-analysis of neonatal outcomes of COVID-19 vaccination in pregnancy. <i>Pediatric Research</i> , 2023, 94, 34-42.	1.1	10
1506	Safety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial. <i>The Lancet Regional Health Americas</i> , 2023, 18, 100423.	1.5	16
1507	Acute adverse events of Sars-CoV2 vaccines: Experiences from a health care worker vaccination campaign in two municipal hospitals in northwest Germany. <i>Vaccine: X</i> , 2023, 13, 100257.	0.9	0
1508	A Comprehensive Analysis of COVID-19 Vaccine Discourse by Vaccine Brand on Twitter in Korea: Topic and Sentiment Analysis. <i>Journal of Medical Internet Research</i> , 0, 25, e42623.	2.1	6
1509	Perspective Chapter: Cardiovascular Post-Acute COVID-19 Syndrome â€” Definition, Clinical Scenarios, Diagnosis, and Management. , 0, , .		1
1510	Seroprevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Patients with Neuromuscular Disorders. <i>Viruses</i> , 2023, 15, 79.	1.5	3
1513	Vitamin D3 Supplementation at 5000 IU Daily for the Prevention of Influenza-like Illness in Healthcare Workers: A Pragmatic Randomized Clinical Trial. <i>Nutrients</i> , 2023, 15, 180.	1.7	4
1514	Effect of 2 vs 3 Doses of COVID-19 Vaccine in Patients With Inflammatory Bowel Disease: A Population-based Propensity Matched Analysis. <i>Inflammatory Bowel Diseases</i> , 2023, 29, 1563-1571.	0.9	6
1516	The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster. <i>Infection and Drug Resistance</i> , 0, Volume 15, 7811-7821.	1.1	2
1518	Safety and immunogenicity of COVID-19 vaccination in immunocompromised patients. <i>Chinese Medical Journal</i> , 2022, 135, 2656-2666.	0.9	1
1519	Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases. <i>International Journal of COPD</i> , 0, Volume 18, 47-56.	0.9	6
1520	Effect of COVID-19 (SARS-CoV-2) Vaccination on Patients with Atopic Dermatitis Treated with Dupilumab: A Multicenter, Observational Study. <i>Annals of Dermatology</i> , 2023, 35, 38.	0.3	1
1521	Lung-Targeted Transgene Expression of Nanocomplexed Ad5 Enhances Immune Response in the Presence of Preexisting Immunity. <i>Engineering</i> , 2023, 27, 127-139.	3.2	0
1522	Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis. <i>Cornea</i> , 2023, 42, 731-738.	0.9	4
1523	A hepatitis B virus core antigenâ€”based virusâ€”like particle vaccine expressing SARSâ€”CoVâ€”2 B and T cell epitopes induces epitopeâ€”specific humoral and cellâ€”mediated immune responses but confers limited protection against SARSâ€”CoVâ€”2 infection. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	2
1524	Upper respiratory tract mucosal immunity for SARS-CoV-2 vaccines. <i>Trends in Molecular Medicine</i> , 2023, 29, 255-267.	3.5	17

#	ARTICLE	IF	CITATIONS
1525	Risk of COVID-19 Infection After Full Immunization in Patients With Inflammatory Bowel Disease on Treatment: A Research Network Analysis. <i>Cureus</i> , 2023, , .	0.2	0
1526	Evaluation of Short-Term Side Effects Following the First Dose of COVID-19 Vaccines Among Physicians and Dentists: A Cross-Sectional Study from India. <i>Journal of Multidisciplinary Healthcare</i> , 0, Volume 16, 161-174.	1.1	6
1527	Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi. <i>Vaccines</i> , 2023, 11, 299.	2.1	5
1528	An Old Acquaintance: Could Adenoviruses Be Our Next Pandemic Threat?. <i>Viruses</i> , 2023, 15, 330.	1.5	7
1529	Menstrual Irregularities Post-COVID-19 Infection/Vaccination in Indian Population. <i>Journal of SAFOG</i> , 2023, 14, 694-699.	0.1	0
1530	Reactogenicity of various COVID-19 vaccination regimens. <i>Cardiovascular Therapy and Prevention (Russian Federation)</i> , 2023, 21, 3476.	0.4	1
1531	SARS-CoV-2 epidemiology, antibody dynamics, and neutralisation capacity in Irish healthcare workers in the era of booster COVID-19 vaccinations. <i>Frontiers in Medicine</i> , 0, 10, .	1.2	3
1532	Clinical efficacy and long-term immunogenicity of an early triple dose regimen of SARS-CoV-2 mRNA vaccination in cancer patients. <i>Annals of the Academy of Medicine, Singapore</i> , 2023, 52, 8-16.	0.2	1
1533	Impacts of viral pathogenesis and vaccine immunization on the host humoral immune response in SARS-CoV-2 and associated variants of concern (VOCs) infection. , 2023, , 237-262.		0
1534	Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants. <i>Bioengineering</i> , 2023, 10, 148.	1.6	3
1536	Data-Driven COVID-19 Vaccine Development for Janssen. <i>INFORMS Journal on Applied Analytics</i> , 2023, 53, 70-84.	0.7	0
1537	Management of Atopic Dermatitis During the COVID-19 Pandemic: Key Questions and Review of the Current Evidence. <i>Dermatitis</i> , 0, , .	0.8	0
1538	Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
1539	Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. <i>JAMA Network Open</i> , 2023, 6, e2251974.	2.8	12
1540	Risk reduction of hospitalisation and severe disease in vaccinated COVID-19 cases during the SARS-CoV-2 variant Omicron BA.1-predominant period, Navarre, Spain, January to March 2022. <i>Eurosurveillance</i> , 2023, 28, .	3.9	0
1541	Covid-19 Vaccine Efficacy: Accuracy Assessment, Comparison, and Caveats. <i>Journal of Data Science</i> , 2024, , 45-55.	0.5	0
1542	COVID-19 Vaccination in Korea. <i>Infection and Chemotherapy</i> , 2023, 55, 135.	1.0	9
1543	Ad26.COVS.S and SARS-CoV-2 spike protein ferritin nanoparticle vaccine protect against SARS-CoV-2 Omicron BA.5 challenge in macaques. <i>Cell Reports Medicine</i> , 2023, 4, 101018.	3.3	3

#	ARTICLE	IF	CITATIONS
1544	Tracking the COVID-19 vaccines: The global landscape. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	17
1545	Bidirectional and persistent immunomodulation of Astragalus polysaccharide as an adjuvant of influenza and recombinant SARS-CoV-2 vaccine. <i>International Journal of Biological Macromolecules</i> , 2023, 234, 123635.	3.6	6
1546	A systematic review and meta-analysis of the seroconversion rates and adverse effects of COVID-19 mRNA vaccine and COVID-19 viral vector vaccine in kidney transplant recipient patients. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	1
1547	Decreased breadth of the antibody response to the spike protein of SARS-CoV-2 after repeated vaccination. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1548	Progress in vaccine development for infectious diseasesâ€”a Keystone Symposia report. <i>Annals of the New York Academy of Sciences</i> , 2023, 1524, 65-86.	1.8	3
1549	Efficacy of SARS-CoV-2 vaccines and the doseâ€”response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet Microbe</i> , The, 2023, 4, e236-e246.	3.4	46
1550	Post â€”acute sequelae of COVID-19 and cardiac outcomes in U. S. military members. <i>International Journal of Cardiology Cardiovascular Risk and Prevention</i> , 2023, 17, 200183.	0.4	3
1551	Potential treatments of COVID-19: Drug repurposing and therapeutic interventions. <i>Journal of Pharmacological Sciences</i> , 2023, 152, 1-21.	1.1	7
1552	Nanomedicine for drug resistant pathogens and COVID-19 using mushroom nanocomposite inspired with bacteriocin â€” A review. <i>Inorganic Chemistry Communication</i> , 2023, 152, 110682.	1.8	4
1553	The effect of mixed vaccination rollout strategy: A modelling study. <i>Infectious Disease Modelling</i> , 2023, 8, 318-340.	1.2	0
1554	Assessing parameter sensitivity in a university campus COVID-19 model with vaccinations. <i>Infectious Disease Modelling</i> , 2023, 8, 374-389.	1.2	0
1555	Precision recruitment for high-risk participants in a COVID-19 cohort study. <i>Contemporary Clinical Trials Communications</i> , 2023, 33, 101113.	0.5	0
1556	Infection prevention and vaccination in the rheumatic diseases. <i>Joint Bone Spine</i> , 2023, 90, 105568.	0.8	0
1557	The occurrence of emerging compounds in real urban wastewater before and after the COVID-19 pandemic in Cali,ÂColombia. <i>Current Opinion in Environmental Science and Health</i> , 2023, 33, 100457.	2.1	3
1558	Immune correlates analysis of the PREVENT-19 COVID-19 vaccine efficacy clinical trial. <i>Nature Communications</i> , 2023, 14, .	5.8	36
1559	The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study. <i>British Journal of Dermatology</i> , 2023, 188, 542-551.	1.4	1
1560	SARS-CoV-2 vaccine breakthrough infections in Virginia, January 17, 2021 â€” June 30, 2021. <i>Vaccine</i> , 2023, 41, 1295-1298.	1.7	0
1562	Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies. <i>Blood Advances</i> , 2023, 7, 5691-5697.	2.5	4

#	ARTICLE	IF	CITATIONS
1563	Defending against SARS-CoV-2: The T cell perspective. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	20
1564	Insight into SARS-CoV-2 Omicron variant immune escape possibility and variant independent potential therapeutic opportunities. <i>Heliyon</i> , 2023, 9, e13285.	1.4	4
1565	A case series of bacillus Calmette-Guérin scar reactivation after administration of both mRNA and viral vector COVID-19 vaccines. <i>British Journal of Clinical Pharmacology</i> , 0, , .	1.1	0
1566	COVID-19 vaccination and venous thromboembolism risk in older veterans. <i>Journal of Clinical and Translational Science</i> , 2023, 7, .	0.3	2
1567	Safety and Immunogenicity of Betuvax-CoV-2, an RBD-Fc-Based SARS-CoV-2 Recombinant Vaccine: Preliminary Results of the First-in-Human, Randomized, Double-Blind, Placebo-Controlled Phase I/II Clinical Trial. <i>Vaccines</i> , 2023, 11, 326.	2.1	4
1569	Antisense oligonucleotides to therapeutically target SARS-CoV-2 infection. <i>PLoS ONE</i> , 2023, 18, e0281281.	1.1	4
1570	COVID-19 therapy and vaccination: a clinical narrative review. <i>Drugs in Context</i> , 0, 12, 1-11.	1.0	10
1571	Diagnostic performance of a novel antigen-capture ELISA for the detection of SARS-CoV-2. <i>Analytical Biochemistry</i> , 2023, 666, 115079.	1.1	7
1572	Molecular epidemiological analysis of SARS-CoV-2 genovariants in Moscow and Moscow region. <i>Voprosy Virusologii</i> , 2023, 67, 496-505.	0.1	1
1573	Characterizing and Predicting Post-Acute Sequelae of SARS CoV-2 Infection (PASC) in a Large Academic Medical Center in the US. <i>Journal of Clinical Medicine</i> , 2023, 12, 1328.	1.0	8
1574	Palliative Care in a Pandemic: A Multicenter Cohort of Critically Ill Patients with Coronavirus Disease 2019. <i>Surgical Infections</i> , 2023, 24, 190-198.	0.7	0
1575	Global incidence pattern and factors associated with common cutaneous reactions related to COVID-19 vaccination of 2.55 million participants in real-world settings: A systematic review and meta-analysis. <i>Journal of Global Health</i> , 0, 13, .	1.2	5
1576	Serological response to vaccines against SARS-CoV-2 in patients with inflammatory bowel disease. <i>Gastroenterology & Hepatology (English Edition)</i> , 2023, 46, 48-53.	0.0	0
1577	No association of malignant B-cell non-Hodgkin lymphomas with ipsilateral SARS-CoV-2 vaccination. <i>Cancer Medicine</i> , 0, , .	1.3	1
1578	Evolving Trends for the Clinical Presentation of Primary Rhegmatogenous Retinal Detachments From Early to Late Phases of the COVID-19 Pandemic. <i>Ophthalmic Surgery Lasers and Imaging Retina</i> , 2023, 54, 78-83.	0.4	0
1579	The Impact of SARS-CoV-2 Lineages (Variants) and COVID-19 Vaccination on the COVID-19 Epidemic in South Africa: Regression Study. <i>Jmirx Med</i> , 0, 4, e34598.	0.2	6
1580	Impact of COVID-19 on Cardiovascular Disease. <i>Viruses</i> , 2023, 15, 508.	1.5	15
1582	Evaluation of the safety profile of COVID-19 vaccines in patients with MS, NMOSD, and MOGAD. <i>Neurological Sciences</i> , 2023, 44, 1841-1848.	0.9	1

#	ARTICLE	IF	CITATIONS
1583	Persons with HIV Develop Spike-Specific Lymph Node Germinal Center Responses following SARS-CoV-2 Vaccination. <i>Journal of Immunology</i> , 2023, 210, 947-958.	0.4	0
1584	Determinants of humoral immune response to SARS-CoV-2 vaccines in solid cancer patients: A systematic review and meta-analysis. <i>Vaccine</i> , 2023, 41, 1791-1798.	1.7	6
1585	Axes of social inequities in COVID-19 clinical trials: A systematic review. <i>Frontiers in Public Health</i> , 0, 11, .	1.3	1
1586	Harnessing the Power of Venomous Animal-Derived Toxins against COVID-19. <i>Toxins</i> , 2023, 15, 159.	1.5	0
1587	Analysis of Antibodies Induced after SARS-CoV-2 Vaccination Using Antigen Coded Bead Array Luminex Technology. <i>Vaccines</i> , 2023, 11, 442.	2.1	0
1588	Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease. <i>Immunity</i> , 2023, 56, 669-686.e7.	6.6	43
1589	The risk of miscarriage following COVID-19 vaccination: a systematic review and meta-analysis. <i>Human Reproduction</i> , 2023, 38, 840-852.	0.4	8
1590	Renal Biopsy Diagnosis of Acute Tubular Injury after Pfizer-BioNTech COVID-19 Vaccination: A Case Report. <i>Vaccines</i> , 2023, 11, 464.	2.1	2
1591	Review on COVID-19 Vaccines. <i>Research Journal of Pharmacy and Technology</i> , 2022, , 5868-5874.	0.2	0
1592	Adverse Reactions of COVID-19 Vaccines: A Scoping Review of Observational Studies. <i>International Journal of General Medicine</i> , 0, Volume 16, 609-618.	0.8	13
1593	Safety and Effectiveness of Maternal COVID-19 Vaccines Among Pregnant People and Infants. <i>Obstetrics and Gynecology Clinics of North America</i> , 2023, 50, 279-297.	0.7	13
1594	A Novel Mathematical Model That Predicts the Protection Time of SARS-CoV-2 Antibodies. <i>Viruses</i> , 2023, 15, 586.	1.5	7
1595	The COVID-19 Vaccination Coverage in ICU Patients with Severe COVID-19 Infection in a Country with Low Vaccination Coverageâ€”A National Retrospective Analysis. <i>Journal of Clinical Medicine</i> , 2023, 12, 1749.	1.0	2
1596	Focal Crescentic Glomerulonephritis Following COVID-19 Viral Vector Vaccination. <i>Cureus</i> , 2023, , .	0.2	0
1597	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. <i>Heliyon</i> , 2023, 9, e13952.	1.4	28
1598	The Clinical Effectiveness and Safety of Vaccinations against COVID-19 in HIV-Positive Patients: Data from Observational Study in Poland. <i>Vaccines</i> , 2023, 11, 514.	2.1	5
1599	Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
1600	T follicular helper cell responses to <sc>SARSâ€CoV</sc>â€2 vaccination among healthy and immunocompromised adults. <i>Immunology and Cell Biology</i> , 2023, 101, 504-513.	1.0	1

#	ARTICLE	IF	CITATIONS
1601	Immunisation against COVID-19 in Pregnancy and of Women Planning Pregnancy. <i>Viruses</i> , 2023, 15, 621.	1.5	4
1602	The safety and immunogenicity of inactivated COVID-19 vaccine in old pulmonary tuberculosis patients. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2023, 42, 503-512.	1.3	1
1603	Safety and Biodistribution of Nanoligomers Targeting the SARS-CoV-2 Genome for the Treatment of COVID-19. <i>ACS Biomaterials Science and Engineering</i> , 2023, 9, 1656-1671.	2.6	10
1604	Deepening Our Understanding of COVID-19 Vaccine Decision-Making amongst Healthcare Workers in Southwest Virginia, USA Using Exploratory and Confirmatory Factor Analysis. <i>Vaccines</i> , 2023, 11, 556.	2.1	1
1605	Bioinformatics analysis based on high-throughput sequencing data to identify hub genes related to different clinical types of COVID-19. <i>Functional and Integrative Genomics</i> , 2023, 23, .	1.4	2
1606	The Coming of Age of Nucleic Acid Vaccines during COVID-19. <i>MSystems</i> , 2023, 8, .	1.7	5
1607	Maternal SARS-CoV-2 vaccination and infant protection against SARS-CoV-2 during the first six months of life. <i>Nature Communications</i> , 2023, 14, .	5.8	19
1608	Characteristics of COVID-19 vaccinated and unvaccinated patients admitted to Careggi University Hospital, Florence, Italy. <i>Internal and Emergency Medicine</i> , 2023, 18, 821-830.	1.0	2
1609	Update on the effectiveness of COVID-19 vaccines on different variants of SARS-CoV-2. <i>International Immunopharmacology</i> , 2023, 117, 109968.	1.7	17
1610	A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	10
1611	Susac syndrome following COVID-19 vaccination: a case-based review. <i>Clinical Rheumatology</i> , 0, , .	1.0	1
1612	Effect of SARS-CoV-2 mRNA-Vaccine on the Induction of Myocarditis in Different Murine Animal Models. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5011.	1.8	1
1613	Response to the letter to the Editor regarding the article "Vaccine versus infection - COVID-19-related loss of training time in elite athletes". <i>Journal of Science and Medicine in Sport</i> , 2023, 26, 181-182.	0.6	0
1614	Impact of Vaccination and the Omicron Variant on COVID-19-related Chest CT Findings: A Multicenter Study. <i>Radiology</i> , 2023, 307, .	3.6	11
1615	Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2. <i>American Journal of Epidemiology</i> , 0, , .	1.6	1
1616	Bibliometric Analysis of Global Scientific Production on COVID-19 and Vaccines. <i>International Journal of Environmental Research and Public Health</i> , 2023, 20, 4796.	1.2	2
1617	Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine. <i>Npj Vaccines</i> , 2023, 8, .	2.9	13
1618	Difference in Immunogenic Responses to COVID-19 Vaccines in Patients With Cancer Receiving Chemotherapy Versus Nonchemotherapy Treatment. <i>JCO Global Oncology</i> , 2023, , .	0.8	1

#	ARTICLE	IF	CITATIONS
1619	Comparative Performance Evaluation of Personal Protective Measures and Antiviral Agents Against SARS-CoV-2 Variants: A Narrative Review. <i>BMC Clinical Pathology</i> , 2023, 16, 2632010X2311612.	0.7	3
1620	Indirect Dispersion of SARS-CoV-2 Live-Attenuated Vaccine and Its Contribution to Herd Immunity. <i>Vaccines</i> , 2023, 11, 655.	2.1	3
1621	Effectiveness of the pre-Omicron COVID-19 vaccines against Omicron in reducing infection, hospitalization, severity, and mortality compared to Delta and other variants: A systematic review. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	17
1622	Ocular manifestations of COVID-19 in pediatric patients. <i>Therapeutic Advances in Ophthalmology</i> , 2023, 15, 251584142211499.	0.8	1
1625	New-Onset Amyotrophic Lateral Sclerosis in a Patient who Received the J&J/Janssen COVID-19 Vaccine. <i>Kansas Journal of Medicine</i> , 2023, 16, 69-70.	0.1	2
1626	Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants. <i>Npj Vaccines</i> , 2023, 8, .	2.9	7
1627	Effects of SARS-CoV-2 Omicron BA.1 Spike Mutations on T-Cell Epitopes in Mice. <i>Viruses</i> , 2023, 15, 763.	1.5	4
1629	Challenges and Recent Advancements in COVID-19 Vaccines. <i>Microorganisms</i> , 2023, 11, 787.	1.6	1
1630	The effect of HIV on COVID-19 vaccine responses. <i>Current Opinion in HIV and AIDS</i> , 2023, 18, 135-141.	1.5	4
1631	Paediatric safety assessment of BNT162b2 vaccination in a multistate hospital-based electronic health record system in the USA: a retrospective analysis. <i>The Lancet Digital Health</i> , 2023, 5, e206-e216.	5.9	1
1632	Humoral Immune Response of Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Prime-Boost Vaccination against SARS-CoV-2 Variants in Korea. <i>Infection and Chemotherapy</i> , 2023, 55, 99.	1.0	0
1633	SARS-CoV-2 specific T-cell humoral response assessment after COVID-19 vaccination using a rapid direct real-time PCR amplification. <i>Clinical Chemistry and Laboratory Medicine</i> , 2023, 61, 1652-1660.	1.4	3
1634	A Novel Approach to Obtain Vaccine Effectiveness Continuous Profiles. Example Case: COVID-19 in Elderly Mexicans. <i>Vaccines</i> , 2023, 11, 719.	2.1	1
1635	CVSARRP: A framework to predict the risk of adverse to severe adverse reactions for 10855 diseases after COVID-19 vaccination. <i>Heliyon</i> , 2023, 9, e14828.	1.4	1
1636	Effectiveness of COVID-19 mRNA Vaccines in Preventing COVID-19-Associated Outpatient Visits and Hospitalizations Among American Indian and Alaska Native Persons, Januaryâ€“November 2021: A Test-Negative Caseâ€“Control Analysis Using Surveillance Data. <i>Open Forum Infectious Diseases</i> , 2023, 10, .	0.4	1
1637	Protection from SARS-CoV-2 Variants by MVAs expressing matched or mismatched S administered intranasally to mice. <i>Npj Vaccines</i> , 2023, 8, .	2.9	1
1638	Hybrid immunity provides protective advantage over vaccination or prior remote COVID-19 alone. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	2
1639	Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial. <i>ELife</i> , 0, 12, .	2.8	6

#	ARTICLE	IF	CITATIONS
1640	A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19. <i>International Journal of Molecular Sciences</i> , 2023, 24, 6369.	1.8	4
1641	Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis. <i>Viruses</i> , 2023, 15, 856.	1.5	10
1643	A linear SARS-CoV-2 DNA vaccine candidate reduces virus shedding in ferrets. <i>Archives of Virology</i> , 2023, 168, .	0.9	3
1644	Diagnosis, treatment protocols, and outcomes of liver transplant recipients infected with COVID-19. <i>World Journal of Clinical Cases</i> , 0, 11, 2140-2159.	0.3	1
1645	Safety and immunogenicity of heterologous ChAdOx1-nCoV19 and BNT162b2 vaccination: A meta-analysis of the heterologous COVID-19 vaccination outcomes. <i>Vaccine</i> , 2023, 41, 3003-3010.	1.7	1
1646	Factors associated with COVID-19 vaccination during Juneâ€“October 2021: A multi-site prospective study. <i>Vaccine</i> , 2023, 41, 3204-3214.	1.7	2
1647	Effects of SARS-CoV-2 vaccination on the severity of COVID-19 infection in patients on chronic dialysis. <i>Journal of Nephrology</i> , 0, , .	0.9	1
1649	SARS-CoV-2 RBD Conjugated to Polyglucin, Spermidine, and dsRNA Elicits a Strong Immune Response in Mice. <i>Vaccines</i> , 2023, 11, 808.	2.1	1
1650	Implications of potential clinically relevant interactions between COVIDâ€“19 vaccines and concomitant medications. <i>Reviews in Medical Virology</i> , 0, , .	3.9	0
1651	Signal detection of <scp>COVID</scp> â€“19 vaccines adverse events using spontaneous reports from South Korea. <i>Pharmacoepidemiology and Drug Safety</i> , 0, , .	0.9	0
1652	Vaccine Basics and the Development and Rollout of COVID-19 Vaccines. , 2024, , 326-348.		0
1653	Side effects of COVID-19 vaccinations in patients treated for breast cancer. <i>Clinical and Experimental Medicine</i> , 0, , .	1.9	2
1654	High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike. <i>Nature Communications</i> , 2023, 14, .	5.8	12
1655	Impact of coronavirus disease 2019 (COVIDâ€“19) vaccination on menstrual bleeding quantity: An observational cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2023, 130, 803-812.	1.1	13
1656	DNA immunization with in silico predicted T-cell epitopes protects against lethal SARS-CoV-2 infection in K18-hACE2 mice. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
1657	Timing and sequence of vaccination against COVID-19 and influenza (TACTIC): a single-blind, placebo-controlled randomized clinical trial. <i>Lancet Regional Health - Europe</i> , The, 2023, 29, 100628.	3.0	9
1658	Insight into the liver dysfunction in COVID-19 patients: Molecular mechanisms and possible therapeutic strategies. <i>World Journal of Gastroenterology</i> , 0, 29, 2064-2077.	1.4	4
1659	Impact of vaccination against the novel coronavirus infection (COVID-19) with Sputnik V on mortality during the delta variant surge. <i>Journal of Infection and Public Health</i> , 2023, 16, 922-927.	1.9	0

#	ARTICLE	IF	CITATIONS
1660	A quantitative systems pharmacology model of the pathophysiology and treatment of COVID-19 predicts optimal timing of pharmacological interventions. <i>Npj Systems Biology and Applications</i> , 2023, 9, .	1.4	3
1661	Primary Prophylaxis of COVID-19: A Comprehensive Review of approved vaccines. <i>Research Journal of Pharmacy and Technology</i> , 2023, , 917-923.	0.2	0
1662	COVID-19 vaccination in patients with primary immunodeficiencies: an international survey on patient vaccine hesitancy and self-reported adverse events. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
1664	The incidence and clinical characteristics of myocarditis and pericarditis following mRNA-based COVID-19 vaccination in Republic of Korea adolescents from July 2021 to September 2022. <i>Osong Public Health and Research Perspectives</i> , 2023, 14, 76-88.	0.7	2
1665	Humoral immune response to two doses of COVID-19 mRNA-based vaccines in people living with HIV: A systematic review and meta-analysis. <i>Reviews in Medical Virology</i> , 2023, 33, .	3.9	2
1666	Development of Adenovirus-Based Covid-19 Vaccine Candidate in Indonesia. <i>Molecular Biotechnology</i> , 2024, 66, 222-232.	1.3	0
1667	Levels and durability of neutralizing antibodies against SARS-CoV-2 Omicron and other variants after ChAdOx-1 or BNT162b2 booster in CoronaVac-primed elderly individuals. <i>Heliyon</i> , 2023, 9, e15653.	1.4	1
1668	A caputo fractional order epidemic model for evaluating the effectiveness of high-risk quarantine and vaccination strategies on the spread of COVID-19. <i>Healthcare Analytics</i> , 2023, 3, 100179.	2.6	5
1669	Modeling the SARS-CoV-2 Omicron variant dynamics in the United States with booster dose vaccination and waning immunity. <i>Mathematical Biosciences and Engineering</i> , 2023, 20, 10909-10953.	1.0	1
1670	Immune Imprinting and Implications for COVID-19. <i>Vaccines</i> , 2023, 11, 875.	2.1	10
1671	Prevalence and characteristics of COVID-19 vaccine breakthrough infection in Upper Egypt. <i>Egyptian Journal of Bronchology</i> , 2023, 17, .	0.3	2
1704	COVID-19: Epidemiology, Etiology, Clinical Manifestations, Diagnosis, Therapeutic Options, and Prevention. <i>Contemporary Endocrinology</i> , 2023, , 3-18.	0.3	0
1715	Therapeutic Interventions for COVID-19. , 0, , .		0
1721	Overview of the cardio-metabolic impact of the COVID-19 pandemic. <i>Endocrine</i> , 2023, 80, 477-490.	1.1	1
1749	The role of vaccines in the COVID-19 pandemic: what have we learned?. <i>Seminars in Immunopathology</i> , 0, , .	2.8	13
1760	Genetic-Based Vaccine Vectors. , 2023, , 1374-1396.e11.		0
1762	Coronavirus Vaccines. , 2023, , 248-257.e4.		0
1794	Nanotechnology of inhalable vaccines for enhancing mucosal immunity. <i>Drug Delivery and Translational Research</i> , 0, , .	3.0	0

#	ARTICLE	IF	CITATIONS
1798	Ibuprofen, other NSAIDs and COVID-19: a narrative review. <i>Inflammopharmacology</i> , 2023, 31, 2147-2159.	1.9	2
1805	Viral vectors for vaccine production. , 2023, , 143-173.		0
1814	Effects of Biological Sex and Pregnancy on SARS-CoV-2 Pathogenesis and Vaccine Outcomes. <i>Current Topics in Microbiology and Immunology</i> , 2023, , 75-110.	0.7	0
1823	New-onset aplastic anemia after SARS-CoV-2 vaccination. <i>International Journal of Hematology</i> , 0, , .	0.7	0
1850	B-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity. , 2024, 21, 144-158.		4
1851	Potential and risks of nanotechnology applications in COVID-19-related strategies for pandemic control. <i>Journal of Nanoparticle Research</i> , 2023, 25, .	0.8	0
1862	A Review of COVID-19 Vaccines, Immunogenicity, Safety, and Efficacy Toward Addressing Vaccine Hesitancy, Inequity, and Future Epidemic Preparedness. , 0, , .		0
1884	Innovation-driven trend shaping COVID-19 vaccine development in China. <i>Frontiers of Medicine</i> , 2023, 17, 1096-1116.	1.5	0
1896	In search of a pan-coronavirus vaccine: next-generation vaccine design and immune mechanisms. , 2024, 21, 103-118.		4
1905	Silent battles: immune responses in asymptomatic SARS-CoV-2 infection. , 2024, 21, 159-170.		3
1906	Targets of SARS-CoV-2: therapeutic implications for COVID-19. , 2024, , 3-14.		0
1924	Enhancing Immunological Memory: Unveiling Booster Doses to Bolster Vaccine Efficacy Against Evolving SARS-CoV-2 Mutant Variants. <i>Current Microbiology</i> , 2024, 81, .	1.0	0
1945	Intervention Trials. , 2024, , 1-30.		0